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Abstract 
The majority of patients with chronic myeloid leukaemia (CML) achieve a complete 
cytogenetic response (CCR) on imatinib. However, we cannot predict which patients will 
have a suboptimal response. We set out to investigate ways of predicting poor cytogenetic 
response to imatinib in patients with CML. 
We examined patients with CML for the possession of particular alleles of the rs2290573 and 
IL-I P +3953 polymorphisms because these polymorphisms had been linked with the rate of 
achievement of a major cytogenetic response (MCR). Following the discovery of a 
polymorphism (K247R) within the P-Ioop of BCR-ABL, we determined its frequency within 
both CML patients and healthy blood donors, and used in vitro biochemical and cellular 
assays to test its drug sensitivity. We examined patients with primary cytogenetic resistance 
to imatinib for the expression of genes associated with drug transport (hOCT 1, MDR 1, 
ABCG2, ABCCl, ABCA2, ABCC2, ABCC3, ABCC6 and MVP) and compared this to 
patients who achieved a complete cytogenetic response to imatinib. We used gene expression 
profiling of CML unselected white cells, and of CML CD34+ cells, to look for genes 
associated with poor cytogenetic response. 
We could not find a correlation between the possession of the rs2290573 and IL-I p +3953 
polymorphisms, and rate of MCR in our patients. The K247R polymorphism was rare, but 3 
out of 5 patients with the arginine allele failed to achieve a major MCR. Despite its position 
in the P-Ioop, in vitro assays showed K247R to have a drug sensitivity phenotype highly 
similar to wild type BCR-ABL. Imatini b non-responders had significantly lower pre imatinib 
gene expression levels of hOCT 1, and significantly higher levels of ABCC3. compared to 
responders. In addition, in imatinib non-responders \ve found that the expression level of a 
.. 
II 
variety of drug transport genes changed with time on imatinib, but these changes did not reach 
statistical significance. Gene expression profiling of CML total white cells revealed that 
imatinib responders and non-responders had highly similar gene signatures, and that the noise 
created by different sample source, handling and cell phenotype limited the detection of 
changes in gene expression. We successfully developed a technique for selecting CD34+ cells 
from cryopreserved CML mononuclear cells, and preliminary analysis of the CD34+ cell 
microarray data does not identify any genes that are significantly differentially expressed 
between cytogenetic responders and non-responders. 
Possession of the rs2290573 and IL-I ~ +3953 polymorphisms did not aid prediction of 
achievement of MCR in our CML popUlation. In patients with CML, possession of the 
arginine allele of K247R should not be confused with the development of a kinase domain 
mutation, and the failure of 3 out of 5 patients to achieve a MCR is likely to be a chance 
finding in a small cohort, but further collection of response data on patients with K247R is 
required. Differences in drug transport gene expression may influence patients' responses to 
imatinib, by potentially causing inadequate intracellular imatinib concentrations. Gene 
expression profiling of CML unselected WBC does not allow prediction of response to 
imatinib, and work is ongoing to see if the technique proves more useful when using RNA 
derived from CML CD34+ cells. 
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1 Introduction 
1.1 Chronic myeloid leukaemia (CML) 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease that originates in 
an abnormal, pluripotent, bone marrow stem cell, and is consistently associated with 
the Philadelphia (Ph) chromosome and/or the BCR-ABL fusion gene t -3• The fusion 
gene is found in all cells of myeloid lineage, and may be found in some lymphoid 
cells too. The disease is biphasic or triphasic: the initial indolent chronic phase (CP) is 
followed by one or both of the aggressive transformed stages known as accelerated 
phase (AP) and blast crisis (BC)4. The worldwide incidence of CML is I to 1.5 cases 
per 100,000 population per year, with a slight male predominance, and an average age 
at diagnosis between the fifth and sixth decades of life4. Prior to the advent of 
imatinib, treatment with interferon alpha (lFN) based regimes led to a median survival 
of 5 years. 
1.1.1 The Philadelphia (Ph) chromosome 
The Ph chromosome is formed by a reciprocal translocation, t(9;22)(q34;q 11), that 
creates a shortened 22q- (the Ph chromosome) and a derivative 9q+5.6. The fusion of 
the ABL gene on chromosome 9, with the break-point cluster region (BeR) gene on 
chromosome 22, results in the formation of the BCR-ABL fusion gene. The 
mechanisms behind the formation of the Ph chromosome are unknown. One theory is 
that chromosomal breaks, and consequent ligations, occur entirely at random and with 
relatively equal frequency between any two chromosomes in a cell. The "success" of 
the Ph chromosome is due to the selective growth advantage afforded to the cell by 
- I -
BCR-ABL. An alternative idea is that the genome contains areas where chromatin is 
more sensitive to DNA damage, thus leading to non-random reciprocal 
translocations7• Indeed, ionising radiation is a known risk factor for CML8.9• 
1.1.2 The BCR-ABL fusion gene 
The ABL gene is ubiquitously expressed, and appears to playa major role in the 
regulation of cell cycle progression 10. When ABL is over-expressed, it induces cell 
cycle arrest and thus has a negative effect on cell growth lJ , yet disruption of ABL 
expression in mice does not result in uncontrolled cell growth. ABL expression 
appears to be an essential requirement for normal growth and development, since 
mice homozygous for a null mutation in ABL are runted, Iymphopenic and many die 
in the perinatal period 12•13 • 
The BCR gene is also ubiquitously expressed, but its functions remain unclear. It has 
been demonstrated that the first exon of BCR encodes a 160kD phosphoprotein with 
serine/threonine kinase activit/"\ and that BCR knock-out mice have an increased 
neutrophil respiratory burst, but otherwise apparently normal haematopoiesis 15• 
The BCR-ABL fusion gene encodes a BCR-ABL tyrosine kinase that is constitutively 
active, and can transform haematopoietic cells in vitro and in viV0 16.17 . The essential 
role of BCR-ABL for the pathogenesis of CML has become established during the 
past 20 years of research, and has been confirmed by the therapeutic success of the 
ABL-specific tyrosine kinase inhibitor, imatinib mesylate (hereafter referred to as 
imatinib). 
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1.2 Imatinib 
Protein kinases are enzymes that transfer phosphate from adenosine triphosphate 
(ATP) to specific amino acids on substrate proteins. This protein phosphorylation 
leads to the activation of signal-transduction pathways, which playa critical role in a 
variety of biological processes, including cell growth, differentiation and death 18•19• 
Protein kinases are made up of 2 subfamilies, the protein threonine kinases and the 
protein tyrosine kinases. 
In the late 1980' s, a project designed to identify compounds that might target protein 
kinase C discovered a 2-phenylaminopyrimidine derivative that inhibited both 
serine/threonine kinases and tyrosine kinases2o.21 • Derivative compounds were 
synthesised, and it was found that these compounds also inhibited the ABL tyrosine 
kinase. Imatinib (formerly CGP57148B and STI-571; Gleevec or Glivec, Novartis, 
Basel, Switzerland) had the highest selectivity for the growth inhibition of cells 
expressing BCR-ABL, and hence went on into clinical development. Imatinib has 
been shown to specifically recognise the inactive, and unphosphorylated, 
conformation of the kinase domain of ABL, and inhibits kinase activity by binding to 
the ATP-binding site of the kinase domain22• Enzyme kinetics studies suggest that 
imatinib is a competitive inhibitor of ATP binding23 , and that imatinib interacts 
closely with the kinase domain, engaging at least 21 amino acid residues24. 
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1.2.1 Activity of imatinib in vitro 
Biochemical assays of kinase activity have shown that imatinib potently inhibits the 
ABL tyrosine kinases, including cellular ABL, viral ABL and BCR-ABL 25-27. Kinase 
assay results were confirmed in cell lines expressing constitutively active ABL, 
including p21 OBCR-ABL, and also cell lines derived from patients with CML or Ph 
positive acute lymphoblastic leukaemia (ALL), and these showed 50% inhibitory 
concentration (lC50) values ranging between 0.1 and 0.5!-lM26-30. Cell proliferation 
assay IC50 results were similar7,30-32, with imatinib exposure leading to apoptotic cell 
death. Inhibition of cellular proliferation was confirmed in cells taken from patients 
with CML30, and it was shown that there was selective inhibition of colony formation 
by committed progenitor cells, with minimal effect on normal haematopoiesis at 
imatinib concentrations up to IflM27,31. 
Imatinib has also been shown to inhi bit platelet-derived growth factor receptor 
(PDGFR) and c_KIT25,33,34, but is inactive, or only weakly active, against the 
serine/threonine kinases, epidermal growth factor (EGF) receptor, vascular 
endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptor, 
tyrosine kinases with immunoglobulin and EGF homology-2, c-MET, and non-
receptor SRC family tyrosine kinases25-27. 
1.2.2 Activity of imatinib in vivo 
Studies of the activity of imatinib, in CML models in mice, have shown that imatinib 
causes dose-dependent inhibition of tumour growth:!7, and that continuous inhibition 
of BCR-ABL is required to achieve the greatest anti-tumour effect'~. Mice with a 
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transduction-transplantation model of CML showed prolonged survival if they were 
treated with imatinib, but imatinib treatment within 48 hours of transplantation could 
not prevent the development of CML36. 
1.2.3 Phase I clinical trials 
The phase I clinical trials of imatinib started in June 1998. Imatinib was studied in 83 
patients with CP CML, in whom treatment with regimes containing IFN had failed37. 
Doses of imatinib ranged from 25mg to I,OOOmg daily, with trends towards higher 
grades of adverse events at doses of 750mg or more. A clear dose-response 
relationship was evident, and those 54 patients taking 300mg or more had a 98% rate 
of complete haematological response (CHR) within 4 weeks. Of these patients, 31 % 
had a major cytogenetic response (MCR) (i.e. 35% or less of the cells were Ph 
positive by cytogenetic analysis) and 13% had a complete cytogenetic response 
(CCR) (i.e. none of the cells were Ph positive by cytogenetic analysis). Side effects, 
including nausea, diarrhoea and periorbital oedema, were usually mild and 
myelosuppression was common, but this was felt to reflect effective reduction of 
CML haematopoiesis, rather than bone marrow toxicity. No maximum tolerated dose 
of imatinib was identified. 
Pharmacokinetic studies found that at doses of 300mg or greater, plasma imatinib 
levels were achieved that were equivalent to the effective in vitro drug level of I~M. 
Four hundred milligrams of imatinib was recommended as the standard dose for CP 
CMLn , since the steady state trough levels were approximately 2.13~M, and the half-
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life was 19.3 hours, which meant that once daily dosing was enough to provide 
continuous kinase inhibition38. 
From April 1999 to March 2000, the trial was expanded to include a dose escalation 
study of imatinib in BC and Ph positive ALL39. Forty-eight patients with CML were 
enrolled, of which approximately half had received prior treatment for BC. Again, 
imatinib was well tolerated. With doses of 300mg to 1000mg daily, 11 % of patients 
with myeloid BC achieved a CHR, while another 10% had a reduction in their bone 
marrow blasts to less than 5%. Patients with lymphoid BC had response rates of 20%, 
and 15%, respectively. Disappointingly, the majority of patients showed relapse of 
their disease within weeks to months. 
1.2.4 Phase II clinical trials 
In June 1999, three large multinational phase II trials were started. Imatinib, at a dose 
of 400mg, was given to 532 patients with late CP CML who had failed to respond to 
treatment with IFN40 (Table 1.1). The other 2 trials evaluated imatinib 400mg and 
imatinib 600mg in 235 patients with Ap41 and in 260 patients with myeloid BC42 
(Table 1.1). Patients in CP, who had failed treatment with IFN, had a good response 
to imatinib with 41 % achieving a CCR and 60% achieving a MCR40• Importantly, 
these responses appeared to be durable, with a progression-free survival of 89.2% at 
18 months. As expected, the efficacy in AP patients was less than in CP patients, but 
better than in patients with BC41 .42. These results led to the Food and Drug 
Administration (FDA) approving imatinib for the treatment of advanced phase CML, 
and treatment of Cr..lL after failure of IFN therapy, in r..lay 2001. Two retrospective 
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studies have SInce compared the survival of historical controls managed with 
conventional IFN based therapy, with the survival of patients who received imatinib 
after failure of IFN treatment, and they both found a significant survival benefit for 
the imatinib treated patients43,44, though one study found the survival benefit was only 
significant in the patients who achieved a cytogenetic response on imatini b~, 
Table 1.1 Phase II results with imatinib. 
Chronic phase Accelerated Blast crisis~2 (lFN fai lure)40 phase41 
CHR 95% 34% 8% 
MCR 60% 24% 16% 
CCR 41% 17% 7% 
Disease progression 11 % 40% 80% 
CHR = complete haematological response, MCR = major cytogenetic response, CCR 
= complete cytogenetic response. 
1.2.5 Phase III clinical trials 
Between June 2000 and January 2001, 1,106 patients with CP CML, who were less 
than 6 months from diagnosis, were enrolled into the International Randomised Study 
of Interferon versus STI571 - the "IRIS" or 0106 study45. Patients were randomised 
to first-line imatinib 400mg (n = 533) or to standard treatment with IFN and low dose 
cytarabine (n = 533); they were allowed to cross over to the alternative treatment if 
stringent criteria for intolerance or treatment fail ure were met. After a median follow 
up of 19 months, imatinib showed significantly superior tolerability, haematological 
and cytogenetic responses and also reduced time to progression~5. MCR and CCR 
rates at 18 months were 87.1 % and 76.2% respectively in the imatinib arm and were 
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significantly superior to the MCR and CCR rates (34.7% and 14.5%, p = 0.(01) in the 
IFN and cytarabine arm. At 18 months, the disease had not progressed in 92.1 % of 
the imatinib treated patients, while only 73.5% of the combination treatment patients 
had failed to progress (p = 0.001). There were marked differences in the 
discontinuation and cross over rates between the two treatments. In those initially 
treated with imatinib, only 12.3% discontinued treatment and 2% crossed over to 
interferon. In those treated with IFN and cytarabine, 31.6% discontinued treatment 
and 57.5% crossed over to imatinib. As well as being clinically superior, a 
comprehensive quality of life study also demonstrated the superiority of imatinib over 
IFN46• Based on these results, the National Institute for Clinical Excellence approved 
imatinib for the first line therapy of CML in October 2003. 
Largely due to the large numbers of patients crossing over to the imatinib group at an 
early stage in the trial, no difference in survival between the two groups, on an 
intention to treat basis, has been demonstrated. However, a retrospective comparison 
of the imatinib treated patients, with a historical control group of patients treated with 
IFN, showed superior survival for the imatinib treated patients47• 
A recent revIew of the 42 month follow up data, at the American Society of 
Hematology meeting 2004, confirmed that there had been a slight increase in imatinib 
response rates with further follow up: 91 % MCR and 84% CCR. The overall 
progression-free survival was 94%. It was also clear that diagnostic Sokal scores had 
an impact on response rates, as shown in Figure 1.1, and on progression free survival, 
as shown in Figure 1.2. Achievement of a CCR was associated with a lower rate of 
disease progression at 24 months, compared to those patients who failed to have a 
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cytogenetic response, and that time to achievement of a CCR did not significantly 
affect the progression free survival (Figure 1.3). In patients who achieved a CCR, 
molecular monitoring by real time quantitative polymerase chain reaction (RQ-PCR) 
was performed. Patients who achieved a 3-10g reduction in BCR-ABL transcripts by 
12 months (major molecular response, MMR) had a progression-free survival of 
100% at 24 months, compared to 95% in those patients without a MMR and 85% in 
those who failed to achieve a CCR48. After 2.5 years of follow up, the overall 
survival in the study was 95%. Only time will tell whether these excellent results will 
be maintained. 
Figure 1.1 Estimated rates of CCR at 30 months for patients analysed by Sokal 
score - patients with the lowest score (best prognosis group) had the highest 
CCR rates. (Figure courtesy of Dr. S. G. O'Brien) 
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Figure 1.2 Estimated progression-free survival rates at 30 months for patients 
analysed by Sokal score - patients with the lowest score (best prognosis group 
had the highest progression-free survival rates. (Figure courtesy of Dr. S.G. 
O'Brien) 
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Figure 1.3 Progression-free survival with patients divided into cohorts based on 
their time to achieve a CCR. Patients taking more than 1 year to achieve a CCR 
have a progression-free survival that is not statistically different from patients 
that achieve a CCR. (Figure courtesy of Dr. S.G. O'Brien) 
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1.2.6 Imatinib and allogeneic transplantation 
At the present time, allogeneic haematopoietic stem cell transplantation is the only 
known cure for CML, with its attendant morbidity and mortali ty49.50. Its use is limited 
by donor availability and the high toxicity of the procedure in older patients, but 
improvements in HLA typing, and the use of less toxic regimens, are improving 
results and widening its potential use5!. Although the data regarding the long-term 
efficacy of imatinib in newly diagnosed patients with CML is still immature, 
haematological, cytogenetic and molecular response rates are encouraging. This 
makes it difficult to advise newly diagnosed patients with a suitable donor, whether to 
go for early transplantation, or to take imatinib and rely on having a more risky 
transplant later on, if their response to imatinib is suboptimal. 
1.2.7 AMN 1 07 
AMN 107 is a BCR-ABL tyrosine kinase inhibitor that has recently been developed 
from imatinib, resulting in a compound with 20 times imatinib's affinity for BCR-
ABL, as well as greater specificity52. Just like imatinib, AMN 107 binds to the 
inactive conformation of the ABL kinase domain. Cell lines expressing the common 
BCR-ABL kinase domain mutants (see below) are also 20 times as sensitive to 
AMNI07, as to imatinib, except for cell lines expressing the T3151 mutant BCR-
ABL 53. Thus, AMN 107 would be predicted to have the potential to treat patients with 
refractoriness to imatinib, though there is still the potential for the development of 
resistance by selection of clones that favour the active conformation of the BCR-ABL 
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tyrosine kinase. Phase I clinical trials are in progress, and preliminary results are 
encouraging54• 
1.2.8 BMS-354825 
BMS-354825 is a dual SRCIABL inhibitor that has approximately 300 times the 
affinity of imatinib for the ABL kinase, and binds the kinase domain in both the 
active and inactive conformations. In vitro studies have shown that BMS-354825 
inhibits all the imatinib resistant BCR-ABL mutants, except for T3151 (see below)55.56. 
BMS-354825 would be predicted to be able to treat patients with imatinib resistance, 
and since there are fewer contact points with the kinase domain than with imatinib, it 
has the potential to be less likely to induce resistance5? However, BMS-354825 is 
less specific than imatinib and there is the potential for long-term toxicity due to SRC 
inhibition. Phase I trials are in progress, and preliminary results show that 73% of 
patients with imatinib-resistant CP CML have achieved a complete CHR, and that the 
drug appears to be well tolerated58. 
1.3 Imatinib resistance 
In patients treated with imatinib, patients' response rates, and the durability of these 
responses, are highly dependent on the phase of the patient's disease when imatinib is 
started37.39-42.45. Primary resistance and secondary, or acquired, resistance to imatinib 
have been seen at all disease stages, but is a particular problem in more advanced 
disease. A number of mechanisms of resistance have been described, with most work 
having been done in patients with acquired resistance. 
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1.3.1 Kinase mutations (KM) 
Point mutations within the ABL kinase domain have been reported as the most 
frequent mechanism for BCR-ABL reactivation within a clone of leukaemic cells59-64. 
KM lead to imatinib resistance by disrupting the critical contact points between 
imatinib and BCR-ABL, or by inducing a transition from the inactive state of the 
BCR-ABL tyrosine kinase, to the active state65,66. KM are found in 50% to 90% of 
patients with acquired resistance23,59-61.63,67, but appear to be less frequent in patients 
with primary cytogenetic resistance to imatinib59,62,68. In some patients, KM detected 
at disease relapse on imatinib, have been found to be evident prior to the patient 
receiving imatinib62,63,69, consistent with the theory that the selective pressure exerted 
by imatinib favours the outgrowth of pre-existing resistant cell clones. However, 
Willis et aCD recently detected KM at low levels in patients prior to their starting 
imatinib. With follow up, these patients did not invariably go on to show imatinib 
resistance, leading to the hypothesis that additional factors might be required to 
induce a fully drug resistant phenotype7D• 
Characterisation of the mutants by biochemical and cellular in vitro assays generally 
reveals a decreased sensitivity of the mutants to imatinib, although the degree of 
resistance varies. KM are most commonly found within the ATP binding loop (P-
loop), the A-loop, and at amino acid residues T315 and M351. 
1.3.1.1 P-Ioop mutations 
The P-loop encompasses the amino acids 244, through to 255. which interact with the 
phosphate groups of ATP. P-loop mutations are the most commonly identified KM. 
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and have been shown to be 70 to 100 times less sensitive to imatinib in kinase assays, 
and 10 times less sensitive to imatinib in cell proliferation assays71, They are 
associated with a particularly poor prognosis, as compared to patients with other types 
of mutation67, 
1.3.1.2 A-loop mutations 
The A-loop is made up of amino acids 381 to 402 of ABL, and it regulates kinase 
activity, Mutations in the A-loop are thought to prevent the BCR-ABL kinase from 
adopting its inactive conformation, and so prevent imatinib from binding, A-loop 
mutations account for less than 10% of KM detected72, They exhibit moderate 
resistance in in vitro assays64.71, 
1.3.1.3 Mutations of T315 
T315 forms a hydrogen bond with imatinib, and mutations at T315 generally cause 
almost complete insensitivity to imatinib60.71 , T315 mutations account for just over 
20% of KM detected72 , T3151 mutants are also resistant to the novel kinase inhibitors 
AMN 107 and BMS_35482552.53.55.56, 
1.3.1.4 Mutations of M351 
M351 helps to stabilise the auto-inhibited conformation of ABL, by its interaction 
with the ABL SH2 domain. Even though BCR-ABL is constitutively active, it still 
maintains some of the mechanisms responsible for auto-inhibition of ABL. Thus. 
mutations in M351 alter the interaction between the SH2 domain and the kinase 
domain, leading to a shift in the equilibrium towards the active conformation of the 
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BCR-ABL, to which imatinib cannot bind72, M351 mutations account for 
approximately 150/0 of KM detected, and cause mild imatinib insensitivity72, 
1.3.2 Amplification and over expression of BCR-ABL 
Fluorescence in situ hybridisation (FISH) has been used to demonstrate the 
amplification of BCR-ABL, at the genomic DNA level, in CML patients resistant to 
imatinib60, In another report, increased BCR-ABL mRNA levels were seen in 
imatinib resistant patients61 , Both these mechanisms are thought to lead to increased 
BCR-ABL protein expression, and hence imatinib resistance, 
1.3.3 Clonal evolution 
Although karyotypic abnormalities, in addition to the Ph chromosome, have been 
detected in patients at the time of disease relapse on imatinib6 1.73,74, the pattern of 
clonal evolution (CE) does not appear to be different from that seen in patients having 
treatment with IFN75, Therefore, CE is more likely a sign of advancing disease, rather 
than a mechanism of resistance, 
1.3.4 Drug transport mechanisms 
Recent studies have examined drug transport as a potential mechanism for imatinib 
resistance, Imatinib has been shown to be a substrate for the ATP-binding cassette 
transporters which cause drug efflux, including P-glycoprotein (MDR 176-83), 
ABCG280,84,85 and ABCC 177, and these transporters have been linked to imatinib 
resistance in CML cells78,80,81.86, Imatinib has also been shown to be a substrate for the 
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human organic cation transporter 1 (hOcr 1 )83, which causes imatinib influx. Thomas 
et al.fr3 proposed that imbalance of influx and efflux transport mechanisms. might lead 
to inadequate intracellular concentrations of imatinib, and hence a lack of response. 
1.3.5 Quiescent stem cells 
The normal stem cell population contains a large non-cycling Go fraction. Patients 
with CML also have a leukaemic population of these "quiescent stem cells .. 87• These 
BCR-ABL positive, CD34+ cells were able to spontaneously exit Goand enter a 
continuously cycling state with subsequent up regulation of IL-3 expression88. There 
is concern that imatinib will not be able to eliminate these malignant haemopoietic 
progenitor cells. It has been shown that imatinib does suppress growth of malignant 
CD34+ cells by inhibiting abnormally increased cell proliferation but it does not 
affect the apoptotic rate of these cells89. Further investigation of 15 patients in CCR 
showed that all still had evidence of BCR-ABL in their bone marrow CD34+ cells, as 
detected by FISH, and that the level of expression of BCR-ABL was higher in the 
CD34+ cells than in the bone marrow mononuclear cells. Also, serial evaluation of 
patients showed persistence of the BCR-ABL positive progenitors despite continued 
treatment with imatinib90• It has also shown that primitive, quiescent Ph positive 
progenitor cells from patients are insensitive to imatinib in vitro91 , and that CD34 
positive, CD38 negative CML stem cells have BCR-ABL kinase activity despite the 
presence of imatinib92• These data strongly suggest that some malignant haemopoietic 
precursors are not eliminated by imatinib, and with this comes the risk of disease 
relapse93 • Further research into therapeutic measures to eliminate these imatinib 
resistant stem cells is required. 
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1.4 Predicting response to imatinib 
The data from the IRIS trial 45 demonstrated that at least three quarters of patients with 
newly diagnosed chronic phase CML achieved a CCR on imatinib, and 39% would 
have a MMR after 12 months of treatment94• However, we do not know which 
patients will have an optimal response to drug therapy or the durability of their 
responses. Allogeneic stem cell transplant is the only known curative treatment for 
CML, but is associated with a high risk of mortality. Being able to predict who will 
and who will not have an optimal response to imatinib would be of great value in 
helping clinicians decide which patients should preferably undergo allografting and 
which should consider drug therapy as first line treatment. 
1.4.1 Sokal and Hasford scoring systems 
The 'traditional' prognostic indicators, such as Sokal95 and Hasford96 scores, are 
mathematical calculations derived from clinical and laboratory parameters at 
diagnosis. The Sokal score was derived using patients treated with busulphan or 
hydroxyurea. The Hasford score was generated using patients only treated with 
interferon. Thus, these scores were not designed using data from patients treated with 
imatinib, and not all of their criteria, for example age, are as relevant to prognosis as 
they used to be97 . However, it does appear that with increasing follow up of patients 
on first line imatinib, these scores are starting to divide patients into high, 
intermediate and low risk groups. The problem with these scores is that they do not 
identify an individual patient's prognosis, but rather give a prognosis for a group of 
patients. In patients \\' here an allogeneic transplant is a potential option, one would 
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like to be able to predict that individual's response to imatinib, and so offer patients a 
well-informed choice about treatment risks and benefits. It would be a huge 
achievement to be able to accurately predict an individual patient's response to 
imatinib. Currently, the prognostic values of a number of techniques are under 
investigation. 
1.4.2 Cytogenetic response 
Data from the IRIS trial45, which were presented at the American Society of 
Hematology meeting, were suggestive that knowledge of patients' cytogenetic 
responses after 6 or 12 months of imatinib treatment would allow the prediction of 
whether a patient was likely to achieve a CCR or not. They found that those patients 
with at least 95% Ph positive metaphases after 6 months of imatinib treatment were 
highly unlikely to achieve a CCR with 30 months of follow up. In addition, those 
patients who had achieved a MCR after up to I year of imatinib were very likely to 
achieve a CCR in the future. Patients without an MCR at 1 year were much less 
likely to achieve a CCR, though this was based on a much smaller number of patients. 
1.4.3 Deletions of the derivative chromosome 9 
The development of fluorescent in situ hybridisation (FISH) techniques in the mid 
1990' s to detect BCR-ABL led to the discovery of unexpected deletions in the 
derivative chromosome 9, in 10% to 15% of patients with CML 98,99. These deletions 
were discovered to be adjacent to. and usually spanning, the translocation breakpoint 
of the derivative chromosome 9. They were very large, and varied considerably 
between patients99• The deletions appear to occur at the time of Ph translocation. as 
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different cohorts of patients have identical frequencies of deletions 1oo.101 and samples 
from individual patients, taken at diagnosis and then disease progression, show that 
not one of them acquires a deletion 1oo. IOI , Deletions of the derivative chromosome 9 
have been shown to be associated with a poor prognosis99.IOI,I02, with patients having a 
median survival approximately half that of other patients. These early studies 
included patients treated with hydroxyurea and IFN based regimes99-103 and one study 
suggested that patients with deletions were more likely to relapse after allografting l02 , 
With regard to treatment with imatinib, the latest evidence suggests that treatment 
with imatinib overcomes the difference in survival seen between patients with and 
without deletions l04- 106, 
1.4.4 Telomere shortening 
Reduction in telomere length has been demonstrated in some cancers, including 
CMLI07, and evidence has suggested that it may prove to be a useful prognostic tool. 
In patients treated with interferon, those with longer telomeres had better cytogenetic 
responses, progression free survival and overall survival 108; however, this did not hold 
true when this study was extended to include patients on other treatments, Telomere 
length was also found to correlate with reduced time from diagnosis to AP, but not to 
BC I09, In patients treated with imatinib, the median telomere length of peripheral 
blood granulocytes was found to decrease as the fraction of Ph negative cells 
increasedllO.lll. Interestingly, Drummond et al. found that of CML patients at 
diagnosis, patients with a high risk score had the greatest amount of telomere 
shortening, and that telomere shortening occurred rapidly during disease 
progression 112, Thus, telomere shortening has the potential to act as a marker of 
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disease progression in CP1l3 , and in the future may find a role in helping to predict a 
patient's prognosis. 
1.4.5 Gene polymorphisms 
Polymorphisms in genes that are related to disease, drug target, absorption, 
distribution, metabolism and drug excretion may affect an individual's response to 
their disease treatment and hence may allow prediction of their response to that 
treatment. In order to investigate the potential of pharmacogenetic analysis to identify 
genetic markers associated with rate of MCR on imatinib, Dressman et al. 114 
examined genotypes from 88 newly-diagnosed patients in the IRIS trial45, and looked 
at 68 candidate polymorphic loci in 26 genes. The 26 genes included tyrosine 
kinases, cytokines and genes associated with drug transport. They found two 
polymorphisms that were significantly associated with achievement of a MCR on 
imatinib. 
The rs2290573 polymorphism maps to the putative tyrosine kinase gene 
DKFZP434C 131, and the effect of the rs2290573 polymorphism on the function of 
DKFZP434C 131 is unknown. Dressman et al. 114 found a significant correlation 
between the presence of the "cc" genotype of the rs2290573 gene polymorphism and 
reduced rate of MCR on first line imatinib. A "CC" genotype was linked to a MCR 
rate of 47%, compared to a "CT" or "TT" genotype that had a MCR rate of 88% 
(p<O.05)115. 
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IL-l~ is a member of the IL-l family and acts as an agonist of the pro-inflammatory 
response. Both the IL-l ~ +3953 and IL-l ~ -511 polymorphisms have been linked to 
increased IL-l production in vitro 116,1 17, and the IL-l ~ +3953 polymorphism has been 
associated with adult periodontitis "8.119 and inflammatory bowel diseasel20-122. These 
2 polymorphisms have been shown to be in linkage disequilibrium with each 
h 117123 D I h d . 'f' I' b ot er ' . ressman et a . s owe a SIgn! Icant corre atIOn etween the "CC" 
genotype of the IL-IB -511 polymorphism and achievement of a MCR; however this 
correlation was not sustained with further patient follow Up114. 
The TP53 gene encodes the p53 tumour-suppressor protein. Bergamaschi et al. 124 
recently found that possession of the A 1 allele, of the TP53 gene (codon 72) 
polymorphism, was significantly more frequent in patients with CML than controls. 
Interestingly, they found that the highest frequency of this allele was seen in patients 
with a high risk Sokal score, and in patients who remained at least 65% Ph positive 
during the first 6 months of imatinib therapy. Dressman et al.".'; also studied this 
polymorphism in their patients, but they failed to see a correlation with achievement 
ofa MCR. 
Amirzargar et al. l25 examined the genotype frequency of the T helper types 1 and 2 
cytokine polymorphisms in patients with CML, and compared this with normal 
controls. They found several genotypes were significantly more common in CML 
patients, and this led them to postulate, based on their knowledge of the functional 
effects of these polyrnorphisms, that CML patients might have higher TGF-~ levels, 
and lower IL-4 and IL-I0 levels, than normal controls. We note that Dressman et 
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al. 1l4 also studied polymorphisms in the TNF, ILl-a and IL-l~ genes, finding no links 
with rate of MeR, other than for the IL-l ~ -511 polymorphism. 
1.4.6 Gene expression profiling 
Microarray gene expression profiling allows for the simultaneous assessment of the 
gene expression levels of tens of thousands of genes. Some of the earliest clinical 
studies using gene expression profiling took place in acute leukaemia, since access to 
pure tumour cell populations was relatively easy. After examining the gene 
expression profiles of 38 patients with either acute myeloid leukaemia (AML) or 
ALL, Golub et al. 126 developed a class predictor using the 50 genes that were most 
differentially expressed between AML and ALL. This predictor correctly assigned 36 
out of 38 samples to their correct diagnosis, and was able to accurately assign a 
diagnosis of AML or ALL to 29 out of 34 samples from an independent set of 
unknown leukaemia samples. Although there are more direct, and less costly, ways 
of classifying acute leukaemia, this study proved that microarray technology was 
capable of identifying underlying biological categories in patient samples 127. 
Gene expression profiling has been shown to be a useful technique that enables the 
prediction of response to treatment in several haematological malignancies, including 
ALL128-130, AML131 ,132 and non-Hodgkins lymphoma (NHL)133·134. Indeed, in diffuse 
large B-cell lymphoma this has led to the identification of 6 genes whose expression, 
as measured by RQ-PCR, accurately predicts survival 135. It would therefore appear 
that gene expression profiling could potentially be used for predicting response to 
imatinib in patients with CML. and that ultimately a simpler, RQ-PCR method could 
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be used to predict response to the same therapy regime, based on the expression levels 
of a few select genes. 
1.4.7 Gene expression profiling in patients with CML 
Studies on the gene expression profile of CML patient cells have found that their 
expression profile differs from healthy cells l36, and that it changes with advancement 
of the diseaseI36.137. It has also been shown that cells with deletions of the derivative 
9q+, have a different gene expression pattern from those without these deletions 1oo• 
Imatinib sensitive and resistant CML cell lines, derived from KCL22 cells, have 
different gene profiles, and the expression pattern of resistant cells changes with 
culture in the presence of imatinib l38. In patients with Ph positive ALL, gene 
expression profiling has been shown to allow prediction of patients' sensitivity to 
imatinib129, and similar work has been published for patients with CMLI39-142. 
A study by Kaneta et al. 143 identified 79 genes that were expressed differentially 
between responders and non-responders to imatinib, where response was classed as a 
MCR after 5 months therapy and non-response as remaining at least 65% Ph positive 
by FISH. On the basis of the expression patterns of 15 or 30 genes they formulated a 
scoring system that accurately predicted response in a further 4 test cases, though 
follow up of the test cases was short at less than 200 days. 
Work by McLean and colleagues l41 also examined gene expression profiles on whole 
blood samples taken from 66 CML patients in the IRIS study prior to treatment with 
imatinib. Patients with a CCR after 12 months of imatinib treatment were compared 
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with non-responders (>65% Ph positive by FISH after 12 months treatment) and a set 
of 31 genes was identified which was predictive of cytogenetic response in 9.+% of 
patients (62 of 66). However, this group did not attempt to show the reproducibility 
of their results by testing them in an independent set of patients. 
Yong et ai. presented their work at the American Society of Hematology meeting, 
2003. They looked at the gene expression profile of CD34+ cells, taken from 
leukopheresis samples, from 19 CML patients taken within 3 months of diagnosis, to 
examine whether patients had "indolent" disease (minimum CP duration of 7 years) 
or "aggressive" disease (maximum CP duration of 3 years). They identified a 
predictive set of 28 genes, with a number of genes involved in myeloid differentiation 
being up regulated in responders but down regulated in non-responders. They 
confirmed the expression of their discriminating genes by RQ-PCR and stated that 
they were hoping to validate their results in an independent group of CML patients. 
1.5 Overall aims of our studies 
The treatment of patients with CML has been dramatically changed by the advent of 
imatinib therapy. It would be very useful to predict which patients will not achieve a 
CCR on imatinib, so that these patients could be targeted for more aggressive initial 
therapy. We set out to identify genetic markers that associated with patients' 
responses to imatinib, with the hope of using these to predict an individual patient's 
response to treatment. We approached this in two ways: firstly by examining 
individual candidate genes and polymorphisms, and secondly by examining overall 
gene expression patterns. 
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2 General methods 
2.1 Introduction 
I have included here a description of all the methods we have used for DNA 
extraction, RNA extraction, cDNA synthesis, polymerase chain reactions (PCR), real 
time quantitative PCR (RQ-PCR) and western blotting. 
2.2 DNA Extraction 
2.2.1 Phenol/Chloroform extraction of DNA from cell pellets 
Cell pellets were thawed at room temperature and the cells were then resuspended in 
900lli TNE buffer (SOmM Tris-HCI (pH7.S), ISOmM NaCI and 10mM EDT A). Next, 
10111 20% SDS and 10111 proteinase K (10mg/ml) were added and mixed by inverting 
the sample 2 or 3 times. Samples were incubated at 37°C overnight. The next day, 
900lli neutralised, water saturated phenol was added to each sample at room 
temperature, and the sample inverted at a rate of one inversion per second for 10 
minutes to ensure a good emulsion was made. Samples were then centrifuged for 
I min at SOOg and the upper phase removed to a fresh tube. Next, 900lli of 
chloroform:isoamyl alcohol (24: I) was added and the sample was inverted at a rate of 
one inversion per second for 5 minutes, prior to centriugation at SOOg for 1 minute. 
The upper phase was removed to a ISml tube, and 4S01l1 (half volume) 7.SM 
ammonium acetate was added and the mixture gently inverted 6 times. Three 
millilitres of absolute alcohol 'vas added to each tube and the sample was inverted 2 
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or 3 times. The sample was then incubated at room temperature for a minimum of 20 
minutes to allow the DNA to precipitate. 
2.2.2 Spooling of DNA 
The end of a sterile glass Pasteur pipette was heated in a bunsen flame to seal its tip. 
The glass pipette was used to 'spool' the DNA precipitate, which was then air dried 
for a few seconds and the DNA was then unwound into a fresh tube containing 500~1 
TE buffer (1 OmM Tris-HCI (pH8.0) and 1 mM EDT A). The DNA was either stored at 
room temperature for a few days, or left overnight at 37°C if required the next day, to 
allow the high molecular weight DNA to re-dissolve. 
2.3 RNA Extraction 
2.3.1 RNeasy® Mini Kit (Qiagen, Valencia, CA) 
RNA was extracted according to the manufacturer's instructions 
(http://wwwl.qiagen.comlliterature/handbooks/INT/RNAStabilizationAndPurification 
FromClinicaISamples.aspx). In brief, cells for RNA extraction were lysed and 
homogenised in the presence of guanidine isothiocyanate containing buffer, and either 
stored at -80°C or used immediately. Ethanol was added to provide the correct 
binding conditions, and the sample was then placed onto an RNeasy mini column. 
Here, the total RNA was bound to the membrane, and any contaminants were washed 
away with Buffer RWI and Buffer RPE (supplied by the manufacturer). RNA was 
then eluted into 30~1 of water. The RNA was used immediately, or stored at -80°C. 
2.3.2 PicoPure™ RNA Isolation Kit (Arcturus, Mountain View, 
CA) 
RNA was extracted according to the manufacturer's instructions 
(http://www.arctur.com/researchportal/resources/download.htm) and included a step 
for DNase treatment (User Guide, Appendix A). This protocol was used in preference 
to the RNeasy® Mini Kit when we were using an input of less than 5 x 106 cells; pilot 
studies had shown that we could achieve higher RNA yields with the PicoPure ™ 
RNA Isolation Kit, than with RNeasy®, at cell numbers ~5 x 106. In brief, the cells 
for RNA extraction were lysed in the presence of guanidine isothiocyanate containing 
buffer, at 42°C for 30 minutes, and centrifuged. The RNA containing supernatant 
was either stored at -80°C, or used immediately. Ethanol was added to provide the 
correct binding conditions, and the sample then placed onto a purification column. 
Here, the total RNA was bound to the membrane, and the sample washed once with 
Wash Buffer I (WI). The sample was then treated with the RNase-Free DNase kit 
(Qiagen), according to the manufacturer's instructions, then washed a second time 
with WI. The sample was then washed twice with Wash Buffer 2 (W2) and then the 
RNA was eluted into 11~1 of water. The RNA was either used immediately or stored 
at -80°C until required. 
2.3.3 Ethanol precipitation of RN A 
When required, we precipitated RNA in order to concentrate it. RNA was made up to 
a volume of 100~1 with water, and 5!-l1 5M sodium chloride and 200!-l1 100% ethanol 
were added. The sample was placed in liquid nitrogen until it froze solid, and then it 
was centrifuged at 16,OOOg, at 4°C. for 20 minutes. The RNA pellet was then washed 
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twice with 500!-l1 70% ethanol, and then residual ethanol was removed and the sample 
allowed to air dry for 10 minutes. The RNA was then suspended in lO!-l1 RNase free 
water and either used immediately, or stored at -80°C. 
2.4 eDNA Synthesis 
2.4.1 SuperScript™ III First-Strand Synthesis System for RT-
PCR (Invitrogen, Carlsbad, CA) 
In order to manufacture single stranded cDNA from RNA extracted using the 
RNeasy® Mini Kit, we used the Invitrogen kit, SuperScript™ III First-Strand 
Synthesis System for RT-PCR, according to the manufacturer's instructions 
(http://www.invitrogen.com/content.cfm?pageid= 1 0745#sensitive). In brief, we used 
up to 4~g of total RNA made up to 16!-l1 with RNase free water, and added 2~1 
50ng/~1 random hexamers and 2!-l1 of 10mM dNTP mix. This mixture was incubated 
at 65°C for 5 minutes, before the addition of 4~1 lOx RT buffer (manufacturer 
supplied), 25mM magnesium chloride, 0.1 M dithiothreitol (OTT), 2!-l1 (40U/~I) 
RNase OUT and 2~1 of 200U/!-l1 SuperScript™ III reverse transcriptase. Samples 
were then incubated at 25°C for 10 minutes, 50°C for 50 minutes and 85°C for 5 
minutes. Next, 2~1 (2U/~1) E. coli RNase H was added and the sample incubated at 
37°C for 20 minutes. The final reaction volume was 42~1. The quality of the 
resulting cDNA was then assessed by PCR for ABL, and the cDNA was either used 
immediately or stored at -80°C. 
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2.5 Polymerase Chain Reactions (PCR) 
2.5.1 peR for ABL 
We designed a peR to detect the ex on 112 boundary of the ABL gene (Figure 2.1) so 
that we could not only assess the quality of any cDNA that we made, but also to go on 
and develop the assay for use as a standard in RQ-PCR experiments. 
Figure 2.1 Sequence of ABL (5' - 3') and situation of primers for the peR of the 
exon 112 boundary. 
Exon 1 b / 2 Boundary 
GGCATGGGGGTCCACACTGCAATGTTTTTGTGGAACAT AAGCCCTTCAGCG 
I Forward Primer I ~ 
GCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGA 
... 
Reverse Primer 
Forward primer = 5' - ggcatgggggtccacact - 3' 
Reverse primer = 5' - tccaacgagcggcttcac - 3' 
We used a DY ADTM DNA engine PCR machine and included a positive control 
(ABL-b plasmid O.lng/pl) and a negative control (water) with each experiment. The 
master mix and temperature protocol that we used are shown below: 
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Table 2.1 Master mix 
Reagent Volume for 20pl Reaction 
lOx PCR Buffer (Roche) 2~1 
dNTP's 1~1 
Forward Primer 1~1 
Reverse Primer 1~1 
MgS04 0.8~1 
Deionised Water 14~1 I 
Taq DNA polymerase (Roche) 0.2~1 
, 
Template cDNA To Add 1~1 
Total Volume 21pl 
ABL peR- Temperature Programme 
1. 95°C for 5 minutes 
2. 95°C for 15 seconds 
3. 60°C for 20 seconds 
4. 72°C for 20 seconds 
5. Cycle to step 2 for 34 more times 
6. Incubate at 72°C for 3 minutes 
7. Incubate at 4°C forever 
The PCR product underwent electrophoresis on a 1.5% agarose gel, stained with 
ethidium bromide, and this was then inspected for the presence of a band of 105 base 
pairs in length (Figure 2.2). 
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Figure 2.2 1 % Agarose gel electrophoresis of ABL peR product. 
ABL peR -{> w-...,.....-· .. 
product 
Negative Control 
<3--Invitrogen 
lKb+ DNA 
ladder 
<3-- 200 bp 
<3-- 100 bp 
2.5.2 Nested PCR for the kinase domain of ABL or BCR-ABL 
In order to perform sequencing of the kinase domain of ABL or BCR-ABL, we 
needed to perform nested PCR to amplify this region. We used the AccuPrime™ Taq 
DNA Polymerase System (Invitrogen). We used the following master mix (Table 
2.2) and temperature protocol for the 2 rounds of PCR, combined with the appropriate 
ABL or BCR-ABL primers (Table 2.3). 
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Table 2.2 Master mix for the nested PCR reaction. 
Reagent Volume (Ill) 
Accuprime Buffer II 5 
Forward primer 10JlM 2 
Reverse primer 10JlM 2 
Accuprime Taq polymerase 0.5 
Water 39.5 
Template 1 
Temperature Protocol for the nested PCR 
1. 95° for 2 minutes 
2. 95° for 30 seconds 
3. 60° for 30 seconds 
4. 68° for 1 minute 30 seconds 
5. Go to step 2 for 35 more cycles 
6. 68° for 5 minutes 
7. 4° forever 
Table 2.3 Primers for the nested PCR. 
Primers BCR-ABL ABL 
1 sl round 
nested 5'-TTCAGAAGCTTCTCCCTGACAT-3' 5' -GCTTGCCTGCCCTGCA-3' 
PCR-
I sl round 5'- 5'-
nested CCTTCTCTAGCAGCTCATACACCTG- CCTTCTCTAGCAGCTCATACACCTG-
PCR- 3' 3' 
2nd round 
nested 5' -ACAGCA TTCCGCTGACCATC-3' 5'-GGCATGGGGGTCCACACT-3' 
PCR-
2nd round 
nested 5' -GCCAT AGGT AGCAA TTTCCC -3' 5' -GCCAT AGGT AGCAA TTTCCC-3' 
PCR-
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2.5.3 Sequencing of the kinase domain of ABL or BCR-ABL 
Nested PCR products were run on a 1 % agarose gel, stained with ethidium bromide, 
and the PCR product of the correct length (approximately 1,400 base pairs) was cut 
out of the gel (Figure 2.3). The DNA was extracted from the gel pieces using the 
Montage™ DNA Gel Extraction Kit (Millipore, Billerica, MA) according to the 
manufacturer's instructions 
(http://www.millipore.com/publications.nsf/docs/pf1230enOO). The DNA was 
precipitated by the following method: 5% 5M ammonium acetate and 200% ethanol 
were added to the sample and the mixture was then placed in liquid nitrogen until 
frozen solid; the mixture was centrifuged at 16,000g, at 4°C, for 30 minutes, and then 
the DNA pellet was washed twice with 70% ethanol and air dried before suspending 
in 10~1 water. The precipitated DNA was then prepared using the master mix shown 
in Table 2.4 and the primers shown in Table 2.5, and sent for automated sequencing at 
the Vollum Institute, Oregon Health and Science University. 
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Figure 2.3 1 % Agarose Gel Electrophoresis of BCR-ABL nested PCR product. 
--[> 
Invitrogen 
lKb+ 
DNA 
ladder 
1,650 bp ---t> 
1 ,000 bp --t> 
Table 2.4 Sequencing master mix 
Reagent Volume (J.tl) 
Template 5/--l1 
Water 4.8/--l1 
Primer I/--lM 3.2 
<!-- 1,400 bp 
peR 
product 
Table 2.5 Primers used for automated sequencing. 
Primers BCR-ABL ABL 
Sequencing 5'-TGGTI AT AT ATICAACGG-3' 5'-TGGTICAT ATCATICAA GG-3' 
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2.5.4 AZul Restriction enzyme digestion 
In order to screen people for the alleles of the K247R polymorphism in ABL and 
BCR-ABL, the kinase domain was amplified by nested PCR. Howe er, there are 
numerous AZul restriction sites within the kinase domain, and we therefore had to 
amplify only a short segment of the kinase domain during the second PCR reaction to 
provide ourselves with a clear result (Figure 2.4). We therefore used a different 
master mix and temperature protocol for the second round of nested PCR, from that 
which we used prior to sequencing (fable 2.6). 
Figure 2.4 Sequence (5' to 3') for the PCR product following the second round 
of PCR, prior to AluI restriction enzyme digestion (AluI cuts AG1CT) . 
.tggttcatcatcattcaacggtggccgacgggctcatcatcaccacgctccattatccagccccaaagcgcaacaagccca 
ctgtctatggtgtgtcccccaactacgacaagtgggagatggaacgcacggacatcaccatgaagcacaagctgggcgg 
gggccagtacggggaggtgtacgagggcgtgtggaagaaatacagcctgacggtggccgtgaagaccttgaaggagg 
acaccatggaggtggaagagttcttga 
Codon 247 of the kinase domain is shown in red and the primers are in green. The 
more common lysine allele of K247R is shown; the arginine allele of K247R has the 
equence agg at codon 247. 
Temperature protocol for the second round of PCR, prior to AZul digestion. 
1. 95° for 2 minute 
2. 95° f r 30 ec nd 
3. 60°f r30 
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4. 68° for 1 minute 
5. Go to step 2 for 35 more cycles 
6. 68° for 5 minutes 
7. 4° forever 
Table 2.6 Master mix for second peR reaction, prior to AluI digestion. 
Reagent Volume (JlI) 
Accuprime Buffer I 5 
Forward primer 10}lM 2 
Reverse primer 10}lM 2 
Accuprime Taq polymerase 0.5 
Water 39.5 
Template 1 
Ten microlitres of the nested PCR product was incubated with 1 JlI (I O,OOOU/ml) Alul 
(New England Biolabs, Beverly, MA), 5JlI lOx NEBuffer 2 and 34JlI water, at 37°C 
for 2 hours; the product was then run on a 1 % agarose gel, stained with ethidium 
bromide, and the results viewed under ultraviolet lighting. Since Alul cuts AG ~ CT, 
the PCR product from people in possession of the arginine allele of K247R would 
remain undigested (263 base pairs), while the more common lysine allele of K247R 
would be digested (lSI base pairs + 112 base pairs) (Figure 2.5). 
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Figure 2.5 1 % Agarose gel electrophoresis of ABL nested peR products 
following AluI Digestion. 
0 ' RangeRuler ™--t> 
100 bp DNA 
ladder 
200 bp --t> 
100 bp --t> 
Complete digestion of the PCR 
product from a patient who is 
homozygous for the lysine allele of 
K247Rin ABL 
Partial digestion of PCR 
product from a patient 
<r- who is heterozygous for 
the arginine allele of 
K247R in ABL 
2.6 Real time quantitative PCR (RQ-PCR) 
2.6.1 ABL plasmid 
In order to develop a RQ-PCR system for assessment of gene expression levels, we 
needed a plasmid containing the exon 112 ABL sequence that we could detect by 
PCR. We used TOPO T A Cloning® version K2 (Invitrogen) to insert the ABL PCR 
product (described above) into the pCR®2.1-TOPO vector; this reaction was then 
transformed into chemically competent One Shot® E. coli. E. coli were incubated 
overnight on plates containing imMedia™ Amp Blue for lacZ+ AmpR recombinant E. 
coli trains. White colonies were selected and ABL PCR was performed to check that 
the plasmid in these colonies contained the correct sequence. The ABL plasmid was 
then transformed into DH5a E. coli (Invitrogen). Plasmid-containing colonie were 
selected, and grown on in 200ml LB, at 37°C in a large rotating incubator, overnight. 
- 7-
The plasmid was then harvested using the Plasmid Midi Kit (Qiagen), and the plasmid 
checked for the correct sequence by ABL PCR. 
2.6.2 ABL plasmid dilutions for RQ-PCR 
In order to perform RQ-PCR we needed 7 standard dilutions of the ABL plasmid. 
From a lOnghtl ABL plasmid solution, we made the following standard 
concentrations for RQ-PCR: 
• 1 x IO-lnghd 
• 1 x IO-2ng/l-t1 
• 1 x IO-3ng/l-t1 
• 1 x lO-4ng/l-t1 
• 1 x lO-5ng/l-t1 
• 1 x 1 0-6ng/ I-tl 
• 1 x lO-7ng/l-t1 
A graph of the resulting fluorescence with cycle number for these standards is shown 
in Figure 2.6. 
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Figure 2.6 Graph showing fluorescence emitted with increasing cycle number 
during RQ-PCR of the standard concentrations of ABL plasmid. 
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2.6.3 RQ-PCR protocol 
,..-' 
RQ-PCR was performed on a 96 well plate, using the MJ Research Opticon ™ 2.0 
DNA Engine. We used the Assays-on-Demand™ Gene Expression Products (Applied 
Biosystems, Foster City, CA) to supply us with primer and Taqman probe sets for the 
genes whose expression level we wished to measure (test genes). We designed a 
Taqman probe, labelled with VIC reporter dye, for our ABL PCR (sequence 5 ' -
CAGCGGCCAGTAGC - 3'), which was made for us by Applied Biosystems. In 
order to provide good quality RQ-PCR data, we used 3 replicates of each standard 
dilution, 3 replicates of ABL RQ-PCR for each patient sample, and 2 replicates of 
RQ-PCR for each test gene for each patient For the RQ-PCR, we used 18j..l1 of 
rna ter mix (fable 2.7 and Table 2.8) plus 2j..l1 of template (ABL plasmid or patient 
DNA diluted 1 in 3 with water). 
Table 2.7 ABL RQ-PCR master mix. 
Component Volume xl 
Platinum® Quantitative PCR SuperMix-UDG lOftl 
Forward Primer, 10ftM 1ftl 
Reverse Primer, 10ftM 1 ftl 
Fluorogenic Probe, 10J,lM Iftl 
PCR grade water 5ftl 
Please note that the Platinum® Quantitative PCR SuperMix-UDG contains uracil 
DNA glycosylase (UDG) and dUTP to prevent the reamplification of carryover PCR 
products between reactions. The principle is that inclusion of dUTP ensures that any 
amplified DNA will contain uracil, and the UDG removes uracil residues from single 
or double stranded DNA and so prevents dU-containing DNA from serving as a 
template in future PCRs. 
Table 2.8 Test gene RQ-PCR master mix. 
Component Volume xl 
Platinum Quantitative PCR SuperMix-UDG 10ft l 
Assays-on-Demand™ primer and probe mix 1 ftl 
PCR grade water 7 ftl 
The temperature protocol used was as follows: 
1. 50°C for 2 minutes 
2. 95°C for 2 minutes 
3. 95°C for 15 seconds 
4. 60°C for 30 seconds 
5. 72°C for I second 
6. Read plate 
7. Cycle steps 3 to 6 for 45 cycles 
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2.7 Western Blotting 
2.7.1 Protein Lysates 
Protein Iysates were made from 5 x 106 cells. Cells were washed twice with cold PBS 
and then placed in 100~1 NP40 lysis buffer (l % NP40, 150mM sodium chloride, 
20mM Tris/HCI (pH 8.0), 10% glycerol and 1 mM EDT A) containing the protease 
inhibitors, ImM 4-(2-Aminoethyl)-bezenesulfonylfluoride.HCI (AEBSF) and 
IOf.lg/ml aprotinin, and the phosphatase inhibitor, ImM sodium vanadate. The 
sample was then rocked for 30 minutes at 4°C. Following centrifugation at 
14,000g for 10 minutes at 4°C, the supernatant was removed to a fresh 
microcentrifuge tube. The sample was immediately placed into liquid nitrogen 
until frozen solid, and then stored at -80°C. 
2.7.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and 
protein transfer 
We used the Criterion ™ Precast Gel System (Bio-Rad Laboratories, Hercules, CA) 
for our SDS-PAGE and protein transfer. Equal volumes of protein Iysates, suspended 
in equal volumes of 1 x SDS gel-loading buffer (50 mM Tris/HCI (pH 6.8), 2% SDS, 
2% ~-MercaptoethanoL 0.1 % bromophenol blue and 10% glycerol), were heated to 
100°C for 4 minutes, then centrifuged to bring the liquid to the bottom of the 
microcentrifuge tube, immediately prior to loading onto a Criterion ™ Precast Gel 
(10% Tris-HCI) (Bio-Rad). The gel underwent electrophoresis at 200Y for I hour 
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and the proteins were then transferred onto Immobilon-P membranes (Millipore 
Corp., Bedford, MA), at IOOY for I hour and 10 minutes. 
2.7.3 Western blotting of Abl 
In order to detect expression of Abl, membranes were placed in 5% non-fat milk in 
Tris-buffered saline Tween-20 (TBST) solution (lOmM Tris-base (pH8.0), 0.875% 
sodium chloride and 0.05% Tween-20) and rocked for 1 hour. The membrane was 
then washed twice with TBST, and placed in a 1 in 1000 solution of CST 2862 rabbit 
polyclonal antibody (Cell Signaling Technology, Beverly, MA) in TBST. The 
membrane was rocked in the primary antibody solution at room temperature for 2 
hours, and then washed 3 times with TBST. The membrane was next placed in a 
solution of TBST containing 2!l1 of goat anti-rabbit horseradish peroxidase 
conjugated antibody (Promega, Madison. WI), per 10ml TBST, and rocked for 1 hour 
at room temperature. The immunoblot was then washed 3 times in TBST to remove 
excess antibody, placed into a I: 1 mixture of peroxide and luminol for 30 seconds, 
and then chemiluminescence was detected using the Lumi-Imager system (Roche, 
Indianapolis, IN). 
2.7.4 Western blotting of tyrosine phosphorylated proteins 
The protocol for the western blotting of tyrosine phosphorylated proteins was 
identical to that used for detecting Abl, except for initially placing the membranes in 
5% bovine serum albumin in TBST. rather than using milk, and for the antibodies 
used. We used the 4G 10 primary antibody (kindly provided by Dr. Brian Druker) and 
a goat anti-mouse horseradish peroxidase conjugated secondary antibody (Promega). 
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3 rs2290573 and IL-lf3 +3953 gene polymorphisms 
and response to imatinib 
3.1 Introduction 
Dressman et a1 114. set out to use pharmacogenetic analysis, on a subset of 88 patients 
from the IRIS trial45, to identify genetic markers associated with achievement of a 
MCR. They studied a panel of 68 single nucleotide polymorphisms, in 26 genes, but 
they did not state why these particular genes were chosen. After adjustment for 
multiple comparisons, they found a significant correlation between the presence of the 
"cc" genotype of the rs2290573 gene polymorphism and reduced rate of major 
cytogenetic response (MCR) on first line imatinib. Dressman et al. also showed a 
significant correlation with the "cc" genotype of the IL-l B -511 polymorphism and 
achievement of a MCR, however this correlation was not sustained with further 
patient follow Up114. IL-l ~ is a member of the IL-l family and acts as an agonist of 
the pro-inflammatory response. The IL-l ~ -511 and IL-l ~ +3953 polymorphisms 
have been shown to be in linkage disequilibrium with each other I17.123 • We set out to 
test their findings in our population of patients with CML, being treated in Newcastle 
upon Tyne. 
3.2 Aims 
I. To test the hypothesis that the presence of the "cc" genotype of the 
rs2290573 gene polymorphism is associated with a reduced rate of MCR, in 
patients with Cr-vlL on imatinib. 
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2. To test the hypothesis that achievement of a MeR, by patients with CML on 
imatinib, correlates with the presence of the IL-I ~ +3953 gene polymorphism. 
3.3 
• 
• 
Key Points 
In a population of CML patients being treated with imatinib in Newcastle 
upon Tyne, we found that the genotypes of the rs2290573 polymorphism, and 
the IL-l ~ +3953 polymorphism, did not correlate with the rate of MCR. 
In order to test Dressman et al.'s findingsl14, we would need to examine CML 
patients of identical ethnic and racial background who have received imatinib 
as first line therapy, and to directly assess the IL-l ~ -511 genotype 
3.4 Methods 
3.4.1 Patients 
One hundred and twenty two patients with CML, who had been treated with at least 6 
months of imatinib and on whom we had follow up data available, were identified at 
the Royal Victoria Infirmary, Newcastle upon Tyne (Table 3.1). All patients had 
peripheral blood total white cells available for DNA extraction, and gave consent for 
entry into this study (Appendix I). One hundred and three healthy blood donors from 
the Newcastle upon Tyne region of the UK, who had had DNA extracted by phenol / 
chloroform extraction from peripheral blood total white cells, were used as controls. 
All donors had given their informed consent for their DNA to be used for the 
determination of allele frequencies as part of a control population. 
+-+-
Table 3.1 Characteristics of 122 imatinib treated CML patients in Newcastle 
upon Tyne. 
Characteristic 
Age at start of imatinib therapy (years): 
Median 
Ran e 
Disease phase at start of imatinib therapy: 
Chronic phase (early chronic phase) 
Accelerated phase 
Blast crisis 
Time from diagnosis to start of imatinib therapy (months): 
Median 
Ran e 
Number of atients havin treatment for CML, before starting imatinib: 
Length of patient follow up (months): 
Median 
Range 
3.4.2 DNA extraction 
Value 
52 
21 - 77 
97 (23) 
12 
13 
28.7 
0- 1083.2 
10 
23.6 
6.1-37.9 
Total genomic DNA was extracted from the cells by SDS lysis, proteinase K 
digestion, phenol/chloroform extraction and ethanol precipitation. 
3.4.3 PCR and single strand conformational polymorphism 
(SSCP) analysis of the rs2290573 polymorphism 
Novartis provided the sequence of the rs2290573 polymorphism, and primers were 
designed (Table 3.2) using the genomic sequence obtained from the NCBI website 
and mac vector™ software. Template DNA was amplified by PCR; the components 
for each individual PCR reaction were as follows: 10~1 of lOx KCI buffer, 16~1 of 
dNTP's, 5~1 20~M forward primer, 5~1 20~lM reverse primer, 0.5~1 AmpliTaq® 
(Applied Biosystems. Warrington. UK). 63.5~1 water and 1 ~l template DNA. The 
PCR temperature protocol was as follows: denature at 94°C for 30 seconds, 30 cycles 
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of 60°C for 1 minute then 72°C for 1 minute, extend at 72°C for 10 minutes to 
terminate the reaction. PCR products underwent electrophoresis on a 1.5% agaro e 
gel , in the presence of ethidium bromide, to check both their size and specifici ty. 
SSCP analysis of the PCR product was performed on 10% polyacrylamide gels 
(ProtoFLOWgel; Flowgen, Ashby de la Zouch, UK) at 20°C. Silver staining revealed 
single stranded conformers (Figure 3.1). Three examples of each homozygote were 
sequenced to determine which was homozygote for the C allele and which for the T 
allele, and also to confirm the accuracy of the SSCP analysis. (Assistance in 
establishing the SSCP assay for the rs2290573 polymorphism was given by Miss Julie 
Gardner.) 
Figure 3.1 Silver stained polyacrylamide gel demonstrating SSCP analysis of the 
rs2290S73 polymorphism. 
mozygote Heterozygote 
Table 3.2 Primers used for peR of the rs2290S73 polymorphism. 
Primer Direction Primer Sequence 
Forward 5' -CCTCCCTT ACCAAAGACCTGAGAC-3' 
Reverse 5' -GCACTGTCCA TCCAAGAAGCC-3" 
3.4.4 peR and TaqJ restriction enzyme digestion analysis of the 
IL-lf:l +3953 polymorphism 
Work previously done in our laboratory by Cullup et al. I23•144 examined the allele 
frequency of the ILIB-3953 and ILIB-511 in 229 normal blood donors, in the North 
East of England. We chose to examine the IL-l ~ +3953 polymorphism in our 
patients, since the requirements for the IL-l ~ -511 polymorphism assay were 
unavailable at the time, and the IL-l ~ +3953 polymorphism had been shown to be in 
linkage disequilibrium with IL-l ~ _511 117.123 • To investigate the allele frequency and 
genotype of the IL1B-3953 gene polymorphism in 84 patients with CML, we used 
primers as described by Santtila et ai. 117• Template DNA was amplified by PCR. The 
components for each individual PCR reaction were as follows: 1011-1 of lOx KCl 
buffer, 1611-1 of dNTP's, 511-1 20l-lM forward primer, 511-1 20l1-M reverse primer, 0.511-1 
AmpliTaq® (Applied Biosystems). 63.511-1 water and 111-1 template DNA. TaqJ 
digestion of the 249 bp PCR product resulted in fragments that either remained intact 
(allele 2) or were cut into 2 fragments of 135 bp and 114 bp (allele 1). PCR and 
restriction enzyme digestion conditions were as described previousll~. Digestion 
products were analyzed on a 2% agarose gel, stained with ethidium bromide. 
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3.4.5 Statistical analysis 
Statistical analysis was performed using SPSS version 12 software. The Hardy-
Weinberg equation was used to calculate expected allele frequencies. 
3.5 Results 
In order to verify the integrity of our clinical dataset, we examined our patient 
population for achievement of a MCR over time from starting imatinib, after 
stratifying for those patients in chronic phase and those with advanced disease (Figure 
3.2). We were able to detect expected differences in our patient population over time, 
i.e. that chronic phase patients were more likely to achieve a MCR (Log rank 
p=O.0002), than those with more advanced disease40-42. 
- 48 -
Figure 3.2 Achievement of a MeR with time on imatinib, in 123 patients 
stratified for disease phase at time of starting imatinib. 
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MCR = major cytogenetic response, AP = accelerated phase, BC = blast crisis, CP = 
chronic phase 
The allele frequencies of the rs2290573 polymorphism were examined in 103 healthy 
blood donors and results are shown in Table 3.3. We noted that the observed and 
expected genotype frequencies were very close, consistent with the alleles being 
inherited in a co-dominant manner. The aJIele frequencies of the rs2290573 and IL-
I ~ +3953 polymorphisms in patients with CML were found to be very similar to the 
allele frequencies seen in healthy blood donors from the North East of England J23 
(Table 3.4 and Table 3.5), suggesting that the patients had been drawn from the same 
ethnic population. No selection bias was evident in recruiting patients for the study, 
nor any effect of genotype on the incidence of CML or entry into the study. 
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Table 3.3 Observed and expected genotype frequencies for the rs2290573 
polymorphism in 103 blood donors. 
Observed genotype frequency Expected genotype frequency 
C homozygotes 17 / 103 (16.5%) 17.5/ 103 (17.0%) 
CT heterozygotes 52/ 103 (50.5%) 50.5/ 103 (49.0)% 
T homozygotes 34/ 103 (33.0%) 35.0/ 103 (34%) 
Table 3.4 Allele frequencies for the rs2290573 polymorphism in 103 blood 
donors and 74 patients with CML. 
Blood donors CML patients 
C allele frequency 86/206 (41.7%) 68/ 148 (45.9%) 
T allele frequency 120/206 (58.3%) 80/ 148 (54.1 %) 
Table 3.5 Allele frequencies for the IL-IP +3953 polymorphism in 229 blood 
donors and 84 patients with CML. 
Blood donors CML patients 
Allele 1 frequency 344 / 458 (75.0%)123 129/ 164 (78.6%) 
Allele 2 frequency 114/458 (25.0%)123 35/ 164 (21.4%) 
In order to assess whether possession of particular alleles of the rs2290573 or IL-l ~ 
+3953 polymorphism were associated with the incidence of MCR in our patients, we 
used Kaplan-Meier analysis, plotting MCR response as a time dependent variable, 
stratified by genotype, as shown in Figures 3.3 to 3.6. We found that no significant 
difference in response could be detected when comparing patients with different 
alleles, even when the analysis was restricted to patients in chronic phase (not shown). 
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Figure 3.3 Achievement of a MCR with time on imatinib, with 74 patients 
stratified for possession of the rs2290573 polymorphism allele C. 
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Figure 3.4 Achievement of a MCR with time on imatinib, with 74 patients 
stratified for possession of the rs2290573 polymorphism allele T. 
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Log Rank p = 0.64 
Figure 3.5 Achievement of a MeR with time on imatinib, with 84 patients 
stratified for possession of the IL-lfJ +3953 polymorphism allele 1. 
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Figure 3.6 Achievement of a MeR with time on imatinib, with 84 patients 
stratified for possession of the IL-lfJ +3953 polymorphism allele 2. 
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Log rank p = 0.96 
Dressman et al. l 14 found an association between the "CC" genotype of the r 2290573 
polymorphism and a reduced rate of MCR; however, we could not confirm the 
association between genotype and rate of MCR in our patient population (Figure 3.7). 
Figure 3.7 Achievement of a MCR with time on imatinib, with 74 patients 
stratified for possession of the "CC" genotype of the rs2290573 polymorphism. 
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We et out to test the findings of Dressman et al. 1l4 by examining a population of 
imatinib treated CML patients in Newcastle upon Tyne. We genotyped our patients 
for the presence of the rs2290573 and IL-l~ +3953 gene polymorphisms, and found 
them to have allele frequencies for these polymorphisms that were highly similar to 
that of healthy I cal blood donors. However, we were unable to confirm the 
c rrelation between p e i n of a particular genotype and rate of MCR that had 
b n fund by Dr man et al. 114 • 
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Aside from a simple non-verification of Dressman's work, although it has been found 
that most gene association studies fail to be verified in subsequent studies 145, there are 
a number of features of our study which differ from that of Dressman, and might 
contribute to a different result. Firstly, our patient populations are different. 
Dressman et a1 114• studied chronic phase CML patients who received imatinib as first 
line therapy, whilst the majority of our patients were at a more advanced stage of their 
illness with most patients being in late chronic phase. It may well be that we were not 
able to detect an association between the polymorphisms and MCR because the 
polymorphisms are associated with effects that are only seen in the early stages of 
CML. However, when we examined only chronic phase patients, we still could not 
detect an association with rate of MCR. Secondly, the majority of our patients had 
received treatment for their CML prior to receiving imatinib and it may be that the 
association between the polymorphisms and MCR only holds true when imatinib is 
the first line therapy - indeed, Dressman et al. failed to detect the association when 
looking at 20 patients who had received imatinib after failing interferon 1l4• 
Thirdly, Dressman et al. 114 found that after dividing the patients by racial group, the 
correlation of the "CC" genotype of the rs2290573 polymorphism with reduced rate 
of MCR was only upheld in Caucasian patients. Indeed, even though the frequency of 
the "CC" genotype in our patients (25.7%) was similar to the frequency seen in all 
Dressman et al. 's patients (23%), it was significantly higher (chi-square test, p = 
0.047) than that seen in their Caucasian population (13.0%). The majority of our 
population of patients with CML were Caucasian, but our CML population was 
derived from a different ethnic background than Dressman et al.·s population. It is 
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thus possible that this difference in ethnicity of the populations made us unable to 
detect the effects that Dressman et al. found. 
Fourthly, we did not examine our patients for the IL-l f3 -511 polymorphism, but 
examined them for the IL-l f3 +3953 polymorphism that is in linkage disequili brium 
with IL-l f3 _511 117•123• In addition, the IL-I f3 -511 polymorphism was associated with 
rate of MCR, but not after a further 6 months of patient follow up, and so any weak 
correlation with genotype and rate of MCR may have been lost with our indirect 
method of analysis. 
We have failed to confirm Dressman et al. 's findingsl14, which may be due to the 
differences in our studies, or it may be that their findings were due to type I errors, 
despite statistical correction for multiple comparisons. We therefore believe that to 
truly test Dressman et al. 's findingsl14, we would need to examine CML patients of 
identical ethnic and racial background who have received imatinib as first line 
therapy, and to directly assess the IL-l f3 -511 genotype. 
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4 A single nucleotide polymorphism in ABL and 
imatinib sensitivity 
4.1 Introduction 
Acquired resistance to imatinib is frequently associated with kinase domain mutations 
(KM) that interfere with drug binding60·61.63.64.73. KM cluster in certain regions of the 
BCR-ABL kinase and confer varying levels of drug resistance72 . Additionally, it has 
been observed that mutations within the A TP binding loop (P-Ioop) are associated 
with a poor prognosis compared to other mutation types, irrespective of their degree 
of imatinib resistance67. Whilst analyzing patients for KM, who were being treated at 
the Department of Haematology of the University of Leipzig for CML, we identified 
a single nucleotide polymorphism (SNP) at codon position 247 (numbering according 
to ABL type la l46) within the P-loop domain of BCR-ABL, leading to the substitution 
of arginine for lysine (K247R). Since 3 out of 4 patients with this P-Ioop 
polymorphism had an inadequate response to imatinib, we hypothesized that the 
arginine allele may modulate imatinib sensitivity, or to one of the novel BCR-ABL 
tyrosine kinase inhibitors, AMNI07 and BMS-354825. 
4.2 Aims 
l. To determine the incidence of the arginine allele, of the K247R 
polymorphism, within a population of patients with CML being treated at the 
Department of Hematology of the University of Leipzig, Germany. 
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2. To determine the incidence of the arginine allele, of the K247R 
polymorphism, within a healthy population of blood donors from the North 
East of England. 
3. To use in vitro biochemical and cellular assays to examine the drug sensitivity 
of BCR-ABL expressing the arginine allele of K247R. 
4.3 
• 
Key Points 
The arginine allele of K247R was found to be rare in both patients with CML 
being treated in Leipzig, and in healthy blood donors from the North East of 
England. 
• In vitro biochemical and cellular assays showed that BCR-ABL expressing the 
arginine allele of the K247R polymorphism had an imatinib, AMNI07 and 
BMS-354825 sensitivity that was very similar to that seen with wild type 
BCR-ABL. 
• When screening patients with CML for the development of KM, clinicians 
should not mistake the presence of the arginine allele, of the K247R 
polymorphism, for a functional KM. 
• Continued collection of clinical data would be required on patients with CML 
who express the arginine allele of K247R in BCR-ABL, to confirm that our in 
vitro findings are true in vit'o. 
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4.4 Methods 
4.4.1 Patients 
Whilst screening patients with CML for KM, we identified 4 patients treated at the 
Department of Haematology of the University of Leipzig, Germany, who possessed 
the arginine allele of the K247R SNP, within BCR-ABL. Clinical features of these 
patients are shown in Table 4.1. Presence of the arginine allele, found in samples 
taken both before and after commencement of imatinib treatment, was confirmed by 
repeated nested PCR and automated sequencing, using BCR-ABL and ABL specific 
primers (Table 4.2). 
Table 4.1 The clinical characteristics of all the patients with BCR-ABL 
expressing the arginine allele of the K247R polymorphism. 
Patient CUR Best Cytogenetic Time to Best Length of ID Response Cytogenetic Response Follow Up 
EL Yes 100% Ph+ 6 months 6 months 
KE Yes 4%Ph+ 6 months 12 months 
PN Yes 36% Ph+ 21 months 24 months* 
CR Yes 96% Ph+ 15 months 15 months 
CHR = complete haematoiogicai response 
* = 88% Ph+ at 24 months 
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Table 4.2 Table of primers used in the nested PCR, sequencing and single strand 
conformational polymorphism (SSCP) analysis. 
Primers BCR-ABL ABL 
151 round 
nested 5' -TICAGAAGCITCTCCCTGACAT -3' 5' -GCITGCCTGCCCTGCA-3' : 
PCR-
151 round 5' - 5'-
nested CCTTCTCTAGCAGCTCATACACCTG- CCITCTCTAGCAGCTCATACACCTG-
PCR- 3' 3' 
2nd round 
nested 5' -ACAGCA TICCGCTGACCA TC-3' 5' -GGCA TGGGGGTCCACACT -3' 
PCR-
2nd round 
nested 5'-GCCATAGGTAGCAATTTCCC-3' 5' -GCCAT AGGT AGCAA TTTCCC -3' 
PCR-
Sequencing 5' -TGGTTCATCA TCA TTCAACGG-3' 5' -TGGTTCA TCATCA TTCAACGG-3' 
SSCP- 5' - TGGTTCATCATCA TTCAACGG-3' -forward 
SSCP- 5' -AGGCTGT A TTICITCCACACG-3' -
reverse 
4.4.2 Sequence analysis of BCR-ABL and ABL in CML patients 
In order to determine the frequency of the arginine allele within the Leipzig based 
CML population, all CML patients from the Department of Haematology of the 
University of Leipzig with available cDNA (n = 167) underwent screening. RNA was 
extracted from bone marrow total white cells and reverse transcribed into cDNA as 
described31 • All patients gave their consent for entry into this study (Appendix 2). 
BCR-ABL and ABL were specifically amplified by nested PCR, followed by 
automated sequencing. The presence of the arginine allele was confirmed by repeat 
sequencing. and by A/u/ (New England BioLabs, Beverly, MA) digestion of the 
nested PCR product, as the nucleotide exchange (AAG to AGG) eliminated the Ailil 
restriction site. 
4.4.3 Screening for the arginine allele of K247R in healthy blood 
donors 
In order to examine the allele frequency of K247R in Western Europeans, Dr. Peter 
Middleton screened 213 blood donors from the Newcastle upon Tyne region of the 
UK, who had given informed consent for their DNA to be used for the determination 
of allele frequencies as part of a control population. Genomic DNA was extracted by 
phenol, chloroform and ethanol precipitation from the buffy coat of a 4.5ml EDT A 
blood sample from each individual. Screening for the arginine allele of K247R was 
performed by single strand conformational polymorphism (SSCP) analysisl47. Primer 
sequences (Table 4.2) flanking the K247R site were predicted for the genomic DNA 
sequence using Macvector Version 7.2 analytical software and allowed amplification 
of a 205 bp region spanning the K247R polymorphism; annealing temperature 57°C, 
final primer concentration 0.2~M. The polymorphism was demonstrated by SSCP 
analysis on 12% polyacrylamide gels (ProtoFLOWgel; Flowgen, Ashby de la Zouch, 
UK) at room temperature. Silver staining revealed single stranded conformers 
(Figure 4.1). Presence of the arginine allele was confirmed by AluI digestion of the 
PCR product. 
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Figure 4.1 Silver stained polyacrylamide gel demonstrating the single stranded 
conformers seen with the WT ABL allele and with the K247R arginine allele. 
WTABL 
K247R arginine allele 
WI ABL = ABL expressing the lysine alJele of the K247R polymorphism, K247R 
arginine allele = ABL expressing the arginine allele of the K247R polymorphism 
4.4.4 Statistical analysis of the allele frequency 
The frequency of the arginine allele in Leipzig CML patient, and in normal blo d 
d n r ,wa c mpared by the chi - quare te t u ing Yate ' correction. 
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4.4.5 Mutagenesis of the AatII/KpnI ABL kinase 
To introduce the K247R arginine allele single base change into full-length p210BCR-
ABL, we performed PCR-based site-directed mutagenesis of the AatlllKpnI wild type 
(WT) ABL kinase fragment subcloned into pGEM7 148 (Promega, Madison, WI) which 
had been made previously71. Thus, a forward primer was designed that contained the 
A to G base change and spanned the kinase at position 247, while the reverse primer 
was 9 bases 3' of the SNP (Table 4.3). The PCR reaction was set up with 100ng of 
plasmid, 50pmol of each primer, 0.2mM dNTP's, 1.5mM MgCI 2, 5% DMSO, 2.5U 
PfuTurbo® DNA Polymerase (Stratagene, La Jolla, CA), 1 x Cloned Pfu DNA 
Polymerase reaction buffer (Stratagene) and made up to 100111 with water. The 
temperature protocol was as follows: denature at 95°C for 2 minutes~ 30 cycles of 
95°C for I minute, 55°C for I minute, 72°C for 5 minutes~ extend at 72°C for 7 
minutes. The PCR products underwent electrophoresis on a 1_2% agarose gel at 
IIOV, and the DNA species in the size range 3000 - 4000 base pairs was excised. 
The PCR product was purified using the High Pure PCR Product Purification Kit 
(Roche, Indianapolis, IN) and T4 phosphorylation was done with T4 polynucleotide 
kinase (Fermentas. Hanover, MD). DH5a cells (Invitrogen, Carlsbad, CA) were 
transformed with the phosphorylated DNA, after ligation with T4 DNA ligase 
(Roche), and then plated overnight on imMedia™ Amp Agar (Invitrogen, Carlsbad, 
CA). Colonies were selected and the DNA extracted using the QIAprep Spin 
Miniprep Kit (Qiagen, Valencia, CA). The DNA was sent for conventional 
sequencing to confirm correct insertion of the desired base change. 
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Table 4.3 Primers required for PeR-based site directed mutagenesis of the 
AatII/KpnI ABL kinase fragment. 
Direction Primer 
Forward 5' -ATGAAGCACAGGCTGGGCGGG-3' 
Reverse 5' -GGTGATGTCCGTGCGTTCCATC-3' 
G = base change from adenine to guanine 
4.4.6 Mutagenesis of full-length p210BCR-ABL and generation of 
vectors 
Following AatIIIKpnI digestion of the K247R kinase fragment in pGEM7, the K247R 
ABL kinase fragment was subcloned into full-length p210BCR-ABL in pGEM5 14S 
(Stratagene) (pGEM5_p210BCR-ABL) as described above. Following EcoRI (New 
England BioLabs) digestion of pG EM5-p21 OBCR-AB\ the full-length p21 OBCR-ABL 
fragment containing the K247R base change (p21 OBCR-ABL-K247R) was then subcloned 
into the EcoRI site of the mammalian expression vector pSRa. The mammalian 
expression vector pSRa containing p21 OBCR-ABL and p210BCR-ABL-TII51 were generated in 
an identical fashion, as previously described71 . 
4.4.7 Infection of m urine haem opoietic cells 
Bosc23 cells 149 were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS). 1 unitlml penicillin. 1 f-l,g/ml streptomycin and 4rnM L-glutamine. For the 
d . f II . 210BCR-ABL-K247R 8 23 II . I pro lletlOn 0 ee s expressmg p . ose ee s were transIent y 
- 63 -
transfected with pSRa containing p210BCR-ABL-K247R, and the viral supernatant was 
harvested 48 hours later. Immunoblotting of Bosc23 cell lysates confirmed 
expression of BCR-ABL. 
BalF3 cells were incubated with the filtered Bosc23 viral supernatant containing 
8~g/ml polybrene and 15% WEHI conditioned media as a source of IL-3. Stable 
transfectants were selected by maintaining cells in RPMI 1640 supplemented with 
10% FBS, lunitlml penicillin, l~g/ml streptomycin, 4mM L-glutamine, 15% WEHI 
and 0.75mg/ml G418 sterile solution (Stratagene). Cells with stable BCR-ABL 
expression were further selected by removal of WEHI. Ba/F3 cells expressing 
p210BCR-ABL and p210BCR-ABL-T315I had been generated previously, in an identical 
fashion7I ; cryopreserved samples of these cells were thawed and maintained in RPMI 
1640 supplemented with 10% FBS, 1 unitlml penicillin, 1 ~g/ml streptomycin, 4mM L-
glutamine. Equivalent BCR-ABL expression of the cell lines was confirmed by 
immunoblot analysis (Figure 4.2). 
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Figure 4.2 Immunoblot demonstrating tyrosine phosphorylated BCR-ABL and 
expression of BCR-ABL in the BaJF3 cell lines expressing p210BCR-ABL, 
p210BCR-ABL-K247R and p210BCR-ABL-T31SI. 
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p-Tyr Immunoblot 
ABL Immunoblot 
P-Tyr Immunoblot = tyrosine phosphorylated BCR-ABL detected by mouse 
monoclonal phosphotyrosine antibody, ABL Immunoblot = BCR-ABL expression 
detected by rabbit monoclonal ABL antibody, Ba/F3 cells + WT = Ba/F3 cells 
expressing p210BCR-ABL, Ba/F3 cells + K247R = Ba/F3 cells expressing p210BCR-ABL-
K247R, Ba/F3 cells + T3151 = Ba/F3 cells expressing p21 OBCR-ABL-TIISI 
4.4.8 Cell proliferation assays 
Exponentially growing parental Ba/F3 cells (supplemented with IL-3) and Ba/F3 cells 
expressing p210BCR-ABL, p210BCR-ABL-K247R and p210BCR-ABL-TIISI were plated in 
quadruplicate at 5000 cell /well in 96-well plates. Cells were incubated in the 
pre ence ofimatinib (0 - l~M), AMN-I07 (0 - l~M) (kindly provided by Novarti 
Pharmaceutical ) and BMS-354825 (0 - 32nM) (kindly provided by Bri tol-Myer 
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Squibb). Cell proliferation was measured with a methanethiosulfonate (MTS) based 
viability assay (CellTiter 96 Aqueous One Solution Reagent; Promega, Madison. WI). 
as previously described7l ; results from day 3 were used to construct the best-fit 
curves, and calculate the cellular IC50 in Microsoft Excel. 
4.4.9 Immunoblotting 
Ba/F3 cell lines (1 x 106 cells) were incubated for 3 hours in 1.25ml media containing 
escalating doses of imatinib (0 - 6.4~M). Cells were collected by centrifugation and 
lysed in SDS sample buffer. Lysates were resolved by SDS-PAGE and transferred to 
Immobilon-P membranes (Millipore Corp., Bedford, MA) for immunoblotting. 
Tyrosine phosphorylated BCR-ABL was detected with mouse monoclonal 
phosphotyrosine antibody 4G 10; BCR-ABL expression was detected using the rabbit 
polyclonal ABL antibody CST 2862 (Cell Signaling Technology, Beverly, MA). 
4.4.10 Generation of GST -ABL fusion proteins 
The ABL kinase domain (KD), consisting of ABL amino acids 220-498, was 
subcloned into the BamHI site of pGEX KG (Amersham Biosciences, 
Buckinghamshire, UK) as described previously65. Single base changes within the KD, 
i.e. K247R and the mutation T315I, were constructed using the GeneTailor ™ Site 
Directed Mutagenesis System (Invitrogen, Carlsbad, CA). We generated glutathione 
S-transferase (GST) fusion proteins of WT, K247R and T3151 by inducing 
exponentially growing transformed DH5a ™ -T 1 R E. Coli with 0.5mM isopropyl-l-
thio-~-D. The cells were lysed via French pressing and sonication, after addition of 
phosphate buffered saline (PBS) containing 0.8mM 4-(2-aminoethyl)-benzenesulfonyl 
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fluoride hydrochloride, 0.8mM phenylmethylsulfonyl fluoride, aprotinin 16~g/ml, 
0.4% Triton X-IOO and 1 complete protease inhibitor cocktail tablet (Roche). 
Binding to glutathione-sepharose overnight at 4°C, purified the GST -ABL fusion 
proteins. Bound proteins were washed thrice with PBS, once with O.SM LiCI and 
once again with PBS. Proteins were then eluted in 1.S ml of elution buffer containing 
SOmM Tris, pH 8.0, lS0mM NaCI and 30mM glutathione, and then diluted I: I with 
80% glycerol. A Bradford assay was used to determine the concentration of each 
protein. 
4.4.11 Kinase autophosphorylation assays 
Dr. Thomas O'Hare carried out kinase autophosphorylation assays in the presence of 
imatinib (O-S~M) as described previousl/ 50. In brief, SOOng of fusion protein in 30~1 
of kinase buffer (20mM Tris, pH 7.S, 10mM MgCI2, 10~M sodium vanadate, I~M 
dithiothreitol, 1 % dimethyl sulfoxide (Me2SO)), was incubated in the presence of 
imatinib for 10 minutes, after which S~M [y_32PI ATP was added and the kinase 
reaction allowed to proceed for 30 minutes. The reactions were terminated by 
addition of SDS loading dye and boiling; the samples were analysed by SDS-PAGE. 
ABL autophosphorylation signal intensity was quantified with a PhosphorImager 
(Molecular Dynamics). ABL immunoblots to demonstrate equal protein loading were 
performed with a-Abl Ab-2 (Oncogene Science, Cambridge, MA). 
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4.4.12 In vitro peptide substrate phosphorylation assays with 
GST-ABL kinase domains 
The effects of imatinib (0 - 5IlM), AMN-I07 (0 - 51lM) and BMS-354825 (0 - 32nM) 
on GST -ABL kinase activity were examined using a synthetic peptide substrate 
(biotin-EAIY AAPFAKKK-amide~ Upstate Biotechnology, Charlottesville, VA), as 
described previousl/ so. Immediately prior to the phosphorylation assay, all fusion 
proteins were dephosphorylated by incubation for 1 hour, at 30°C, in the presence of 
LAR phosphatase (New England BioLabs)~ the reaction was terminated by the 
addition of 2mM sodium vanadate. Dr. Thomas O'Hare performed peptide substrate 
phosphorylation assays at 30°C for 15 minutes in a 25111 reaction mixture: 8mM 3-(N-
morpholino) propanesulfonic acid (MOPS), pH 7, 0.2mM ethylenediaminetetraacetic 
acid (EDTA), 50llM Abletide, 30mM MgCI2, 10mM ~-glycerol phosphate, I mM 
ethylene glycol tetraacetic acid (EGT A), 0.002% Brij-35, O.4mM dithiothreitol 
(OTT), 0.2mg/ml BSA, O.4mM sodium orthovanadate, 10nM WT, K247R or T315I 
GST -ABL kinase, and 100llM ly_32PI ATP (5000cpm/pmol). Reactions were 
terminated by placing a fraction of the reaction mixture onto a p81 phosphocellulose 
filter and immersing in 0.75% phosphoric acid. Filters were washed 3 times in 0.75% 
phosphoric acid, rinsed in acetone and air dried. Phosphate incorporation was 
determined by scintillation counting, with correction for background binding, as 
determined by omitting peptide substrate from the kinase reaction. The WT and 
K247R GST -ABL fusion proteins underwent kinase assays in the presence of 
imatinib, AMN-I07 and BMS-354825; the T315I GST -ABL fusion protein was 
examined only in the presence of imatinib. 
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4.5 Results 
4.5.1 The arginine allele of the K247R polymorphism in patients 
with CML 
Since only cDNA was available from the CML patients, we sequenced both BCR-
ABL and ABL-specific PCR products. Amplification of ABL was successful in 167 
patients and in 157 of these BCR-ABL could also be amplified. The arginine allele 
was identified in BCR-ABL PCR products from 4 patients. ABL PCR products from 
these 4 patients were WT in 3 patients with 100% Ph+ metaphases, whilst 1 case 
exhibited both the WT and arginine alleles. As the latter patient was in partial 
cytogenetic remission at the time of the sample. this likely reflected amplification of 
paternal and maternal alleles from normal cells, while the template in the other 3 
patients was derived from leukemic cells and thus reflected the non-translocated WT 
ABL allele. The arginine allele (50%) was also found in the ABL PCR product of 
one additional patient. AluI digestion confirmed the sequencing results in all cases. 
Since there is no evidence of allele specific variation in ABL expression, such as 
imprinting l51 , the allelic frequency in the CML population is 51167 x 2 = 1.5%. 
Two hundred and thirteen Western European blood donors, recruited from the North 
East of England, were examined for the presence of the arginine allele in ABL by 
SSCP analysis. One out of213 individuals was found to be heterozygous for this 
allele (allele frequency 1/213 x 2 = 0.2%). The frequency of the arginine allele in 
ABL in controls was thus different from that of the CML patients, but not 
significantly (p = 0.12, chi-square test with Yates' correction). The frequency of the 
arginine allele within a healthy German population has recently been found to be 1 % 
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to 2%, which is equivalent to the frequency in the German CML population (personal 
comment from Dr. Jan Cornelissen). 
4.5.2 Cellular assays 
MTS assays were performed in order to assess the sensitivity of Ba/F3 cell lines 
expressing p210BCR-ABL, p210BCR-ABL-K247R and p210BCR-ABL-TI151 to imatinib, AMN-I07 
and BMS-354825. All 3 drugs showed a concentration-dependent, anti-proliferative 
effect on Ba/F3 cells expressing p210BCR-ABL, p210BCR-ABL-K247R and p210BCR-ABL-TI151 
(Figure 4.3, Table 4.4). The IC50 's for the p210BCR-ABL cell line, and the p210BCR-ABL-
K247R cell line, were similar. As expected, parental Ba/F3 cells and Sa/F3 cells 
expressing p210BCR-ABL-TI151 were insensitive to all 3 drugs, at all concentrations (Table 
4.4). 
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Figure 4.3 Graph showing the effect of increasing concentrations of imatinib on 
cell proliferation. 
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Parental Ba/F3 cells (Ba/F3), and Ba/F3 cells expressing p210BCR-ABL-WT (BCR-ABL), 
p210BCR-ABL--K247R (K247R) and p2IO BCR-ABL-TI151 (T315I) were cultured in the presence 
of increasing concentrations of imatinib (O-lflM). The number of viable cells was 
measured by MTS assay after 3 days, 
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Table 4.4 Results of the cellular aod biochemical assays of drug sensitivit~,. 
parental Ba/F3 
WT 
K247R 
T3151 
parental Ba/F3 
WT 
K247R 
T3151 
parental Ba/F3 
WT 
K247R 
T3151 
Imatioib ICso (nM) 
Ba!F3 cellular assays Purified GST-ABL kinase assaJs 
Cellular BCR-ABL tyrosine Peptide 
proliferation Phosphorylation Autophosphorylation substrate 
>1000 NA NA NA 
215 440 300 90 
275 360 450 90 
>1000 >6400 >5000 >5000 
AMNI07 ICso (oM) 
Ba!F3 cellular assays Purified GST -ABL kinase assays 
Cellular BCR-ABL tyrosine Peptide 
proliferation phosphorylation Autophosphorylation substrate 
>1000 NO NO NA 
30 NO NO 25 
35 NO NO 50 
>1000 NO NO NO 
BMS-354825 ICso (oM) 
Ba!F3 cellular assays Purified GST-ABL kinase assays 
Cellular BCR-ABL tyrosine Peptide 
proliferation phosphorylation Autophosphorylation substrate 
>32 NO NO NA 
1.9 NO NO 3.2 
2 NO NO 2.1 
>32 NO NO NO 
NO = not done, NA = not applicable, WT = Ba/F3 cells expressing p210BCR-ABL in the 
cellular assays and WT GST -ABL fusion protein in the kinase assays, K247R = 
Ba/F3 cells expressing p21 OBCR-ABL-K247R in the cellular assays and K247R GST -ABL 
fusion protein in the kinase assays, T3151 = Ba/F3 cells expressing p210BCR-ABL-T3151 in 
the cellular assays and T3151 GST -ABL fusion protein in the kinase assays. Most 
assays were performed more than once, with cell lines being plated in quadruplicate 
for the cellular proliferation assays and then measured in duplicate, BCR-ABL 
tyrosine phosphorylation and GST -ABL kinase activity were observed in triplicate, 
while kinase autophosphorylation assays were performed only once. 
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BCR-ABL tyrosine phosphorylation assays on Sa/F3 cells expressing p21 OBCR-ABL, 
210BCR-ABL-K247R d 210 BCR-ABL-TIl5I rf d . - " p an p , were pe orme In the presence of Imattnlb. 
Imatinib inhibited tyrosine phosphorylation, in a concentration-dependent manner, in 
BalF3 cells expressing p210BCR-ABL and p210BCR-ABL-K247R; the ICso's were similar for 
these 2 cell lines (Table 4.4). Since the tyrosine phosphorylation ICso's for p210BCR-
ABL d 210BCR-ABL-K247R' th f - .. b . '1 . an pIne presence 0 Imatllll were so Simi ar, we did not repeat 
these experiments in the presence of AMN-l 07 or BMS-354825. 
4.5.3 Biochemical assays 
To determine the ability of imatinib, AMN-I 07 and BMS-354825 to directly inhibit 
kinase activity of purified ABL-kinase in a cell-free system, we carried out 
biochemical experiments with the use of GST -ABL kinase fusion proteins. All 3 
drugs inhibited WT and K247R GST-ABL kinases in a dose-dependent manner, with 
these kinases showing similar ICso's with each drug (Table 4.4). T3151 GST -ASL 
kinase was used as a positive control and was only examined in the presence of 
imatinib. As we expected, T315I GST -ABL fusion protein showed no reduction in 
kinase activity even at the highest imatinib concentrations (Table 4.4). In addition, 
we found that imatinib inhibited autophosphorylation of WT and K247R GST -ABL 
kinases in a dose-dependent fashion, but was unable to inhibit T315I 
autophosphorylation (Figure 4.4, Table 4.4). Due to the similarity of the 
autophosphorylation results of the WT and K247R GST -ABL kinases in the presence 
of imatinib, these experiments were not repeated in the presence of AMN-I07 or 
BMS-354825. 
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Figure 4.4 Figure illustrating the effect of increasing concentrations of imatinib 
on GST -ABL kinase auto phosphorylation. 
WT 
T3151 
a 10 25 50 1 00 250 500 1 000 5000 
[imatinib] nM 
Kinase autophosphorylation assays were performed on WT, K247R and T3151 GST-
Abl kinase proteins, in the presence of increasing concentrations of imatinib (O-5~M). 
4.6 Discussion 
We have identified a rare single nucleotide polymorphism (K247R) within the P-Ioop 
domain of ABL. It would appear that the incidence of the arginine allele in patients 
with CML being treated in Leipzig, is similar to that of the healthy German 
population, and close to that seen in blood donors from the North East of England. 
While this work was in progress, Irving et al. reported one healthy control 
heterozygous for the arginine allele and suspected that K247R may be a rare 
polymorphism, in accordance with our data '52. 
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I 
While all 4 patients with the arginine allele expressed within BCR-ABL achieved a 
complete hematological response, 3 failed to achieve a major cytogenetic response to 
imatinib (median follow up 13,5 months, range 6 to 24 months), Since K247R is 
localized with the P-loop of BCR-ABL, a mutational hotspot in patients with acquired 
resistance to imatinib, we hypothesized that the arginine allele may reduce the 
sensitivity to imatinib and possibly other ABL inhibitors, However, no significant 
d'ff b t 210BCR-ABL d 210BCR-ABL-K247R d ' I'f ' I erences e ween p an p were note In pro I eratlOn 
assays, while BaF/3 cells expressing p21 OBCR-ABL-T3151 were resistant. Consistent with 
this, ICso values of imatinib for p21 OBCR-ABL and p210BCR-ABL-K247R were similar with 
respect to inhibition of BCR-ABL tyrosine phosphorylation in cellular Iysates, 
Comparable results were seen with in vitro kinase assays using GST -ABL KD, with 
autophosphorylation or substrate phosphorylation as the endpoint. Proliferation 
assays carried out in the presence of AMN-I07 and BMS-354825 also showed no 
difference in sensitivity between p210BCR-ABL and p210BCR-ABL-K247R, 
The similar imatinib sensitivity of the lysine and arginine alleles of the K247R 
polymorphism is not entirely unexpected since the exchange of arginine for lysine is 
conservative, In contrast, the mutation L248R1V, in immediate proximity to K247R, 
confers a high level of resistance153, These data suggest that the failure of 3 out of 4 
patients, with the arginine allele of the K247R polymorphism expressed in BCR-
ABL, to achieve a MCR may be a chance finding in a small cohort, It remains 
formally possible, though unlikely, that the arginine allele may modulate disease 
biology, perhaps over months to years, irrespective of imatinib sensitivity in in vitro 
assays, To ascertain this, it would be necessary to collect clinical data on more C~ lL 
patients in possession of the arginine allele of K247R expressed in BCR-ABL. 
The importance of our data at the present time is that when screening for the 
development of KM in CML patients on imatinib, patients in possession of the 
arginine allele of K247R expressed in BCR-ABL should not be confused with 
patients who have P-Ioop mutations. The development of a P-loop mutation is a 
cause for concern because these mutations cause imatinib resistance71 , are associated 
with a very poor prognosis,67 and hence a change in therapeutic strategy for these 
patients is often considered. The arginine allele of K247R does not affect sensitivity 
to imatinib in vitro, and without other evidence of inadequate response to imatinib, or 
emergence of imatinib resistance, should not be seen as a trigger to change patients' 
management. 
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5 Mechanisms of primary cytogenetic resistance to 
imatinib 
5.1 Introduction 
Acquired resistance to imatinib is most frequently due to the development of either a 
point mutation within the BCR-ABL kinase domain59-61.63.67, or over expression of the 
BCR-ABL protein60•61 • Less is known about the mechanisms behind cytogenetic 
refractoriness (i.e. primary cytogenetic resistance) to imatinib; we therefore decided to 
investigate a population of patients with CML, treated at Oregon Health and Science 
University (OHSU), for the role that kinase mutations (KM), and the expression of 
genes associated with drug transport, might play in primary cytogenetic resistance to 
imatinib. 
5.2 Aims 
1. To examine the prevalence of BCR-ABL kinase domain mutations, in patients 
with CML who have primary cytogenetic resistance to imatinib. 
2. To examine the expression level of a set of genes associated with drug 
transport, in patients with CML who have primary cytogenetic resistance to 
imatinib. 
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5.3 
• 
Key Points 
BCR-ABL kinase domain mutations are less frequent among patients with 
primary cytogenetic resistance to imatinib, than those patients with acquired 
cytogenetic resistance. 
• Prior to starting imatinib, significantly lower expression of hOCT 1 and 
significantly higher expression of ABCC3 are seen in patients who go on to 
show primary cytogenetic resistance to imatinib, than in patients who go on to 
have a complete cytogenetic response to imatinib. 
• It would appear that a variety of drug transport mechanisms might underlie 
primary cytogenetic resistance in our population of patients with CML. 
• Further work is required to investigate whether hOCTl allele status influences 
CML patients' responses to imatinib. 
• Further work is required to ascertain whether imatinib is a substrate for 
ABCC3. 
5.4 Methods 
5.4.1 Patients 
At OHSU we identified 28 patients with CML who had attained a complete 
haematological response (CHR) to imatinib, but who had failed to achieve even a 
minor cytogenetic response, i.e. had remained at least 65% Philadelphia chromosome 
(Ph) positive as assayed by cytogenetic analysis of at least 10 metaphases. These 
patients with primary cytogenetic resistance to imatinib were categorised as non-
responders (NR). All of these patients had had treatment for their CML, prior to 
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imatinib. All 28 NR had a cryopreserved sample of bone marrow (BM) mononuclear 
cells (MNC's) taken at between 9 and 15 months from starting imatinib therapy. 
Fifteen of the NR also had a sample of BM MNC's available that had been stored 
immediately prior to imatinib commencement. 
We also identified 15 patients with CML, based at OHSU, who had attained a CHR 
and who had also achieved a complete cytogenetic response (CCR) to imatinib within 
the first year of treatment. These patients were defined as responders (R) and they all 
had had BM MNC's stored immediately prior to starting imatinib treatment. The 15 
R, and the 15 NR with pre and post imatinib samples, were of similar age, disease 
phase at time of starting imatinib and male to female ratio (Table 5.1), however, the 
15 R had a significantly shorter time from diagnosis to starting imatinib (median 20 
months, range 5.3 to 55.5 months) than the 15 NR (median 41.7 months, range 6.8 to 
10l.8 months) (p = 0.04) (Table 5.1). These 15 Rand 15 NR patients were used for 
our real time quantitative PCR (RQ-PCR) experiments, since they had samples 
allowing us to compare the groups pre-imatinib. All patients consented to enter this 
study (Appendix 2). 
Four samples of healthy BM MNC's were obtained from AllCells (Berkeley, CA), to 
act as normal controls. 
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Table 5.1 Characteristics of the 15 NR and the 15 R used for RQ-PCR. 
Patient Responder / Non lOisease Phase at Start of Age at Time until Start of Sex Diagnosis ID Responder Imatinib Imatinib (days) (years) 
CSOI M R Late CP 50.4 599 
CS03 F R Late CP 51.2 423 
CS05 M R Early CP 30.2 253 
CS07 F R Late CP 31.5 -l72 
CS08 F R Early CP 33.2 262 
CS09 M R Late CP 68.8 1664 
CSII M R Early CP 71.8 1071 
CS23 M R Accelerated (CE) 45.7 1-l1O 
CSI9 M R Accelerated (CE) 76.3 160 
CS27 M R Accelerated 53.7 1269 
CS28 M R Late CP ()..t.9 636 
CS33 M R Early CP 40.-l 277 
CS34 M R Late CP 51.0 693 
CS35 F R Early CP 57.7 31-l 
CS37 F R Late CP 65.8 1290 
LCCOI M NR Late CP 50.1 680 
LCC02 M NR Late CP 59.7 1377 
LCC04 F NR Accelerated 55.8 l-l25 
LCC09 M NR Late CP 76.8 1330 
LCCII F NR Late CP 60.0 597 
LCC13 F NR Late CP 66.9 3054 
LCCI4 M NR Late CP 46.1 1084 
LCC15 F NR Early CP 57.3 20-l 
LCC16 M NR Late CP 58.2 1250 
LCCI7 M NR Accelerated (CE) 23.5 2012 
LCC18 F NR Late CP 64.0 1271 
LCCI9 M NR Late CP 69.7 1682 
IJT2-l F NR Late CP 41.5 1246 
LCC27 M NR Early CP 61.3 270 
LCC28 M NR Accelerated (CE) 63.3 386 
M = male, F = female, R = imatinib responder, NR = imatinib non-responder, CP-
chronic phase, Accelerated (CE) = accelerated phase with cytogenetic clonal 
evolution being the sole criteria 
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5.4.2 Sample preparation 
At the time of BM aspiration, BM samples were enriched for MNC's by density 
gradient centrifugation with Ficoll-Paque ™ PLUS (Amersham Biosciences, Uppsala, 
Sweden). BM MNC's were suspended in 60% RPMI Medium 1640 (Invitrogen, 
Carlsbad, CA), 30% Foetal Bovine Serum (Hyclone, Utah) and 10% dimethyl 
sulfoxide (DMSO), and stored in liquid nitrogen. When required, BM MNC's 
samples were thawed at 37°C, and immediately washed in 24ml Dulbecco's 
phosphate buffered saline (PBS) containing 0.1 % human albumin (Baxter Healthcare 
Corporation, Glendale, CA) and 1 % recombinant DNase solution (Pulmozyme®, 
Genentech, San Francisco, CA). RNA was extracted using the RNeasy® Mini Kit 
(QIAGEN, Valencia, CA) and quantified by spectrophotometry. Those samples that 
were more dilute than 400~g/ml underwent ethanol precipitation to concentrate them. 
Where possible, 4~g of RNA was used for cDNA synthesis, however, if the RNA 
yield had been less than 4~g then all available RNA was used. The cDNA was 
synthesised using the SuperScripCM III First-Strand Synthesis System for RT-PCR 
(Invitrogen). Samples of cDNA were deemed to be of good quality if the ABL exon 
1/2 transcript could successfully be amplified by PCR. 
5.4.3 Mutation screening 
The cDNA from post imatinib samples was screened for KM by Dr. Michael 
Heinrich, using denaturing high-pressure liquid chromatography (DHPLC)152.1~. We 
confirmed the presence of KM by using BCR-ABL specific primers to perform nested 
PCR and automated sequencing. 
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5.4.4 Real time quantitative PCR (RQ-PCR) 
5.4.4.1 Use of Taqman technology to assess mRNA levels 
In order to measure gene expression levels in the 15 Rand 15 NR with pre imatinib 
samples, RQ-PCR was performed as described in Chapter 2. The genes investigated 
(Table 5.2) were chosen based on the knowledge of their ability to actively assist 
imatinib entry into cells (hOCT 1)83, cause imatinib efflux from cells (MDRe6-81, 
ABCG280,84,85 and ABCC1 77) or to have been linked to resistance of chemotherapeutic 
drugs (ABCA2155,156, ABCC2157-160, ABCC3161-163, ABCC6164,165, MVpl66-I68). Taqman 
Assays-on-Demand™ Gene Expression Products (Applied Biosystems, Foster City, 
CA) were used to provide primer and probe sets for these genes. The ABL exon 112 
transcript was used as a control target, as described in Chapter 2. 
Table 5.2 Candidate genes: symbol and name 
Gene symbol 
hOCT1 
MDR1 
ABCG2 
ABCCI 
ABCA2 
ABCC2 
ABCC3 
ABCC6 
MVP 
Gene name 
human organic cation transporter 1 
ATP-binding cassette, sub-family B (MDRJT AP), member 1 
ATP-binding cassette, sub-family G (WHITE), member 2 
ATP-binding cassette, sub-family C (CFfRJMRP), member 1 
ATP-binding cassette, sub-family A (ABCI), member 2 
ATP-binding cassette, sub-family C (CFfRJMRP), member 2 
ATP-binding cassette, sub-family C (CFfRJMRP), member 3 
ATP-binding cassette, sub-family C (CFfRJMRP), member 6 
major vault protein 
5.4.4.2 Use of LightCycler technology to assess mRNA levels 
Clinical monitoring of BCR-ABL expression at OHSU is done using LightCycler 
technology with G6PD as a control target l69. Dr. Richard Press kindly quantified 
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BCR-ABL expression, on all Rand NR samples undergoing RQ-PCR, by LightCycler 
technology for us. 
5.4.5 Calculation of the magnitude of change in gene expression 
level 
The magnitude of change in gene expression level, or fold change (FC), was 
calculated as follows, where CT is the threshold cycle or cycle number at which the 
fluorescence emission exceeds the fixed threshold (i.e. the point during the reaction at 
which a sufficient number of amplicons have accumulated in that well, to be at a 
statistically significant point above baseline): 
• Pre imatinib fold change = 2n(pre) 
n(pre) = pre imatinib control gene mean CT - pre imatinib test gene mean CT 
• Post imatinib fold change = 2 n(post) 
n(post) = post imatinib control gene mean CT - post imatinib test gene mean cr 
• Fold change in gene expression with time on imatinib = 2n(post - pre) 
n(post - pre) = n(post) - n(pre) 
5.4.6 Statistical analysis 
Statistical comparisons were made by use of the non-parametric Mann-Whitney test 
in SPSS version 12, since we could not assume a normal distribution of gene 
expression levels. Multiple comparison adjustment of the p-value was performed by 
use of the Bonferroni correction. 
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5.5 Results 
Forty-three patients with CML were studied, of which 28 had primary cytogenetic 
resistance to imatinib and were defined as NR. With follow up, 14 NR went on to 
show disease progression; 1 patient lost their CHR, 11 developed accelerated phase 
(AP) CML (with 9 having cytogenetic clonal evolution (CE) as the sole criteria for 
AP) and 2 developed myeloid blast crisis (BC). The median time to progression was 
19.2 months (range, 2.9 to 49.8 months) with a median follow up of 21 months 
(range, 10 to 58 months). The 15 R showed no evidence of disease progression with 
follow up (median follow up was 39 months; range, 12 to 45 months). 
All NR were examined for the presence of KM at between 9 and 15 months after 
starting imatinib therapy. Four patients were found to each have a single KM: 3 
mutations were within the p-Ioop (Y253H, Y253F and G250E) and 1 mutation was 
within the activation loop (M351 T). As shown in Table 5.2, all patients that had a 
KM showed disease progression during follow up, with new CE, AP or BC. 
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Table 5.3 Characteristics of the 4 NR with BCR-ABL KM at 9 to 15 months 
from starting imatinib. 
Patient ID 25 28 12 , 13 i 
Sex F M F I F I 
Age at Diagnosis (years) 47 63 56 66 I 
Months from Diagnosis to Start of Imatinib 90 13 44 102 
Disease Phase when Started Imatinib CP+CE CP+CE CP CP 
KM Y253H Y253F M351T G250E 
Disease Progression BC CE CE AP 
Months to Progression 16 36 39 6 
Months of Follow Up 14 36 46 12 
CP = chronic phase, CE = cytogenetic clonal evolution, KM = kinase domain 
mutation, BC = blast crisis, AP = accelerated phase 
Prior to treatment with imatinib, BCR-ABL expression levels in Rand NR were not 
significantly different. Mean drug transporter expression levels in Rand NR prior to 
imatinib were compared, and after multiple comparison adjustments, hOcr 1 and 
ABCC3 were the only genes that were significantly differentially expressed between 
Rand NR (p = 0.01 and p = 0.04 respectively) (Figure 5.1). The expression level of 
hOCT I in NR was one eighth that seen in R, while ABCC3 expression was two and 
half times that seen in R (Figure 5.2). Gene expression levels in CML patients did not 
vary significantly from that seen in normal bone marrow. 
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Figure 5.1 Comparisons of the pre-imatinib bone marrow mean gene expre IOn 
levels from non-responders (NR), responders (R) and normal donors . 
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Figure 5.2 The mean pre-imatinib bone marrow hOCT1 and ABCC3 expression 
levels in non-responders (NR) and responders (R) . 
::: 
o 
.-
1.60 
1.20 
0.80 
0040 
0 .00 
• NR pre imatjnib • R pre imatinib 
p = 0.04 
p = 0.01 
h Tl B 
Gen 
- 8 -
After 9 to 15 months of imatinib treatment, there was no significant change in the 
BCR-ABL expression level seen in NR. We compared the pre and post imatinib 
expression level of the drug transporter genes in NR, and found that though there 
appeared to be a trend to increase in some genes, Eg. MDR1 , ABCG2 and ABCA2, 
none of these were significant. There were significant decreases in the expre sion 
level of ABCC3 (p = 0.0003) and ABCC6 (p = 0.01) (Figure 5.3). Overall 14 out of 
15 patients showed either up-regulation of a gene with the potential to cau e imatinib 
efflux, down-regulation of a gene with the potential to cause imatinib influx, or a 
combination of these (Table 5.3). 
Figure 5.3 Comparison of the mean gene expression level in non-responders pre 
and post imatinib. 
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Table 5.4 Two fold increases (+), and two fold decreases (-), in the gene 
expression level of drug transporter genes and BeR -ABL, as seen in NR 
following 9 to 15 months treatment with imatinib. 
c 
0 
Q .-~ ...... ~ ~ M ~ M ~ M ~ \C ~ .5 
...... ~ ~ ~ < U U U U =-
-< =' 
= Q U U U U U U U > ~ Qi I 
.- ~ ~ 0 ~ ~ ~ ~ ~ ~ ~ ...... < ..= < < -< < -< U Qi ~ CI:l 
=- ~ ~ c 
.-~ 
1 '" '" - - - - - - - ....., ND 
2 + + - - - - - - - ....., NO 
4 + '" - - - - - - + - ND 
9 '" + - - - - - - - ....., ND 
11 '" '" - - - - - - - + NO 
13 
'" + + '" '" ....., - - - - G250E 
14 '" - - - - - - - - + ND 
15 - - + - - - - - - - ND 
16 -
'" '" + '" ....., - - - - ND 
17 + + + + '" + - - + ....., ND 
18 '" '" + + ....., + - - ....., - ND 
19 '" '" + + + + ....., '" '" ....., ND 
24 '" + ,....., + - ....., - - - ,....., ND 
27 '" '" '" '" - + - - ....., - ND 
28 '" '" + + ,....., + - + '" - Y253F 
+ = 2 fold increase in gene expression level, - = 2 fold decrease in gene expression 
level, '" = neither a 2 fold increase or decrease in gene expression level, NO = no 
kinase mutation detected 
- 88 -
5.6 Discussion 
We identified 28 NR who were treated with imatinib following failure or intolerance 
of interferon-a (lFN), and who achieved a CHR yet failed to achieve even a minor 
cytogenetic response to imatinib. The majority of patients were in late chronic phase 
prior to receiving imatinib and, in keeping with their poor cytogenetic responses, half 
the patients progressed during follow up. Since KM are found in 50% to 90% of 
patients with acquired resistance to imatinib59-61 ,63,67, we hypothesised that they might 
also playa role in primary cytogenetic resistance. At between 9 and 15 months from 
starting imatinib, we detected KM in only 4 out of 28 NR (14%), in keeping with 
observations by Branford et ai.59 who found that only lout of 10 patients with 
primary cytogenetic resistance, had evidence of a KM. All of our patients with a KM 
showed progression of their disease during follow up. Since only a minority of our 
patients with primary cytogenetic resistance showed evidence of a KM, we do not 
believe that KM can explain the majority of primary cytogenetic resistance in our 
patient population. 
Genes that affect drug transportation have been implicated in resistance to many 
chemotherapeutic drugs, and imatini b has been shown to be a substrate of a number of 
drug transporter proteins 76-81.83-85. Therefore we used RQ-PCR to explore the 
hypothesis that the expression of drug transporter genes might correlate with primary 
cytogenetic resistance to imatinib. When comparing pre-imatinib gene expression in 
15 NR, with 15 R, we found that NR had a significantly lower level of hOC[ I, and a 
significantly higher expression of ABCC3, than R. Since hOC[ 1 actively transports 
imatinib into cells, patients with low baseline expression of hOC[ I may be unable to 
achieve adequate intracellular concentrations of imatinib. and hence fail to achieve a 
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cytogenetic response. We do not know whether imatinib is a substrate for ABCC3 , 
and further work is required to investigate this before we can make any conclusions 
about the potential of ABCC3 to cause imatinib resistance. 
The Applied Biosystems Taqman gene expression assay we used for hOCT 1 and 
ABCC3 had primers and probe designed to cover the ex on 4/5 boundary of the 
functional transcript of hOCT 1, and the exon 8/9 boundary of the full length transcript 
of ABCC3. However, we note that there are 2 single nucleotide polymorphisms 
(SNP's) (P283L and R287G) within the exon 4/5 region of hOCT 1, and that these 
have been linked to significantly diminished transport activity in cell lines, as 
compared to wild type hOCT 1170. No SNP's have been reported around the region 
covered by the ABCC3 assay. Although the Taqman gene expression assays were 
designed such that polymorphisms should not affect performance of the assai?!, 
potentially we may not have been as efficient at detecting hOCTI mRNA transcribed 
from the leucine or glycine alleles, and so have underestimated the expression of 
hOCT 1 in patients with these polymorphisms. If this were to be the case, we would 
have been indirectly detecting the alleles associated with diminished transport 
activity. The allele frequencies of the P283L and R287G polymorphisms are not 
known, though several other hOCTl polymorphisms associated with reduced function 
have been shown to have allele frequencies of between 0.6 and 9.1 in a small study of 
Caucasians l72• Unfortunately, there is no more patient material to allow us to assess 
the allele status of our patients, but it would be interesting to perform further work to 
investigate the hypothesis that hOCTl allele status influences cytogenetic response to 
imatinib in patients with CML. 
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When examining the change in drug transporter gene expression level over time, we 
found that though there was a trend towards increasing expression of genes associated 
with imatinib efflux (MOR1, ABCA2, ABCG2), none of these were significant. In 
order to have least 80% power to detect a significant difference between the 
expression of MOR1, ABCA2 and ABCG2 in Rand NR, we would need to examine 
at least 88 patients (44 Rand 44 NR), 72 patients (36 Rand 36 NR) or 8820 patients 
(4410 Rand 8820 NR) respectively. The only genes to show a significant change in 
expression were ABCC3 and ABCC6, both of which were down regulated. We 
would predict that if ABCC3 or ABCC6 were to transport imatinib it would be by 
drug efflux. ABCC3 was expressed at a high level in NR bone marrow at baseline, 
and if it were a cause of persisting imatinib resistance in our NR we would have 
expected its expression level to remain high. We think that it is unlikely that ABCC3 
expression, or ABCC6 expression, are a major cause of cytogenetic resistance in our 
patients. Ideally we would have liked to measure the changes in gene expression in 
control BM, with time on imatinib, to allow comparison with the changes seen in NR. 
However, by the very nature of our imatinib responding patients, they had all 
achieved a CCR at 12 months, and therefore the majority of their BM MNC's post 
imatinib were no longer BCR-ABL positive, i.e. they would have had a fundamentally 
different cell population from that of our NR, making them unsuitable controls. 
Overall, our patients showed changes in expression in a variety of genes associated 
with drug transport, with some genes (E.g. MORl, ABCG2, hOCTl, ABCA2, and 
ABCC2) being more commonly affected than others. We therefore believe, that in 
our patient population. a variety of drug transport mechanisms may playa role in 
cytogenetic refractoriness to imatinib, and that different levels of expression and 
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activity of transporters may be important. We believe that further work is warranted 
to explore the interaction of drug transporters, inel uding hOer 1, as potential causes 
of primary cytogenetic resistance to imatinib. 
- 92-
6 Gene expression profiling of CML white cells 
6.1 Introduction 
In a landmark study, achievement of a complete cytogenetic response (CCR) was 
associated with progression-free survival, while patients who failed to attain a CCR 
had a significant risk of relapse45• Predicting failure to achieve a CCR would be 
clinically relevant, as patients unlikely to respond to standard treatment may benefit 
from more aggressive initial therapy, such as higher doses of imatinib. As the 
mechanisms underlying primary cytogenetic resistance are less well understood, we 
decided to explore gene expression profiling for identification of genes associated 
with failure to achieve a CCR. By developing a predictive algorithm from the 
expression profiling data of a "training" cohort of patients, studies in several 
haematological malignancies have managed to predict the response of patients in a 
similar "test" cohort; this has included being able to identify Philadelphia 
chromosome positive acute lymphoblastic leukaemia cells, from patients that are 
either sensitive or resistant to imatinib I28,129,135,173,174. We therefore chose to explore the 
use of this gene expression profiling in CML, as a tool for predicting cytogenetic 
response to imatinib. 
6.2 Aims 
I. To test whether gene expression profiling, of RNA extracted from the white 
blood cells of patients with Cf\1L, allows us to develop a tool for predicting 
response to imatinib. 
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6.3 Key points 
• Gene expression profiling, of the RNA from the unselected white cells of 28 
patients with CML, reveals that cytogenetic responders and non-responders 
have similar gene expression profiles. 
• Our study did not allow us to develop a tool for predicting patients' 
cytogenetic responses to imatinib. 
• Using unselected cells from either blood or bone marrow, and using different 
RNA extraction protocols within the same experiment, introduced unwanted 
gene signal (noise) into our analysis, which reduced the power of this study 
to identify relevant significantly differentially expressed genes. 
6.4 Methods 
6.4.1 Patients 
A training set of 14 patients with CML in first chronic phase (CP) was selected from 
several hundred CML patients who had been enrolled in consecutive Novartis-
sponsored trials at the Department of Hematology of the University of Leipzig, 
Germany. Selection was based on each patient's response to imatinib and the 
availability of sufficient material (cellular Iysates for RNA extraction stored prior to 
imatinib therapy). An independent test set of 15 patients was selected, using the same 
criteria, from the coordinating centre of the German CML Study Group at the Faculty 
of Clinical Medicine Mannheim of the University of Heidelberg, Germany. Local 
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institutional review boards approved these studies. All patients consented to entry 
into this study (Appendix 2). 
One patient from the training set was excluded due to an apparent physical defect of 
the chip, which was identified by the pseudo-image of the .cel file (N.B. All 
underlined words or phrases may be found in the Glossary of terms, section 10). 
Details on the remaining patients are given in Table 6.1. There were no significant 
differences in median age [Leipzig: 46.3 years (range, 29 to 58.1 years), Mannheim: 
51.6 years (range, 34 to 72.9), p = 0.11] and duration of disease ILeipzig: 1.2 years 
(range, 4 days to 7.6 years), Mannheim: 4 years (range 87 days to 11.3 years), p = 
0.121. Fifteen patients were female and 13 were male. All patients studied achieved a 
complete haematological response to imatini b. Patients were defined as responders 
(R) to imatinib if they achieved a CCR within nine months or less (n = 16), while 
non-responders (NR) were defined as those who had failed to achieve a major 
cytogenetic response (MCR) within one year of treatment (n = 12). 
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Table 6.1 Patient characteristics 
Ph+ 
metaphases Ph+ 
Patient Treatment 
Training Response Months metaphases Disease prior to / Test Material to until at 12 
identity centre category starting Set imatinib CCR months imatinib 
[%1 1%] 
1399 M Test ND PB R 100 3 0 
2205 M Test ND PB R 100 6 0 
201 M Test IFN (R) BM R 92 6 0 
11008 M Test IFN (R) PB R 72 6 0 
1229 M Test IFN (R) PB R 100 3 0 
1035D M Test IFN (R) PB R 92 3 0 
962 M Test IFN (I) PB R 100 3 0 
2023 M Test IFN (I) PB R 100 6 0 
695696 L Training ND BM R 100 9 0 
481 L Training ND BM R 100 3 0 
518 L Training ND BM R 100 3 0 
998 L Training IFN (R) PB R 100 9 0 
1169 L Training IFN (R) PB R 100 3 0 
96 L Training IFN (R) BM R 47 6 0 
988 L Training IFN (R) BM R 100 9 0 
40 L Training IFN (I) BM R 98 9 0 
2028 M Test IFN (R) PB NR Dry tap* 88 
1866 M Test IFN (I) PB NR 100 100 
2115 M Test IFN (I) BM NR 100 100 
92239 M Test IFN (I) BM NR 96 98 
1844 M Test IFN (I) PB NR 100 100 
2210 M Test IFN (I) PB NR 100 92 
1 M Test IFN (I) BM NR 100 100 
316 L Training IFN (R) BM NR 100 100 
70 L Training IFN (R) BM NR 100 88 
1290 L Training IFN(R) PB NR 100 100 
1258 L Training IFN (R) PB NR 100 100 
67 L Training IFN (I) PB NR 100 100 
8M - bone marrow, CP - chronic phase, IFN (I) - interferon intolerant, IFN (R) -
interferon resistant, L - Leipzig, M - Mannheim, ND - newly diagnosed, NR - non-
responder, PB - peripheral blood, R - responder. 
*Results at 3 months from starting imatinib showed 90% Ph-positive metaphases. 
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6.4.2 RNA extraction and microarray analysis 
RNA samples for the microarray analysis were isolated from total bone marrow (8\1) 
white cells, or peripheral blood (PB) white cells, using guanidine-thiocyanate / 
phenol-chloroform extraction 175 with RNA purification by RNeasy (Qiagen, Hilden, 
Germany) (Leipzig cohort) or cesium chloride-gradient purification 176 (Mannheim 
cohort). RNA was processed by the DNA Core of the IZKF (Interdisciplinary Center 
for Clinical Research) at the University of Leipzig (Leipzig cohort) or by the 
Affymetrix Microarray Core at Oregon Health & Science University (Mannheim 
cohort). In the latter core, each sample of RNA underwent quality assessment on the 
RNA 6000 LabChip using the 2100 Bioanalyzer (Agilent, Palo Alto, CA). Those 
samples whose electropherogram showed the presence of discrete 18S and 28S 
ribosomal RNA peaks and the absence of irregularly-sized low molecular weight 
RNA species (i.e., degraded RNA) were considered to be of good quality and were 
used for microarray analysis. 
Microarray assays were performed according to the standard protocol described in the 
Affymetrix GeneChip Expression Analysis Technical Manual, rev.3 
(http://www.affymetrix.com/support/index.affx). Messenger RNA was amplified and 
labelled from 5p.g (Leipzig) or 4p.g (Mannheim) of total RNA. An aliquot (200ng) of 
the resulting cRNA underwent quality assessment on the RNA 6000 LabChip using 
the 2100 Bioanalyzer (Agilent, Palo Alto, CA). Samples that produced sufficient 
cRNA yield and had cRNA electropherograms that showed a size distribution pattern 
predictive of acceptable microarray assay performance were considered to be of good 
quality. These samples were fragmented and combined with array hybridization 
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controls consisting of biotinylated cRNAs for four bacterial genes (Affymetrix. Santa 
Clara, CA) in hybridization buffer. Ten micrograms of cRNA target were then 
hybridized with the GeneChip HG_U95Av2 array (Affymetrix, Santa Clara, CA) and 
scanned using the GeneArray laser scanner (Affymetrix, Santa Clara, CA). The 
HG_U95Av2 array contains 12,625 transcripts, including 67 control genes. The array 
image scans were processed with Affymetrix Microarray Suite software, version 5.0 
(MAS 5.0). All GeneChip expression arrays contain control probe sets for both 
spiked and endogenous RNA transcripts (e.g., bacterial genes BioB, BioC, BioD, 
CreX and species-specific actin and GAPDH). Following image processing and 
single array analysis of the array pattern with the MAS statistical expression analysis 
algorithml77,17s, six values are examined: background, noise, average signal, percent 
present and ratio of signal values for probe sets representing the 5' and 3' ends of 
actin and GAPDH transcripts. All assays in this study met standard performance 
thresholds for background (less than 90) and RNA integrity ("housekeeping" control 
gene 3'/5'ratios less than 2). 
6.4.3 Data Analysis 
Initial image analysis, signal quantification and intra-chip normalisation (i.e., global 
scaling) was done with MAS 5.0177.17S. An unsupervised hierarchical clusterin~ of 
samples based on MAS 5.0 signal data showed a noticeable difference between the 
two sites. In order to reduce the site difference, Robust Multichip Analysis (RMA)179 
implemented in the Bioconductor (http://w\vw.bioconductor.org) was used as an 
alternative method of signal quantification, pre-processing, and intra- and inter-chip 
normalization. Significance Analysis of Microarrays (SAM)ls0 was performed on the 
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training set to identify differentially regulated genes associated with a lack of 
response to imatinib. Genes that met a q value of :510% were selected for further 
validation in the test set. The unadjusted t-test, p value and fold change of these 
genes were computed using the test set. As the test set failed to replicate the findings 
from the training set, we performed Analysis of Variance (A NOV A) on all patients (n 
= 28) in training and test sets in order to identify sources of variation. For each gene. 
the ANOVA model included the site (Leipzig vs. Mannheim), source of samples (PS 
vs. BM), the response status (R vs. NR) and two-way and three-way interaction terms. 
The p values from the ANOV A F statistics for each effect were adjusted for multiple 
comparisons using the False Discovery Rate (FOR) of Benjamini and Hochberg 181 • 
Data visualisation was performed using a hierarchical clustering analysis and 
Multidimensional Scaling (MDS). Gene annotation was obtained through Affymetrix 
NetAffx site (http://www.affymetrix.com/analysis/i ndex.affx). 
6.4.4 Real time quantitative peR measurement of gene 
. 
expression 
In order to confirm the gene expression seen on the oligonucleotide arrays, a selection 
of genes that were differentially expressed in the training set, prior to multiple 
comparison adjustment, had their gene expression levels measured by real time 
quantitative PCR (RQ-PCR) using primer and probe sets supplied by Applied 
Siosystems. 
- 99-
6.5 Results 
6.5.1 Gene expression profiling of un selected white cells 
Oligonucleotide microarrays were used to explore the gene expression profiles of 
unselected white blood or bone marrow cells from 29 patients with CML in first CPo 
Unsupervised hierarchical clustering of samples, based on log 2 transformed MAS 5.0 
signal values, revealed clustering of patients based on the site of sample processing 
and sample source but not by cytogenetic response (Figure 6.1). The site effect was 
substantially attenuated after RMA normalisation (Figure 6.1) and thus RMA was 
considered to provide better normalisation of the data than MAS 5.0. Our RMA 
normalised data are available for review at: http://www.ncbi.nlm.nih.gov/geo, 
accession number GSE2535. With both methods, one patient sample (67) was found 
to be an outlier. No reason was identified by review of clinical parameters, image file 
or sample quality parameters; therefore, this sample continued on into further 
analysis. 
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Figure 6.1 Two dendrograms (A, B) showing unsupervised hierarchical 
clustering of all 28 patient samples and one 2D multidimensional scaling graph 
(C) of all patients, based on the 15 most significantly differentially expressed 
genes between Rand NR in the training set. 
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not by cytogenetic response. (B) Unsupervised hierarchical clustering, based on 
RMA signal values, showing no obvious clustering by any parameter. (C) 20 
Multidimensional scaling of patients from both training (Leipzig patients) and test 
sets (Mannheim patients). Using the 15 genes most significantly differentially 
expressed between Rand NR in the training set, we were unable to separate R from 
NR in the test set. 
6.5.2 Significance Analysis of Microarrays (SAM) 
Since unsupervised hierarchical clustering failed to separate the patients according to 
cytogenetic response, it was reasoned that the effects of sample source and processing 
might have prevented the identification of genes associated with response to imatinib. 
Employment of SAM revealed 15 genes differentially expressed between Rand NR 
in the training set (Table 6.2), however, differential expression was not confirmed in 
the test set (Fi gure 6.1). 
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Table 6.2 The top 15 differentially expressed genes, with a q value <0.1, 
identified for responders and non-responders in the training set, together with 
the fold change and level of significance of these genes when examined in the test 
set. 
Training Set Test Set 
Probe Set Public Database Fold Fold tv nadjusted Gene Title (Locus Link) T Test P-ID Change Change Number Value 
40215 at UDP-glucose cerami de 7357 +2.1 -1.4 >0.05 - glucosyltransferase 
37985_at lamin Bl 4001 +1.9 -1.3 >0.05 
38402_at lysosomal-associated membrane 3920 +1.8 -1.1 >0.05 protein 2 
2065_s_at BCL2-associated X protein 581 +1.4 1.0 >0.05 
39064_at 5,10-methenyltetrahydrofolate 10588 +1.4 + 1.1 >0.05 
synthetase 
X-ray repair complementing 
1360_at defective repair in Chinese 7518 +1.3 1.0 >0.05 
hamster cells 4 
138_at mitogen-activated protein kinase 11184 -1.3 + 1.1 >0.05 ki nase ki nase ki nase 1 
33 I 34_at adenylate cyclase 3 109 -1.3 -1.1 0.043 
39709_at selenoprotein W, 1 6415 -1.4 1.0 >0.05 
36811_at Iysyl oxidase-like 1 4016 -1.6 -1.2 >0.05 
36757_at histone 1, H3h 8357 -1.6 -1.1 >0.05 
41337_at amino-terminal enhancer of split 166 -1.7 1.0 >0.05 
41743_i_at optineurin 10133 -1.8 +1.2 >0.05 
3908 I_at no gene title given 4502 -1.9 + 1.1 >0.05 
36780_at c1usterin 1191 -2.6 -1.9 >0.05 
The fold change (Fe) is defined as: ±2IL\I, where I~I is the absolute value of the 
difference in mean log (signal) between Rand NR groups. The positive sign (+) 
indicates up-regulation of R compared to NR, while the negative sign (-) indicates 
down-regulation. Note that a fold change of 1.0 is equivalent to no difference in gene 
expression. 
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6.5.3 Analysis of variance 
Since there was no overlap in the differentially expressed genes between the two 
patient cohorts, analysis of variance was performed in order to identify sources of 
variability. All samples were combined, and we performed gene-by-gene ANO\,:-\ to 
evaluate the impact of the site and sample source, in addition to the response status. 
Using a false discovery rate of 0.10 or less, ANOV A identified genes differentially 
expressed between the two sites (4421 genes) and between BM and PB samples (439 
genes). None of the genes met the statistical significance criteria for response status 
or for two or three-way interactions between the sites, source and response status. 
6.5.4 Sample size and power considerations 
Since the results indicated that the differences between Rand NR were subtle, the 
observed differences were used to estimate the theoretical number of samples required 
to identify genes significantly associated with cytogenetic refractoriness. Using gene-
specific mean squared errors (MSE) from the ANOV A model, the average sample 
size required to detect a 1.5-fold change between Rand NR, using 80% power and a 
I % significance level to adjust for multiple comparisons, was 258 patients (129 
responders and 129 non-responders). An even larger sample size would be required 
to develop a robust test set for validation of a classification algorithm. 
6.5.5 Real time quantitative peR 
We confirmed the microarray findings that responders had either a higher or lower 
level of gene expression, compared to non-responders, in 5 out of the 6 genes tested. 
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RQ-PCR of the dCMP deaminase gene (631_g_at) could not confirm the microarray 
findings, however, the difference in expression level between Rand NR was only 
small (R:NR = 1.5: 1). The magnitudes of the fold differences in gene expression 
between Rand NR for all 6 genes, as measured by both microarray analysis and RQ-
PCR, were not significantly different from eachother (Student's paired t-test, p = 
0.53). 
6.6 Discussion 
Predicting cytogenetic response prior to imatinib would be clinically useful, since it 
would allow for early risk stratification. The patients for our study were selected from 
patient populations treated at two different centres, based on cytogenetic response and 
availability of sufficient RNA. Most of the NR did not achieve even a minor 
cytogenetic response, whilst 46.7% of R with available data were in a CCR at 3 
months. Our patient population therefore represented, for most part, the extremes of 
the spectrum of responses. Nonetheless, we found that the pre-therapeutic gene 
expression profiles of unselected white cells did not allow us to identify genes 
consistently associated with lack of cytogenetic response to imatinib. 
Our results fail to confirm two recently published studies. Using eDNA arrays on 
mononuclear cells from 22 CML patients (18 in CP), Kaneta et al. 139 reported 71 
genes associated with MCR. McLean et al. l40 analyzed the transcriptional profile of 
total PB from 66 newly diagnosed patients in CPo From a list of 55 genes, with at 
least 1.7 fold difference between patients with CCR and patients with >65 0(, Ph-
positive metaphases after I J months of treatment. they selected an optimal list of 
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identified 31 predictive genes using a "leave one out" strategy. Remarkably, the 
discriminating genes did not overlap between the two studies, or with the 15 most 
significant genes in our training set. Using RMA and the published genes (with the 
exception of eight genes of Kaneta et al. for which the probe IDs were missing in the 
published manuscripe39), we could not distinguish between Rand NR in our data set. 
There are several potential explanations for the discrepant results. Firstly, different 
cells were analysed. RNA extracted from whole blood, as in the study by McLean et 
al. l40 contains large amounts of globin transcripts, and yields significantly less present 
calls than RNA extracted from selected white or mononuclear cells l82. Secondly, our 
study included patients in late chronic phase pre-treated with various drugs and the 
cytogenetic response in such patients may be influenced by factors different from 
newly diagnosed patients. In addition, since we do not have data on patients' serum 
imatinib concentrations, it may be that some patients did not achieve adequate drug 
levels. Most importantly, we used an independent control group for validation, and 
applied rigorous statistical methods for data analysis. 
Significant differences were evident between samples from Leipzig and Mannheim, 
likely reflecting different methods of sample preparation, and between samples 
derived from PB vs. BM, confirming previously published data136• However, 
regardless of these potential confounding factors, the differences between Rand r\R 
were extremely subtle in either cohort, and associated with very high false discovery 
rates. In addition, our power calculations indicate that although it would theoretically 
still be possible to identify a more robust set of predictive genes, this would require a 
very large patient cohort. 
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In addition to these considerations, CML may differ from other haematological 
malignancies, such as acute myeloid leukaemia 131.173.183 or acute lymphoblastic 
k . 128-130 h " h b leu aemla , were gene expressIOn signatures ave een shown to correlate with 
response to chemotherapy and survival. In these disorders resistance to therapy may 
be a quality of all the blast cells, and thus its signature may be detectable in this 
population. In CML, this may be more comparable to haematologic resistance, rather 
than to cytogenetic resistance. Refractory progenitor cells, the transcriptional 
signature of which may be undetectable in the noise of unselected white cells, may 
mediate the latter. Thus, it is conceivable that enriching for progenitor cells (e.g. 
CD34+ cells) may sufficiently reduce the noise to uncover the transcriptional 
signature associated with cytogenetic resistance. We therefore believe that, if gene 
expression profiling is going to be able to help us to predict patients' responses to 
imatinib, analysing expression profiles of CML CD34-postive progenitor cells may be 
the best method. 
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7 Isolating CML CD34+ cells 
7.1 Introduction 
In order to perform gene expression profiling on CML CD34+ cells, we needed to 
develop a protocol that would allow us to isolate CD34+ cells from CML 
mononuclear cells. We needed a protocol that would be suitable for CD34+ cell 
isolation from cryopreserved cells, and one that would be suitable for CD34+ cell 
isolation from the peripheral blood of newly diagnosed patients. For the latter we 
chose to use immunomagnetic separation of CD34+ cells, using the Direct CD34 
Progenitor Cell Isolation Kit (Miltenyi Biotec, Auburn, CA), because we had 
experience of using this kit l84 and we needed a simple technique that would allow us 
to select cells as soon as possible after phlebotomy, even when the time of arrival of a 
patient's sample was unpredictable. For the CD34+ cell selection from cryopreserved 
cells, we elected to base our method on a flow cytometry technique since this study 
allowed us more time to plan CD34+ isolation procedures and so allowed us to make 
use of this technique's ability to give us a highly pure cell population. Since we had 
no previous experience in using this method of CD34+ cell isolation, we needed to 
develop and test a protocol, before proceeding to the samples we wished to use for the 
microarray experiment. 
7.2 Aims 
1. To develop and test a technique of cell sorting CD34+ cells from CML 
mononuclear cells stored in liquid nitrogen. 
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2. To design a protocol for CD34+ cell isolation from the peripheral blood of 
newly diagnosed patients with CML. 
7.3 Key Points 
• We have developed a technique for isolating highly pure samples of 
CD34+ cells from CML mononuclear cells stored in liquid nitrogen. 
• We have designed a simple protocol for isolating CD34+ cells from the 
peripheral blood of newly diagnosed patients with CML. 
7.4 Methods 
7.4.1 Isolation of CD34+ cells from CML mononuclear cells 
stored in liquid nitrogen 
7.4.1.1 Patient material 
In order to develop the protocol for isolation of CD34+ cells, we identified a large 
number of samples of mononuclear cells (MNC's) that had been separated by density 
gradient centrifugation from one CML patient's peripheral blood leukopheresis 
sample. Samples consisting of 5 x 107 MNC's had been suspended in 50% Iscove's 
modified dulbecco's media (lMDM), 45% fetal bovine serum (FBS) and 5% dimethyl 
sulfoxide (DMSO), and these had then been cryopreserved in liquid nitrogen. 
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7.4.1.2 Sample thawing and enrichment for viable cells 
When required, an aliquot of MNC's was thawed at 37°C and immediately suspended 
in Dulbecco's phosphate buffered saline (PBS) containing 0.1 % human albumin 
(Baxter Healthcare Corporation, Glendale, CA), 1 % recombinant DNase sol uti on 
(Pulmozyme@, Genentech, San Francisco, CA) and 2.SmM magnesium chloride and 
then centrifuged at 980rpm for S minutes at SoC. The sample was enriched for viable 
cells using the Dead Cell Removal Kit (Miltenyi Biotec, Auburn, CA), according to 
the manufacturer's instructions. 
7.4.1.3 Cell staining 
The viable cells were suspended in Hanks' balanced salt solution (HBSS) with 3% 
FSS, 2% HEPES and 1 % recombinant human DNase (Genentech), and incubated 
with 201-11 CD34-fluorescein isothiocyanate (FITC) and 201-11 CD4S-PerCP-CyS.S 
monoclonal antibodies (BD Biosciences, San Jose, CA) for every 1 x 106 cells. 
Excess fluorochrome was washed off and the cells resuspended in HBSS containing 
O.S% FBS, 2% HEPES and 1 % recombinant human DNase (Genentech). For the 
identification of dead cells, propidium iodide (PI) (Roche, Indianapolis, IN) was 
added to the cell solution immediately prior to sorting. 
7.4.1.4 Cell sorting CD34+ cells 
A SD FACSAria ™ (BD Biosciences, San Jose, CA) was used to sort the CD34+ ceIls. 
The SD FACSAria ™ is an electrostatic ceIl sorter that works by ejecting a focused 
stream of cells through a nozzle into air. A laser beam passes through the cuvette 
flow cell and then, depending on the fluorescent signal and scatter results, charged 
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droplets containing cells are deflected into the appropriate collection tubes. In order 
to select CML CD34+ cells, gates were set to select viable mononuclear cells by 
forward scatter (FSC) and side scatter (SSC) (Figure 7.1), and then cell debris and 
clumped cells were excluded by limiting the FSC-width (FSC-W) and FSC-height 
(FSC-H) of the selected cells (Figure 7.2). Next, gates were set to select only PI 
negative cells to ensure that only viable cells were selected (Figure 7.3). Finally. on 
the CD34-FITC and CD45-PerCP-Cy5.5 histogram, CD45-PerCP-Cy5.5 dim cells 
that brightly co-expressed CD34-FITC were selected (Figure 7.4). \Ve chose our final 
gating to allow us to isolate reasonable numbers of stem cells. since all but the very 
earliest stem cells express the CD34 antigen, and to put a limit on the maturity of our 
selected cells, since cells progressively express more CD45 antigen as they mature. 
(N.B. The software attached to the BD FACSAria ™ only allowed us to save scatter 
plots in a black background format.) After sorting a fraction of the selected cells 
underwent flow cytometry, with gates as previously described, to assay the percentage 
of C034+ cells within the sample. 
7.4.1.5 RN A extraction, quantitation and quality assessment 
Remaining selected CD34+ cells were placed in PicoPure 1M extraction buffer 
(Arcturus, Mountain View, CA) and stored at -80°C. RNA was later extracted from 3 
samples and sent to the Affymetrix Microarray Core, at Oregon Health and Science 
University, for quantitation using the NanoOrop® NO-IOOO UV-vis 
spectrophotometer, and assessment of quality on the RNA 6000 LabChip using the 
2100 Bioanalyzer (Agilent, Palo Alto, CA). 
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Figure 7.1 Scatter plot showing mononuclear cells, as measured by forward 
scatter (FSC-A) and side scatter (SSC-A), with gate PI covering the region of 
mononuclear cells, and avoiding the region of cell debris. 
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SSC-A 
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Figure 7.2 Scatter plot showing mononuclear cells, as measured by forward 
scatter width (FSC-W) and forward scatter height (FSC-H), with gate P2 placed 
over the region of intact single mononuclear cells. 
50 100 150 200 250 
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Figure 7.3 Scatter plot showing mononuclear cells, as measured by expre ion of 
CD34-FITC (FITC-A) and propidium iodide (PI-A), with gate P3 over the region 
of viable cells. 
PE-A 
Figure 7.4 Scatter plot showing mononuclear cells, as measured by expression of 
CD34-FITC (FITC-A) and CD4S-PerCP-CyS.S (perCP-CyS.S-A), with gate P4 
over the region of CD4S-PerCP-CyS.S dim cells that brightly co-express CD34-
FITC. 
c:( 
o 
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7.4.2 Isolation of CD34+ cells from the peripheral blood of newl~' 
diagnosed patients with CML 
We identified patients with newly diagnosed CML who were yet to receive any 
treatment for their disease, and who were expected to receive imatinib as first line 
therapy. All patients gave their consent for inclusion in this study (Appendix 1). 
Twenty millilitres of peripheral blood were taken and placed into a sample tube 
containing preservative free heparin, and this was then transported to the laboratory. 
The sample was diluted with minimacs buffer (phosphate buffered saline (PBS) 
containing 0.5% bovine serum albumin (BSA) and 2mM EDT A), according to Table 
7.1. MNC's were then separated from the diluted cell solution by density gradient 
centrifugation, washed 3 times in minimacs buffer, and resuspended in 300l-li 
minimacs buffer per 1 x 108 cells. A maximum of 2 x 108 cells were labelled with 
FeR blocking reagent and Hapten-Antibody, according to the instructions in the 
Direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). Labelled cells were 
placed onto a MS column (Miltenyi Biotec) and CD34 cells were 
immunomagnetically separated from the mononuclear cells, according to the 
manufacturer's instructions. Up to 1 X 105 cells underwent flow cytometry to assess 
the purity of the cells, and up to 2 X 104 cells were stored for later fluorescent in situ 
hybridisation (FISH) analysis of BCR-ABL. The remaining cells were placed in 
1001-l1 of PicoPure Extraction Buffer (Arcturus) per 5 x 106 cells, incubated at 42°C 
for 30 minutes, centrifuged at 3,000 rpm for 2 minutes and then the RNA containing 
supernatant was placed into a fresh microcentrifuge tube and stored at -80°C. 
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Table 7.1 Table of the volumes required for dilution of the peripheral blood 
samples with buffer. 
Peripheral blood white Volume of sample (ml) Volume of minimacs 
cell count (x 109n) buffer (ml) 
10 20 20 
10-25 20 40 
25-50 20 60 I 
50-100 20 80 i 
100-300 20 100 I ! 
>300 20 120 i 
7.5 Results and Discussion 
In order to develop and test a protocol for isolating CD34+ cells from cryopreserved 
CML MNC's, we chose to use MNC's from a single patient with CML so that we 
could directly compare the protocols we designed, and not be concerned that 
differences in the purity of the selected cells were simply a reflection of using 
samples from different patients. The final successful protocol is described in the 
methods section above, and it was repeated on 4 separate occasions to check its 
reliability. 
In the design of the protocol for separation of CD34+ cells from fresh peripheral 
blood, we had previous experience of using the Direct CD34 Progenitor Cell Isolation 
Kit (Miltenyi Biotec)l84 and therefore did not perform any testing of our protocol, but 
proceeded to directly acquiring patient samples. The results of this are discussed in 
Chapter 8. 
- I 15 -
7.5.1 Sample thawing and enrichment for viable cells 
The percentage of viable MNC's immediately after thawing was low, with a median 
viability prior to centrifugation being only 14.6% (range, 12.6% to 30.69c). In order 
to maximise the viability of the cells, we thawed the MNC's rapidly in a 37°C water 
bath and immediately washed them in an albumin containing solution. As a 
consequence of the poor cell viability, there was free DNA within the solution that the 
MNC's were suspended in, and this resulted in cell clumping. We therefore used 
DNase in all our solutions, and this successfully reduced the problem of cell 
clumping, and hence maximised our cell yield. 
In order to remove as many apoptotic and dead cells as possible prior to sorting, we 
used the Dead Cell Removal Kit (Miltenyi Biotec) which immunomagnetically 
removed phosphatidylserine-positive cells. Immediately prior to sorting, the kit 
improved the median viability of the MNC's to 21.7% (range, 12.6% to 24.8%). 
Before using the Dead Cell Removal kit, the BD FACSAria ™ tended to underestimate 
CD34+ cell purity by miscounting a proportion of cell debris as cells. Although the 
improvement in viability with the kit was only small, minimising the cell debris made 
a 10% - 20% improvement in the accuracy of our measurements of cell purity. 
We had initially attempted to use the Direct CD34 Progenitor Cell Isolation Kit 
(Miltenyi Biotec) to enrich the cryopreserved MNC's for CD34+ cells prior to 
carrying Ollt cell sorting; however, we lost a large number of cells without 
significantly enhancing the CD34+ cell purity of the cells prior to sorting. Although 
we did not formally record the viability of the MNC's extracted from the peripheral 
blood of newly diagnosed patients with CML. we noted that their viability was almost 
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always greater than 90%. Thus, it may be that the large difference in viability of the 
MNC's obtained from frozen patient samples, as compared to fresh patient samples, 
resulted in the poor results we saw with the immunomagnetic method of separating 
CD34+ cells from cryopreserved MNC's. 
7.5.2 Cell staining 
Whilst the MNC's were staining, they were kept in a solution containing 3% FBS, 
however, immediately prior to sorting they were placed in a solution containing less 
protein. This reduction in protein reduced the viscosity of the cell sorting stream, and 
hence reduced unwanted spraying of the stream. We chose to use antibodies labelled 
with FITC and PerCP-Cy5.5 since we found these fluorochromes gave us the most 
distinct compensation settings, when used in conjunction with PI. 
7.5.3 Cell sorting CD34+ cells 
In order to maximise our cell viability during sorting, we used the largest available 
nozzle (100 microns) to reduce the pressure placed on cells within the sorting stream. 
To maximise the purity of the sorted cells, we used the "single cell" sort setting 
(Figure 7.5). Our gating strategy was designed to firstly select viable cells that would 
include CD34+ cells, then gate out debris and clumped cells. Next, we picked out 
alive and non-apoptotic cells, and then finally selected our CD34+ cell population. 
Flow cytometry was used to assess the purity of the sorted CD34+ cells (Figure 7.6). 
From a median of 3.06 x 106 stained cells (range, 8.25 x 105 to 5.95 X 106), with a 
median CD34+ cell purity of 2.2% (range, 1.0% to 2.3%), we sorted a median of 2.83 
x lo"~ CD34+ cells (range, 7.95 \ 10-' to 3.92 X 104), with a median CD34+ cell purity 
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of 96.9% (range, 93.4% to 98.0%). We therefore felt confident that our protocol 
could be used to select viable CD34+ cells from cryopreserved CML MNC's, and 
provide a sample of highly pure CD34+ cells that would be suitable for RNA 
extraction. 
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Figure 7.5 Diagram showing how the masks on the BD F ACSAriaTM divide a 
cell containing drop into 32 segments (not to scale). 
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The "single cell" sort option is designed to maximise purity, even at the expense of 
cell yield. The phase mask is set to 16 so that if the desired cell is in either the top or 
bottom quarters of the drop (regions marked A), that drop is aborted. In addition the 
purity mask is set to 32 so that if the desired cell is within either the top or bottom half 
f the drop, the following or proceeding drops are respectively aborted from the ort. 
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Figure 7.6 Scatter plot showing sorted CD34+ cells, as measured by expression 
of CD34-FITC (FITC-A) and CD4S-PerCP-CyS.S (perCP-Cy5.S-A), with gate P4 
over the region of CD4S-PerCP-CyS.S dim cells that brightly co-express CD34-
FITC. 
10' 
PerCP-Cy5-5-A 
7.5.4 RNA extraction, quantitation and quality assessment 
RNA was extracted from 3 samples of sorted CD34+ cells, quantitated and assessed 
for quality. All samples were found to be of good quality by the 2100 Bioanalyzer 
(Agilent) with electropherograms showing the presence of discrete I8S and 28S 
ribo omal RNA peaks and the absence of irregularly sized low molecular weight 
RNA species (i.e. degraded RNA) (Figure 7 .7). The number of CD34+ cell isolated 
wa Ie than 4000 and consequently the RNA yield was low with a median of 
14.95ng RNA extracted (range, 3.66ng to 56.46ng). 
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Figure 7.7 Example of an electropherogram resulting from RNA extracted from 
sorted CD34+ cells. 
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An electropherogram showing fluorescence against time, and the identification of the 
6000 Nano Marker peak, and the 18S and 28S ribosomal peaks. As shown, RNA 
likely to perform well in a microarray assay has I8S and 28S peaks, and the absence 
of a spiky distribution of increased fluorescence between the 6000 Nano Marker and 
the I8S peak. 
In conclusion, despite the poor viability of MNC's post thawing, we were able to 
elect a pure population of CD34+ cells and extract good quality RNA from these 
cells. The number of CD34+ cells that we could isolate limited our RNA yields. We 
therefore proposed that in order to achieve enough RNA for our planned microarray 
experiment, we would need to maximise the number of cells thawed per patient and 
al 0 t u e a econd round of amplificatjon in the RNA labelling step of the array 
hybridi ation protoc I. 
- 121 -
8 Gene expression profiling of CML CD34+ cells 
8.1 Introduction 
Our previous study of gene expression profiling used RNA from a population of cells 
that were heterogeneous by source, sampling handling and cell phenotype. This 
technical variation introduced unwanted noise into our analysis, which in turn reduced 
the power of the system to identify relevant differentially expressed genes. CML is a 
stem cell disorder and we therefore hypothesised that performing gene expression 
profiling on isolated CML CD34+ progenitor cells might allow us to identify a 
transcriptional profile associated with resistance to imatinib, by eliminating the noise 
created by cells of different phenotypes. 
8.2 Aims 
1. To determine whether gene expression profiling of CML CD34+ cells, 
isolated from bone marrow cells stored in liquid nitrogen, would allow us to 
develop a tool for predicting patients' responses to imatinib. 
8.3 Key points 
• At present, it is uncertain whether gene expression profiling of CML 
CD34+ cells, isolated from bone marrow cells stored in liquid nitrogen, 
is going to be useful in developing a tool for predicting patients' 
responses to imatinib. 
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• We experienced difficulties in accurately measuring low concentrations 
of RNA, which may have led to insufficient RNA input into R:'\A 
quality assessment and amplification. 
• Future work should consider using RNA extracted from CD34+ cells 
that has been freshly prepared from newly diagnosed and untreated 
patients with CML, in order to compare the gene profiles of imatinib 
responders and non-responders. 
8.4 Methods 
8.4.1 Patients 
At Oregon Health and Science University (OHSU), 51 patients with CML were 
identified who had had bone marrow (8M) mononuclear cells stored just prior to their 
commencement on imatinib (Table 8.1). All patients had either achieved a complete 
cytogenetic response (CCR) during their first year of imatinib therapy and were 
defined as responders (R, n = 35), or they had remained at least 65% Ph positive by 
cytogenetic analysis during their first year of imatinib treatment and were defined as 
non-responders (NR, n = 16). All patients consented to entry into this study 
(Appendix 2). 
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Table 8.1 Clinical characteristics of the fifty-one patients with CML. 
Characteristic Value 
Sex - no. (%) 
Male 28 (54.9) 
Female 23 (45.1) 
Age - years 
Median 57 
Range 29 -75 
Hemoglobin - gldl 
Median 12.-+ 
Range 9.5 - 16.3 
White cell count - xl(f/1 
Median 12.8 
Range 2.5 - 116.0 
Platelet count - x 103/1 
Median 323 
Range 19 - 1372 
Peripheral blood basophil count - % 
Median 5 
Range 0-31 
Peripheral blood blast count - % 
Median 0 
Range o - 11 
Bone marrow blast count - % 
Median l.75 
Range 0.0 - 18.0 
Disease Phase - no. (%) 
Chronic phase 34 (66.7) 
Early chronic phase 9 
Late chronic phase ')--) 
Chronic phase + cytogenetic clonal evolution 12 (23.5) 
Accelerated phase 5 (9.8) 
Days from diagnosis to starting imatinib - no. 
Median 1059 
Range 71 - 5492 
Treatment prior to imatinib - no. (%) 
Hydroxyurea 45 (88.2) 
Alone 5 
Interferon alpha 45 (88.2) 
Cytarabine 8(15.7) 
Anagrelide 5 (9.8) 
Stem cell transplant 
Autologous 2 (3.9) 
Matched unrelated donor 2 (3.9) 
Other • 5 (9.8) 
• Other treatments were busulphan (n = 3), etoposide (n = 1), interleukin-2 (n = 1) and 
topotecan (n = 1). 
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8.4.2 Samples and CD34+ cell isolation 
Mononuclear cells were purified from BM by density gradient centrifugation and 
cryopreserved in liquid nitrogen. CD34+ cells were isolated according to methods 
described in Chapter 7. After sorting, CD34+ cells were placed in PicoPure ™ 
extraction buffer, according to the manufacturer's instructions (Arcturus, Mountain 
View, CA) and stored at -80°C until time for completion of RNA extraction. Small 
samples of CD34+ cells were also stored for fluorescence in-situ hybridization (FISH) 
to assess the presence of BCR-ABL. 
8.4.3 RN A extraction and gene expression profiling 
RNA extraction, including a step for DNase treatment to reduce DNA interference, 
was completed once all cell sorting had been finished~ we used the PicoPure ™ RNA 
Isolation Kit (Arcturus) and the QIAGEN® RNase-Free DNase Set (QIAGEN, 
Valencia, CA) according to the manufacturers' instructions. The samples of RNA 
were then sent to the Affymetrix Microarray Core at Oregon Health and Science 
University. Here, Dr. Christina Harrington and Mrs. Kristina Vartanian quantified the 
RNA using the NanoDrop® ND-IOOO UV-Vis spectrophotometer (NanoDrop 
Technologies,Wilmington, DE), and assessed its quality using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA). Samples with electropherograms 
showing a size distribution pattern predictive of acceptable microarray assay 
performance l42 were considered to be of good quality. Samples containing 5 to lOng 
(median 9ng) of good quality total RNA underwent amplification and labelling using 
the two-cycle cDNA synthesis and IVT labelling protocol (Affymetrix, Santa Clara, 
CA) (www.affymetrix.com/suPPOlt/technical/manual/expression manual.affx). 
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Following successful amplification, 5~g of labelled target eDNA was hybridized to 
HG-UI33 Plus 2.0 GeneChip arrays (Affymetrix). Arrays were scanned using a laser 
confocal scanner (Agilent) and the image processing and expression analysis were 
performed using Affymetrix GCOS v1.2 software. For each analysis, scaled or 
unsealed, the parameters a 1 and a 2 were set to 0.05 and 0.065 (Affymetrix defaults) 
respectively. These parameters, or p-value cut-offs, set the point at which a probe set 
was called present (P) (p <0.05), absent (A) (p >0.065) or marginal (M) (p value 
between 0.05 and 0.065). Minimal quality control parameters for inclusion in the 
study included P>30%, average signal in keeping with the average signal of other 
samples within that hybridization group, and an actin 3'/5' ratio of <17. The 36 
microarrays included in the study had an average present call of 41.5% (range, 38.8% 
to 47.1 %). 
8.4.4 Statistical analysis 
Robust Multichip Analysis (RMA)179 implemented in Bioconductor 
(http://www.bioconductor.org) was used for signal quantification, pre-processing, and 
intra- and inter-chip normalisation. Levene's test was used to test all genes for equal 
variance in gene expression across Rand NR. Analysis of variance, using a pooled-
variance formula, was used to identify genes that were differentially expressed 
between Rand NR, except for those genes identified as having unequal variance 
across Rand NR where a separate-variance formula was used. Adjustment for 
multiple comparisons was made using the False Discovery Rate (FOR) of 8enjamini 
and Hochberg l81 . Unsupervised hierarchical clustering of all probe sets, and probes 
sets with an adjusted p value of <0.51 (n = 1019), was executed using Cluster 3.0 
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f 185 d I . d . . SO tware ,an resu ts Vlewe USIng Java TreeVlew 1.0.7 software 186. Sample size 
and power calculations were performed in Microsoft Excel, and significance analysis 
of microarrays (SAM)180. Gene annotation was obtained through Affymetrix NetAffx 
site (http://www.affymetrix.com/analysis/index.affx). (Please note that the statistical 
analysis, apart from the unsupervised hierarchical clustering, was kindly done by \tiss 
Solange Mongoue-Tchokote.) 
8.5 Results 
8.5.1 CD34+ cell isolation 
The CD34+ cell isolation procedure was performed on cryopreserved bone marrow 
mononuclear cells from 51 patients with CML. The procedure was regarded as a 
success if greater than 1,000 CD34+ cells were isolated, with a purity of greater than 
80% CD34+ by flow cytometry. The procedure was repeated in 17 patients (twice in 
2 patients) in an attempt to obtain even higher numbers of cells for analysis. Thus, 64 
out of 70 procedures were deemed successful (91.4%), with 5 procedures being 
inadequate due to a resulting CD34+ purity of less than 80% and only 1 procedure 
failing due to a low resulting number of CD34+ cells. Overall we isolated a median 
of 1.0 x 104 CD34+ cells, with 95.9% median purity, from a median of 1.4 x 107 BM 
mononuclear cells (Table 8.2). Although the viability of the mononuclear cells was 
generally low, the viability of the resulting CD34+ cells was good, since only PI 
negative CD34+ cells were selected. Dr. Yassmine Akkari and Dr. Susan Olson are 
currently doing the FISH analysis of the isolated CD34+ cells. 
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Table 8.2 Results from all 73 CD34+ cell isolation procedures. 
Parameter Value 
Total number of BM mononuclear cells immediately post thaw 
Median l.4xl0 -
Range 1.5 x 105 - 4.2 X 107 
Viability of BM mononuclear cells immediately post thaw - % 
Median 21.7 
Range 1.4 - 86.2 
Number of viable BM mononuclear cells immediately prior to 
sorting 
I Median 1.9 x 106 
Range 7.2 x 104 - 1. 1 x 1 0 -
Viability of BM mononuclear cells immediately prior to 
sorting- % 
Median 42.5 
Range 6.2 - 91.7 
Percentage of BM CD34+ cells immediately prior to sorting -
% 
Median 10.9 
Range 1.7 - 68.6 
Number of CD34+ cells isolated and placed into RNA lysis 
buffer 
Median 1.0 x 104 
Range 8. 1 x 1 0 1 - 9. 1 x 1 04 
Purity of CD34+ cells isolated and placed into RNA lysis 
buffer - % 
Median 95.9 
Range 17.5 - 100 
8.5.2 RN A Extraction and Gene Expression Profiling 
Sixty-four samples of RNA were assessed for quantity and quality at the Affymetrix 
Microarray Core - a flow chart of the scheme for RNA processing can be seen in 
Figure 8.1. Unfortunately, 12 samples failed to meet the required quality and quantity 
of RNA. As one would expect from using samples of less than 9.1 x 104 cells, we 
were only achieving low concentrations of RNA, with a median concentration of 
5.5ng/~1 (range, 1.04ng/~1 to 33.6ng/~I). Fifty-two samples of RNA underwent 2 
rounds of amplification, of which only 5 failed to amplify. Thus, 47 samples of Ri\A. 
- 128 -
from 37 patients with CML, were hybridised to the HG-U133 Plus 2.0 GeneChip 
arrays, resulting in good quality gene expression profiling data on 36 patients. 
Figure 8.1 Flow chart of the steps from cell sorting samples from 51 patients 
with CML, through to successful array hybridisation in 36 patients. 
51 atients with CML 
64 samples of RNA, from 47 patients, were 
quantified and assessed for quality 
5 samples failed due to < O<K CD34+ ell purity; 
l ample failed due to containing <1000 celh 
-....:;:::~ -=::=---~----£> 12 samples failed to reach 
quali ty & quantity . landards 
52 samples of RNA , from 41 patients, 
underwent amplification and labelling 
47 samples of labelled RNA, from 37 
patients. were hybridised to arrays 
36 patients with successful arra s 
8.5.3 Statistical Analysis 
5 sample ' of RNA failed to amplify 
--t> 7 amples fai led to hybridise , and 4 ample. were not u. ed 
a there was a higher qUality replicate . ample available 
The ignal intensity log ratios across all arrays were successfully normalised using 
RMA (Figure 8.2 and Figure 8.3). Levene 's test revealed equal variance in gene 
expres ion acros Rand NR in 54544 probe sets, with only 131 probe set having 
unequal variance. Un upervi ed hierarchical clustering of the 36 array by u e fall 
pr be ets, h wed no clu tering by re ponse tatus (Figure 8.4. After ele tina 
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probe sets that were differentially expressed between Rand NR (n = 1019), e\en 
though the probe sets did not reach statistical significance after multiple comparison 
adjustment, we found that the data clustered by response status (Figure 8.5). Only 10 
of the probe sets found to be differentially expressed between Rand NR had an 
adjusted p value of <0.5, and all of these probe sets had a higher signal in R than NR 
(Table 8.3). 
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Figure 8.2 Boxplot of the signal intensity log ratios for all 36 arrays prior to 
normalisation. 
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Figure 8.3 Boxplot of the signal intensity log ratios for aU 36 arrays after 
normalisation with RMA. 
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Figure 8.4 Dendrogram showing unsupervised hierarchical clustering of all 36 
patient samples based on RMA signal values, showing no obvious clustering b 
response status. 
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Figure 8.5 Dendrogram showing unsupervised hierarchical clustering of all 36 
patient samples based on RMA signal values from probe sets identified as being 
differentially expressed between Rand NR, and having an adjusted p value of 
<0.51, showing clustering by response status. 
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Table 8.3 Description of the probe sets identified as being differentially 
expressed between Rand NR, and having a p value of <0.5 after multiple 
comparison adjustment. 
Probe Set Gene Unadjusted Adjusted 
ID 
Gene Title Symbol p value p value 
1554882_at Exci~ion re~air cross-complementing rodent 
repair deficiency, complementation group 8 ERCC8 0.02 0.38 
1559025_at MLL septin-like fusion MSF 0.01 0.38 
210492_at Microfibrillar-associated protein 3-like MFAP3L 0.02 0.38 
21971O_at KIAA 1985 protein KIAAI985 0.02 0.38 
220230_s_at Cytochrome b5 reductase b5R.2 CYB5R2 0.02 0.38 
224045_x_at Chromosome 18 open reading frame 2 C18orf2 0.02 0.38 
231137_at Unknown 0.02 0.38 
235188_at Unknown 0.03 0.-+2 
235449_at 
Leucine rich repeat and sterile alpha motif LRSAMI 0.03 0.42 
containing 1 
243105_at 
Suppressor of variegation 4-20 homolog 1 SUV420HI 0.03 0.-+3 (Drosophila) 
Fold 
Change 
(R-I\Rl 
+1.2 
+ 1.18 
+ 1.16 
+1.1'+ 
+ 1.11 
+ 1.1 
+1.03 
+1.25 
+1.2 
+ 1.18 
The fold change (Fe) is defined as: ±21~', where I~I is the absolute value of the 
difference in mean log (signal) between Rand NR groups. The positive sign (+) 
indicates up-regulation of R compared to NR, while the negative sign (-) indicates 
down-regulation. Note that a fold change of 1.0 is equivalent to no difference in gene 
expression. 
Sample size and power calculations were performed using an alpha of 0.05, and used 
the gene-specific mean squared errors from the ANOYA model. We found that with 
36 patients we only had 51 % power to detect a 1.5 fold change in gene expression, 
75% power to detect a 2 fold change and 98% power to detect a 3 fold change. If we 
accepted a false positive rate of 20%, we would need to increase our patient number 
to 41 to detect a 2 fold change in gene expression, or to 73 to detect a 1.5 fold change. 
Thus, if we wanted to divide our patients into a training set and a test set we would 
ideally want at least 73 patients in each group. 
- 134-
8.6 Discussion 
We set out to test whether gene expression profiling of CD34+ cells, from patients 
with CML, would enable us to predict patients' responses to imatinib. Following on 
from the work we did on the gene expression profiling of unselected CML white cells, 
we deliberately tried to minimise sources of technical variation within our 
experiment. Not only did we select cells of a distinct immunophenotype, and with a 
high threshold of purity, we also only allowed one individual to execute each stage of 
the experiment and we used the same kits and reagents throughout. We chose patients 
with the same criteria as for the unselected white cell experiment, in an attempt to 
polarise our population to the extremes of good and poor responses to imatinib, and 
we deliberately chose to use more patients than the previous experiment, to try and 
maximise the power of this study. 
We found that the CD34+ cell isolation procedure was highly successful in achieving 
a highly pure sample of CD34+ cells from cryopreserved BM mononuclear cells, 
increasing the median percentage of BM CD34+ cells from 10.9% prior to sorting, to 
95.9% after sorting. However, this was at the expense of cell yield, partly because of 
the poor viability of the cells after thawing, and partly because of the need to use the 
"single cell" sort setting on the BD FACSAria ™ (BD Biosciences). The median 
number of CD34+ cells that we were able to isolate from patients' cryopreserved 8M 
mononuclear cells was only 1 x 104, resulting in low yields of RNA. 
Twelve out of 64 RNA samples failed to reach our thresholds for quality and quantity. 
Even though we had found that the NanoDrop® could accurately measure control 
mouse brain RNA down to a concentration of 1 ng/~I, we found that in this study 
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RNA concentrations <3ng/!-llled to difficulties with accurate measurement of Ri\:-\ 
quantity, and hence a tendency to overestimate the true quantity of RNA. This may 
have led to putting forward too little RNA for quality assessment for some of the 
samples that failed, and so being given a falsely low measurement of RNA quality 
(personal communication from Dr. Christina Harrington). However, in general the 
quality of the RNA was found to be good, and those samples of RNA derived from 
>2.0 x 104 CD34+ cells were consistently found to pass our quality and quantity 
thresholds. 
We needed to perform 2 rounds of RNA amplification in order to achieve the required 
5!-lg of RNA to hybridise to the arrays. We used the two-cycle cDNA synthesis and 
IVT labelling protocol that was released by Affymetrix in 2003, as we had shown that 
mouse brain total RNA inputs as low as 1.5ng produced sufficient cRNA for array 
hybridisation, with relatively good array performance l87. For this study, we found that 
we could amplify samples of control human brain RNA, ranging in size from 5ng to 
lOng, to between 58.2!-tg and 125.25!-tg, and that CD34+ cell RNA inputs of less than 
5ng gave us informative, but less sensitive, array data l87 . For samples of RNA 
derived from CML CD34+ cells, we achieved successful amplification of RNA in 47 
out of 52 samples. The fail ure of 5 samples to amplify may be due in part to 
insufficient RNA input, due to inaccurate measurement of initial RNA quantity, and 
also that inexplicably one round of labelling and amplification appeared to under 
perform. 
Previous work on rat brain RNA had shown that the 2 rounds of amplification 
reduced the sensitivity of the array by 5 to 10%, as measured by the percentage of 
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present calls, and that 3' /5' actin ratios increased with RNA inputs of <lOng. but that 
other performance metrics (%P, average signal, background, noise) were good 1s-. \\'e 
therefore accepted a relatively high 3' /5' actin ratio in this study. Hybridisation of 
RNA to the arrays was successful in 40 samples. Seven samples failed quality 
assessment of the array, due to a higher than acceptable actin 3'/5' ratio and / or an 
average signal out of keeping with the other samples within that hybridisation group. 
We successfully normalised the 36 arrays, and then examined unsupervised 
hierarchical clustering of all the data. This revealed no clustering of the arrays by 
response status, sex, purity of the CD34+ cells (~95% pure versus <95% pure), or by 
disease phase at diagnosis (not shown). Although there was not any clustering of the 
arrays by response to imatinib, we were reassured that there was not any unexpected 
clustering of the arrays as we had seen in the unselected CML white cell study. We 
next examined the data for probe sets that were differentially expressed between R 
and NR. After multiple comparison adjustment, none of the probe sets met an 
adjusted p value of <0.05. However, by including only those probe sets with an 
adjusted p value of <0.51 in the hierarchical clustering, we were able to see clustering 
of the arrays by response status. Thus, although the probe sets may not reach 
statistical significance, as a group they were able to divide the patients into Rand NR. 
The top 10 differentially expressed probe sets do not identify any genes that are 
currently known to be involved in CML biology, but the MSF gene has been reported 
as being the fusion partner of MLL in a single case of therapy-related acute myeloid 
leukaemia l88. However, no conclusions should be made at present about the 
usefulness of these probe sets in distinguishing Rand NR, since these probe sets did 
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not meet statistical significance after multiple comparison adjustment and further 
analysis of the data are required. 
There are a number of reasons why we may not have seen significant differences in 
the gene expression profiles of CD34+ cells derived from Rand NR. Firstly, the 
majority of patients had received treatment for their CML prior to receiving imatinib, 
and this may well have altered the genes that their stem cells expressed. Since most 
patients had treatment with interferon and hydroxyurea, and few had other treatments, 
it would be hard to see this influence on the unsupervised hierarchical clustering 
dendrogram, and might explain the lack of separation of Rand NR. Secondly, all the 
CD34+ cells were derived from cryopreserved mononuclear cells and had undergone 
a quite intensive series of events leading to their isolation. It would be surprising if 
the freezing and isolation had not influenced the gene expression of the CD34+ cells 
in some way, and this may explain why the gene expression of Rand NR are so 
similar. Thirdly, our patients all had high levels of Philadelphia chromosome positive 
metaphases in their bone marrow prior to starting on imatinib, and it may be that we 
are simply seeing the influence of overwhelming expression of BCR-ABL from the 
CD34+ cells, and that the changes that differentiate R from NR are so subtle that we 
cannot pick them up with this technology. Fourthly, we were using small amounts of 
input RNA and relying on 2 rounds of RNA amplification, both of which may have 
reduced the sensitivity of the arrays to pick up differences in gene expression. In 
addition, our power calculations reveal that we were underpowered and we would 
have needed 73 patients to reliably detect genes with a 1.5 fold difference in gene 
expression between Rand NR, though this is a much smaller number of patients than 
w~ would have required when using the data from the gene expression profiling of 
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CML white cells. Lastly, we may be searching for a difference in gene expression 
profile that simply does not exist. 
We shall continue our analysis of the data and see if we are able to use different 
statistical methods, and pathway analysis, to develop a robust algorithm predicti ve of 
response to imatinib. We had originally planned to randomly divide our patients into 
a training and test set, as in the un selected cell experiment, however. due to loss of 
patients along the way if we were to continue along this route we would most likely 
have to use a separate cohort of patients to test our results, potentially introducing 
more unwanted variation / noise into our analysis. Although it would appear that we 
have reduced the noise within this experiment (as compared to our CML white cell 
microarray study) by virtue of requiring less patients to detect a 1.5 fold change in 
differential gene expression between Rand NR, we still have a long way to go before 
we can conclude whether these data are going to be more useful in developing a tool 
predictive of response to imatinib. 
8.7 Future work 
We originally set out to explore the question of whether gene expression profiling 
could be a tool for predicting patients' responses to imatinib, by designing an 
experiment using RNA from fresh CD34+ cells, taken from newly diagnosed and 
completely untreated patients with CML. We had planned to recruit patients from the 
STI571 Prospective International Randomised Trial (SPIRIT) (www.spirit-cml.org), 
which had been anticipated to start in early 2003, however, due to problems with 
obtaining funding, SPIRIT only started to recruit patients in I\1ay 2005. Thus there 
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has been a significant delay in patient recruitment, despite our best efforts to recruit 
patients in the meantime. 
We have isolated CD34+ cells from patients' peripheral blood, by immunomagnetic 
separation (Chapter 7), and placed them into RNA lysis buffer. A sample of each 
patient's CD34+ cells was also stored for FISH for BCR-ABL. We anticipated 
perfonning gene expression profiling, using 90 HG-U 133 Plus 2.0 GeneChip arrays 
(Affymetrix) (kindly donated to us by Novartis, Basel, Switzerland), on the patients 
who went on to achieve a CCR at 1 year from starting imatinib, and compare this to 
the patients who remained at least 65% Philadelphia chromosome positive at 1 year. 
At present, Miss Jean Norden has collected CD34+ cell samples from 29 CML 
patients and the median number of CD34+ cells collected is 4 x 105 (range, 2 x 105 to 
3 x 106). From the 17 samples with flow cytometry results of CD34+ cell purity, the 
median purity is 75% (range, 15% to 96%). These 29 samples were sent to Oregon 
Health and Science University, in anticipation of undergoing RNA amplification and 
hybridisation to arrays, but unfortunately 18 samples thawed in transit. Since one trial 
shipping, containing control samples, had allowed the samples to thaw en route, and 
the quality assessment of these samples was consistent with degraded RNA, we do 
not anticipate being able to use these 18 samples for our work. Thus, we are left with 
only II potential samples, and are currently debating the practicality of continuing 
this project. 
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8.7.1 Potential strengths 
We believe that by using RNA extracted from isolated CD34+ cells. taken from fresh 
patient material before the patient receives any drug treatment, we shall gain our best 
chance of obtaining gene expression levels that are due to disease, rather than 
confounding factors. By using immunomagnetic columns to obtain the CD34+ cells. 
we are minimising the handling of the cells, compared to cell sorting. and also using a 
simple technique that could potentially be translated to the clinical laboratory should 
we find that gene expression in CD34+ is able to predict patients' responses to 
imatinib. If we can recruit patients as part of a clinical trial, then we shall have access 
to the good quality follow up data that is essential for this study. We have the 
advantage of having worked closely with the Affymetrix Microarray Core at Oregon 
Health and Science University on our two other CML microarray projects. and would 
have the benefit of their experience in using small amounts of RNA for amplification, 
labelling and hybridisation. 
8.7.2 Disadvantages 
The main problem with this approach is obtaining high numbers of consistently pure 
CD34+ cells. From 20ml peripheral blood we have been obtaining a median of 4 x 
105 CD34+ cells, with a median purity of7S%. We know from the data we have on 
RNA extracted from cell sorted CD34+ cells, that 4 x 105 CD34+ cells is going to 
give us approximately SOOng to ll-lg of RNA; we shall therefore still have to perform 
2 rounds of RNA amplification in order to hybridise the RNA to arrays, and have the 
associated 3' bias in the amplification, 5% to 10% drop in sensitivity of the array and 
cost. The purity of the cells, after using one immunomagnetic column, is highly 
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variable and would result in approximately half of the samples being rejected because 
of low CD34+ cell purity. Another option to consider would be using more than 2 
xI08 input cells and run these through 2 larger columns, however, the increased purity 
tends to be at the cost of cell yield, and it is unlikely that we are going to have access 
to greater than 2 x 108 cells in the majority of patients. 
The SPIRIT trial has 3 arms and only a third of patients will receive the standard dose 
of imatinib (400mg once daily); this would slow down our patient recruitment since 
we could only compare patients receiving identical treatment. We were planning on 
using the Affymetrix Microarray Core to perform RNA amplification and array 
hybridisation; however, we will have to run the risk of shipping precious samples that 
might thaw en route. Finally, based on our experiences with the 2 other microarray 
projects, we may simply be chasing differences that are not there, or cannot be 
detected by microarray technology. 
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9 Discussion 
The treatment of patients with CML has been revolutionised by the advent of 
imatinib. Prior to imatinib, an average of 13% of CML patients in chronic phase (CP) 
had a complete cytogenetic response (CCR) on treatment with interferon alpha 
(lFN)'89. Results of the IRIS trial45 have shown that 84% of patients on imatinib 
achieve a CCR, that this usually occurs within the first year of treatment, and it is 
associated with a reduced rate of disease progression. In addition, with the advent of 
AMNI07 and BMS-354825 there is hope of patients achieving a CCR even if they 
fail to respond, or lose their response to imatinib. However, the potentially toxic 
treatment of allogeneic haematopoietic stem cell transplantation remains the only 
known cure for patients with CML 49,50. At diagnosis it would be very useful to be 
able to predict which patients will, or will not, have a cytogenetic response to 
imatinib, so that in those patients with a suitable donor, one could give patients 
accurate and individual advice about the likely success of their treatment options. We 
therefore set out to test candidate markers that associated with CML patients' 
responses to imatinib, with the hope of using these to predict an individual patient's 
response to treatment. We approached this in two ways: firstly by examining 
individual candidate genes and polymorphisms, and secondly by examining overall 
gene expression patterns. 
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9.1 Is the possession of a particular genotype associated 
with response to imatinib? 
Dressman et al. 114 showed an association between the "CC" genotype of the 
rs2290573 polymorphism and reduced rate of MCR, while Bergamaschi et al. 124 
found an association between the possession of the A 1 allele of the TP53 oene 
o 
polymorphism, and CML patients remaining at least 65% Ph positive on imatinib. 
However, we genotyped our Newcastle population of CML patients for the rs2290573 
polymorphism and could find no correlation with rate of major cytogenetic response 
(MCR), or rate of CCR, on imatinib. Dressman et al. 114 had examined their patients 
for an association between rate of MCR and genotype of the TP53 gene 
polymorphism, and also could find no association. Although these single associations 
may be true for one population, it would appear that these findings are hard to 
validate in an independent population of patients with CML. 
There are a number of reasons why these findings could be hard to validate, including 
that there is variation of the underlying association between genotype and response 
between populations, the populations consists of a mix of subpopulations with 
different allele frequencies and disease risks, inadequate power leading to false 
negative results, and false positive results leading to failure to attribute the results to 
chance l45. However, if genotypes shown to be associated with response to treatment 
can be validated in a large and independent population of patients, then genotyping 
polymorphisms would be an attractive method for identifying predictive markers. 
since it has the advantage of being a simple technique that could easily be translated 
to the cI inical laboratory. 
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At the present time, K247R is the only known polymorphism within the codin£ reoion 
~ e 
of ABL. We investigated the effects on drug sensitivity of translocation of the 
arginine allele, of the K247R polymorphism, into BCR-ABL. Although K247R is 
located within the P-Ioop domain of the BCR-ABL kinase, we did not find any in 
vitro evidence for reduced sensitivity of this variant to imatinib, AMN 107 or BMS-
354825. However, since point mutations in the kinase domain can so easily alter 
imatinib sensitivity, one could readily envisage that a single nucleotide polymorphism 
could do the same. As more patients with CML are screened for kinase domain 
mutations, we may well pick up more rare polymorphisms situated within ABL and it 
would be interesting to see if these could influence patients' responses to treatment. 
Imatinib has been shown to be a substrate for a number of genes associated with drug 
transport, including the human organic cation transporter 1 (hOCT 1 f6-83.85.188. Our 
results from a small study of patients with primary cytogenetic resistance to imatinib, 
suggest that expression of drug transport genes, in particular the hOCT 1 gene, may be 
associated with lack of response to imatinib. The hOCT 1 gene contains several 
polymorphisms, where the possession of a particular allele has been associated with 
alteration of its functional activity. Our RQ-PCR assay of hOCT 1 covered a region 
containing the P283L and R287G polymorphisms. The leucine and glycine alleles are 
associated with diminished hOCT 1 transport activi ty I7O, and although our assay was 
designed such that polymorphisms should not affect its performance, we potentially 
may not have been as efficient at detecting hOCT 1 mRNA transcribed from these 
alleles. as from the proline and arginine alleles. Thus. we may have been indirectly 
detecting the alleles associated with reduced hOCT 1 acti vity. It would therefore be 
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very interesting to explore the hypothesis that possession of particular alleles of the 
hOCT! gene polymorphisms are associated with a patient's response to imatinib. 
9.2 Does genotyping allow the prediction of imatinib 
response? 
Currently we are a long way from determining whether genotyping will allow us to 
predict a patient's response to imatinib. In the future, if one could identify robust 
associations between the possession of particular genotypes and patients' responses to 
imatinib, then one could envisage identifying a pattern of genotypes that might be 
predictive of an individual patient's response to imatinib. 
9.3 Do gene expression profiles prior to imatinib associate 
with future cytogenetic response? 
In order to achieve a visual overview of our microarray data, we used the 
conventional approach of unsupervised hierarchical clustering to group together 
patients based on the similarity of their gene expression profiles. When considering 
all the probes on the arrays, we did not see any clustering of patients based on their 
future cytogenetic responses to imatinib. However, by filtering the CD34+ cell data 
for the top most differentially expressed probes between cytogenetic responders (R) 
and non-responders (NR), we then saw division of our patients by response. Thus, 
there would appear to be differences in the pattern of gene expression between Rand 
NR when considering a subset of probes, but these differences are subtle and can 
easily be overwhelmed by the influences of sample source and handling. Indeed, our 
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top most differentially expressed genes from either the white cell data, or CD34+ cell 
data, were not significantly differentially expressed after adjustment for the multiple 
comparisons were made; this may in part be due to both studies being underpowered 
to detect a 1.5 fold change in gene expression, or less, between Rand NR. 
9.4 Does gene expression profiling allow the prediction of 
imatinib response? 
Kaneta et al. 139 and McClean et al. l4Q have both published work that suggests that this 
is possible, but only one of these studies was validated in a test set of patients, albeit 
small. We had designed our gene expression profiling studies to incorporate both a 
training set and a test set of patients, so that we could validate any algorithm for 
prediction that we developed. With the white cell expression profiling data, we found 
that an algorithm that predicted response in our training set, did not predict response 
in our test set; explanations for this included lack of power and confounding factors, 
but also the serious issue of whether there truly were robust enough differences, 
between the gene expression profile of Rand NR, to allow us to develop an algorithm 
to predict response. 
The statistical analysis of the gene expression profiling data from CML CD34+ cells 
is currently ongoing, but we are concerned that though we may have been able to 
minimise systematic variation due to sample handling and cell phenotype, we have 
not been able to significantly improve on the power of our white cell gene expression 
profiling study. Although there appear to be differences in the transcriptional 
signatures of CD34+ cells from Rand NR, we may be underpowered to use these 
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differences to develop and test an algorithm predictive of imatinib response. :\t the 
moment, it appears unlikely that with our gene expression profiling data \\ ill allow us 
to predict an individual patient's response to imatinib. 
9.5 Is gene expression profiling going to be a useful 
technology for predicting CML patients' responses to 
imatinib? 
Gene expression profiling has shown that it allows the prediction of patients' 
responses to drug therapy in several haematological malignancies 128-13'\ and one might 
therefore assume that CML would be no different. However, in the diseases where 
gene expression profiling has shown itself to be useful, the malignant cells that have 
been profiled tend to have a clearly identifiable histological phenotype, whereas in 
CML the malignant cells are of many different phenotypes, unless one simply selects 
one cell phenotype, E.g. CD34+ cells. In the acute leukaemias, remission is defined 
as a reduction in bone marrow blast cells to less than 5%, whereas in CML response is 
measured at the haematological, cytogenetic and molecular levels; perhaps asking 
gene expression profiling to identify the differences between patients who do or do 
not achieve a cytogenetic response is too subtle a question to be asked by this 
technology, unless one restricts oneself to CML stem cells. Indeed, the difference 
between CML and many of the non-Hodgkins lymphomas and acute leukaemias, is 
that in the latter most cells are at a single or similar stage of maturation (arrested at 
this stage by the malignant process) while within CML cells, every stage of 
maturation between pluripotent blasts and mature erythrocytes, neutrophils and 
platelets may be represented. Concentrating on the gene expression profile of 
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selected CML stem cells would overcome the wide diversity of expression profiles 
seen from cells of different phenotypes. 
At the current time, our experience leads us to have some serious concerns about the 
future usefulness of gene expression profiling in predicting CML patients' responses 
to imatinib. Not only is it an expensive and complicated technology to use, it requires 
a multidisciplinary team of scientists, statisticians and clinicians to produce and 
interpret the data, and results so far in CML have not been hopeful. We still believe 
that our initial ideas of examining the gene expression profiles of fresh CD34+ cells, 
from the peripheral blood of newly diagnosed and untreated patients with CML. 
would be our best source of material to answer the question of whether gene 
expression profiling is going to be useful for predicting response to imatinib; but one 
would ideally want unlimited access to funds and patients, so that one could use RNA 
from at least 200 patients (lOa R and 100 NR) to maximise the power of the study, 
and to have enough RNA not to need to perform 2 rounds of RNA amplification prior 
to array hybridisation, and so not risk reduction in sensitivity of the arrays. 
9.6 Summary 
From our studies it would appear that investigating the influences of target genes, in 
particular genes associated with drug transport, and the effect of polymorphisms on 
imatinib response, is more likely to yield dividends in the search for methods that 
might allow us to predict patients' responses to imatinib, rather than using overall 
gene expression patterns. 
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10 Glossary of terms 
I have included here a glossary of the words, or phrases, that have been underlined 
within the body of this thesis . 
. dat file 
This is the image data file that is generated by the scanner - a single intensity value is 
generated for each probe cell on the array . 
. cel file 
This is the cell intensity file, which contains the cell intensities and coordinates from 
the primary image in the .dat file. 
Pseudo-image 
This is a feature-level view of the Affymetrix GeneChip and it is generated by use of 
the .cel file data. To examine the overall quality of the array, the pseudo-i mage can 
be checked for obvious anomalies (bright or dark patches, edge defects, debris, etc.) 
and be used to make sure the gridding was successful 190. 
Background 
Microarray Analysis Suite (MAS) 5.0 is part of Affymetrix's GeneChip Operating 
System (GCOS), and it manipulates the probe intensity data. It calculates the average 
background signal on the array by dividing the chip into 16 rectangular regions, 
selecting the lowest 2% of signal in those regions, and averaging these values. 
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Noise 
Noise is a measure of the variability of the pixel values within a probe cell, averaged 
over all probe cells on an array. MAS 5.0 divides the chip into 16 rectangular 
sections, and takes the standard deviation of the lowest 2% of signal in that section. 
and averages these values. 
A verage signal 
This is the average of all the signal intensities, from all of the probes on the array. 
Present, marginal and absent 
The detection calls of present, marginal or absent are generated by MASS.O. They are 
based on a Wilcoxon signed rank test intended to test the difference in signal 
intensities between the perfect match probe set and its mismatch probe set. Perfect 
match probe sets with a p value <0.04 are called present, those with a p value between 
0.04 and 0.06 are called marginal, and those with a p value >0.06 are called absent. 
Percent present 
Percent present is the percentage of perfect match probe sets that are detected as 
"present" on that array. 
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Normalisation 
Normalisation is the attempt to compensate for systematic technical differences 
between chips, to see more clearly the systematic, biological differences between 
samples l91 . MAS 5.0 normalisation uses a linear regression model, where a baseline 
array is selected against which all other arrays are compared. Robust multichip 
analysis (RMAi79 uses quantile normalisation that assumes that though there may be 
differences between arrays in the expression of individual probes, the distribution of 
the expression values does not vary dramatically between arrays. Signal values on 
each array are ranked. Signal values for each rank are averaged across all the arrays, 
so that after normalisation the arrays share the same set of signal values, but the 
probes associated with those signal values will vary from array to array. 
Unsupervised hierarchical clustering 
Hierarchical clustering is an agglomerative technique where arrays with similar 
expression profiles are joined to form groups, and these groups are further joined until 
a complete single hierarchical tree is formed. Unsupervised hierarchical clustering 
does not use any biological information about functionally related genes to "guide" 
the clustering algorithml92. 
Multi-dimensional scaling 
Multi-dimensional scaling is a form of principal component analysis. It is a complex 
mathematical method of visualising data in 2 or 3 dimensions, where the distance 
separating data points is representative of the dissimilarity of the data points to each 
other. 
- 152 -
11 Appendix 1: Newcastle University consent 
documents 
All patients gave their consent for these studies, in according to the guidelines set out 
by the Declaration of Helsinki. Ethical approval was obtained from the Newcastle 
and North Tyneside Local Research Ethics Committee. 
11.1 Patient information sheet 
Research Study at the Medical School, University of Newcastle upon Tyne 
Pharmacogenomic Investigations into Response and Resistance to 
Imatinib in Chronic Myeloid Leukaemia 
You are being invited to take part in a research study for which we would need a 
small extra sample of blood and/or a mouthwash sample. This would be taken with 
the other blood samples which are taken each time you visit the clinic. If you do not 
wish to take part, your care will not be affected in any way. You will continue to be 
followed up as normal in the clinic, whether you take part or not. 
Before you decide, you will need to understand why the research is being done and 
what it will involve. Please take your time to read the following information 
carefully. Please ask us if there is anything you do not understand or if you would 
like more information. 
We are investigating whether we can predict the response that patients with Chronic 
Myeloid Leukaemia (CML) will have when they are given the drug imatinib (STI57 I , 
Glivec, Gleevec). We are going to try and do this by looking at patients' DNA. This 
area of research is called "pharmacogenomics" because we are striving to understand 
how genes influence the different responses people have to the same drug. Genes 
contain the instructions for making living organisms and are made up of DNA. Our 
bodies use the DNA to make messages known as RNA. Most DNA is identical among 
human beings, but the small variations we all have in our DNA may explain why 
different people have different responses to the same drug. 
Recent research has suggested that understanding more about individual's DNA may 
allow us to predict who will and will not respond to imatinib. \Ve would like to try 
and confirm these findings. We believe that this would be very helpful because 
although imatinib is a highly effective treatment for CML it doesn't work for 
everyone. If doctors could predict who would not respond then alternati ve treatments. 
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such as bone marrow transplant, could be offered earlier. 
This is how you could help. We need blood and/or mouthwash samples from people 
with CML who are taking or are about to start taking the drug imatinib. In a few 
people, we may take a couple of samples over the following year. In our laboratory, 
we will examine the genetic material (either DNA or RNA) in your blood and/or 
mouthwash sample and compare this to your response to imatinib. \Ye will see if we 
can predict your response to treatment. We hope to use what we learn to predict 
people's responses to imatinib in the future. 
If a blood sample is needed, this will be taken at the same time as your routine clinic 
blood tests and so no extra venepuncture should be necessary. In exceptional 
circumstances, it may be necessary to take an extra blood test just for the research. 
Risks associated with taking blood may include pain, bruising or penetration of the 
needle through the vein leading to bleeding from the site of the needle. 
Confidentiality 
You will not be identified in any reports or publications resulting from this research. 
Results from this research will not be placed in your medical records. Information 
about your clinical details and the results of analysis of your samples will be held on a 
computer. We may share this information, with limited access, with colleagues in 
other research groups in the UK and abroad. 
We will consider your sample as a gift to us and our research. In the future, we may 
think of additional research questions where it would be very valuable to go back and 
analyse your samples again. We would like to ask your permission to do this. 
We do not intend to test any of your family members and so we do not forsee that the 
findings of our research will have any wider implications than the prediction of 
response to treatment. 
If you would like more information please do not hesitate to contact: 
Dr Stephen O'Brien 
Department of Haematology 
Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne 
NE14LP 
Tel: 0191 2820568 
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11.2 Patient consent form 
Pharmacogenomic Investigations into Response And Resistance to Imatinib in 
Chronic Myeloid Leukaemia 
Name of Researchers: Dr Stephen O'Brien and Dr Pete Middleton 
I have read the information sheet on the above study and have been given a copy to 
keep. I have had the opportunity to ask questions about the project and understand 
why the research is being done. 
I agree to give a sample my blood and/or mouthwash. I understand how the sample 
will be collected, that giving this sample for research is voluntary and I am free to 
withdraw my approval for collection of the sample at anytime. 
I agree to the storage, on a secure computer system, of information about my clinical 
details and the analysis of my research samples and that this may be shared with 
certain research workers in the UK and abroad. 
I understand that my samples will be treated as gifts from me to the research team. 
I agree to the future use of my samples for research into improving the treatment of 
Chronic Myeloid Leukaemia. 
I know how to contact the research team if needed. 
Name of patient: 
Signature of patient: 
Name of person taking consent: Date of consent: 
Signature of person taking consent: 
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12 Appendix 2: Oregon Health and Science 
University consent documents 
All patients gave their consent for these studies, in according to the guidelines set out 
by the Declaration of Helsinki. Ethical approval was obtained from the Institutional 
Review Board. 
12.1 Patient information sheet 
IRB# 6384 
Approved: 
Revised: 4/5/2004 
OREGON HEALTH & SCIENCE UNIVERSITY 
GENETIC RESEARCH CONSENT AND AUTHORIZATION FORM 
TITLE: Mechanism of Imatinib Mesylate Resistance 
PRINCIPAL INVESTIGATOR Brian J. Druker, MD, (503) 494-5596 
CO-INVESTIGATORS Aleksandra Simic, MD, (503) 494-8945 
Michael Deininger, MD, (503) 494-1603 
Michael J. Mauro, MD, (503) 494-0376 
Richard Maziarz, MD (503) 494-1551 
PeterT. Curtin, MD, (503) 494-1551 
494-1551 
Society 
W. Harvard Fleming, MD, PhD, (503) 
Jose F. Leis, MD, PhD, (503) 494-1551 
Richard D. Press, MD, PhD, (503) 494-2317 
Suzanne Balleisen, ACNP (504) 494-1551 
Carol Jacoby, ACNP (503) -+9-+-0527 
Amy Kulikosky, ACNP (503) 494-1551 
Susan Schubach, FNP (503) 494-5031 
Bryon Allen, FNP (503) 494-1551 
Michael Heinrich, MD (503) 220-8262 \53405 
Tibor Kovacsovics, MD (503) 494-1551 
Brandon Hayes-Lattin, MD (503) 494-1318 
SPONSQR: Leukemia and Lymphoma 
- 156-
PURPOSE: 
You have been invited to participate in this study because you have Chronic 
Myelogenous Leukemia (CML), or Philadelphia chromosome positive Acute 
Lymphoblastic Leukemia. You mayor may not have begun taking Imatinib ~les\late 
(Gleevec). We are collecting blood and bone marrow samples to identify anv . 
relationship between your individual genetic markers and your treatment outcome, 
including improvement with Imatinib treatment or failure to respond to treatment with 
Imatinib. 
Some patients have already donated blood and bone marrow samples for a former 
study examining the effect of Imatinib on leukemia cells. If you have donated 
samples to that former study, we would like your permission to use the blood and 
bone marrow samples you previously donated for a new study to identify any 
relationship between your individual genetic markers and your treatment outcome, 
including improvement with Imatinib treatment or failure to respond to treatment with 
Imatinib. 
Your personal involvement in the study will take approximately 10 additional minutes 
of your time during appointments when routine blood tests or bone marrow 
procedures are done as part of your regularly scheduled medical care. The use of 
individual genetic markers from your blood and bone marrow together with 
information about how you are doing during your treatment with Imatinib will be 
used for this research. 
The DNA/RNA (genetic blueprints) taken from your samples of blood and bone 
marrow may be stored for future use to research scientific questions related to 
leukemia, oncology, other disease processes or other drug research and development. 
SUBJECT ACCESS TO GENETIC INFORMATION: 
Results of these studies are for research purposes only and since they are not expected 
to benefit you directly or to alter your treatment course, the results will not be made 
available to you, members of your family, your personal physician, or other third 
parties. 
PROCEDURES: 
As part of this study, your medical records will be reviewed for past disease history, 
and future information collected about your disease. In addition, your routine clinical 
laboratory results, research laboratory results and clinical information will be entered 
into a research database that is password-protected and secure. 
Samples of your blood and bone marrow will be obtained for use in this study. \\'e 
will obtain the samples at the same time routine blood tests or bone marrow 
procedures are done as part of your regularly scheduled medical care. You may 
refuse to donate the blood or bone marrow aspirate at any time. 
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For the blood samples, an additional one to two teaspoons of blood is needed. Blood 
is ~o~lected throu.gh a needle attached to a syringe after placing the needl~ through the 
skm mto your vem. A small bandage will be applied and the procedure will then be 
completed. 
Bone marrow is obtained by a bone marrow aspirate procedure. A local anesthetic 
(pain killer) will be given to numb a small area on the back of your hip. Then, a 
needle will be placed into the hipbone and about 1 additional teaspoon of bone 
marrow will be taken out for the purpose of this study. This additional sample will be 
collected each time you have a bone marrow aspirate procedure as part of your 
regularly scheduled medical care. The procedure lasts about 10 minutes. 
We are also requesting permission to use your previously donated blood and bone 
marrow samples for use in this study in order to identify any relationship between 
your individual genetic markers and your Imatinib treatment outcome. 
RISKS AND DISCOMFORTS: 
Blood drawing will cause some pain and carries a small risk of bleeding, bruising or 
infection at the puncture site. 
A bone marrow biopsy will cause some pain and carries a small risk of bleeding, 
bruising or infection at the biopsy site. An allergic reaction to the numbing medicine 
is rare (less than 1 in 10,000). Significant bleeding from a bone marrow biopsy is 
rare. Infection of the biopsy site may occur in up to 1 in 100 cases. 
If the results of these studies of your genetic makeup were to be released through a 
breach of confidentiality, this could affect your ability to get insurance or to get or 
keep a job. However, because the study results will not be entered into your medical 
record, there should be no risk to you that your insurance or employment will be 
affected in any way. 
There are no foreseeable risks to you for giving us permission to use your previously 
collected blood and bone marrow samples. 
BENEFITS: 
You will not benefit from participating in this study. However, by serving as a 
subject, you may contribute new information, which may benefit patients in the 
future. 
AL TERNATIVES: 
You may choose not to participate in this study. 
CONFIDENTIALITY: 
Confidentiality of information relating to your sample(s) will be protected to the 
extent permitted by law. To protect you against the risk of loss of confidentiality all 
samples as well as your medical information will be marked with a code number only 
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and will not identify you by name. Only the investigators named on this consent form 
will be authorized to link the code number to you. Research records may be reviewed 
and/or copi~d by the study sponsor (Leukemia and Lymphoma Society): the \!ational 
Cancer InstItute, the US Food and Drug Administration, and the OHSU Institutional 
Review Board. 
All ~ther p~rties including employers, insurance companies, personal physicians, and 
relat~ves w~ll be refu~ed. access to the information or to the samples, unless you 
provIde WrItten permISSIOn, or unless we are required by law to do so. 
Neither your name nor your identity will be used for publication or publicity 
purposes. 
COSTS: 
There will be no extra costs to you for the additional blood or bone marrow samples being 
taken for purposes of this study; however, you or your insurance will still bear the costs 
associated with your routine blood draws and bone marrow aspirate and biopsies as part of 
your standard and usual care for CML. 
COMMERCIAL DEVELOPMENT: 
Under Oregon law, the cell lines and purified DNA derived from your blood or bone 
marrow samples are yours to do with as you determine. By consenting to participate, 
you authorize the use of your samples for the research described in the PURPOSE and 
PROCEDURES sections of this document. In addition, you acknowledge that OHSU 
may make any lawful use of your samples, including, but not limited to, future 
research studies, destroying them, or transferring them to a public or private entity. 
Samples obtained from you in this research may be used to make a discovery that 
could be patented or licensed to a company. There are no plans to provide financial 
compensation to you should this occur. However, should OHSU ever provide your 
samples to anyone else for research or commercial use, it will do so in such a way as 
to protect your privacy and confidentiality as stated in the CONFIDENTIALITY 
section of this document. Further, you will have no responsibility or liability for any 
use that may be made of your samples. 
LIABILITY: 
It is not the policy of the U.S. Department of Health and Human Services, or any 
federal agency funding the research project in which you are participating to 
compensate or provide medical treatment for human subjects in the event the research 
results in physical injury. 
The Oregon Health & Science University is subject to the Oregon Tort Claims Act 
(ORS 30.260 through 30.300). If you suffer any injury and damage from this research 
- 159-
project through the fault of the University, its officers or employees, you have the 
right to bring legal action against the University to recover the damage done to \ ou 
subject to the limitations and conditions of the Oregon Tort Claims Act. Oreoo~ 
Health & Science University is also subject to the Oregon Genetic Privacy la~' (ORS 
192.531 through ORS 192.549) and its requirements concemin g confidentialitv and 
the legal remedies provided by that law for breach of its requir;ments. You h~\'e not 
waived your legal rights by signing this form. For clarification on this subject, or if 
you have further questions, please call the OHSU Research Integrity Office at ~503) 
494-7887. 
PARTICIPATION: 
If in the future you decide you no longer want to participate in this research, we \\'ill 
destroy all your blood or bone marrow samples. However, if your genetic samples 
are already being used in an ongoing research project and if their withdrawal 
jeopardizes the success of the entire project, we may ask to continue to use them until 
the project is completed. 
Dr. Brian Druker, (503) 494-5596 has offered to answer any other questions you may 
have about this study. If you have any questions regarding your rights as a research 
subject, you may contact the OHSU Research Integrity Office at (503) 494-7887. 
You do not have to join this or any research study. If you do join, and later change 
your mind, you may quit at any time. If you refuse to join or withdraw early from the 
study, there will be no penalty or loss of any benefits to which you are otherwise 
entitled. 
Please initial only one of the options below. 
I give my consent for my blood/bone marrow samples, including my 
previously donated samples, to be stored and used for this study only. I reserve 
the right to withdraw my samples unless the withdrawal would jeopardize this study. 
I give my consent for my blood/bone marrow samples to be used for 
this study and stored for possible future use to research scientific questions related to 
leukemia, oncology, other disease processes or other drug research and development, 
but I wish to be contacted for permission prior to any future use. I also reserve 
the right to withdraw my samples in the future. 
I give my consent for my blood/tissue samples to be used for this study 
and future studies to research scientific questions related to leukemia, oncology, other 
disease processes or other drug research and development. I do not need to be 
contacted for permission in the future. However, I reserve the right to withdraw my 
samples in the future. 
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12.2 Patient consent form 
You will receive a copy of this consent form. Your signature below indicates that you 
have read the foregoing and agree to participate in this study. and agree to allow us to 
use your previously collected blood and bone marrow samples. 
Signature of Subject 
Signature of Investigator 
copies to: 
originals to: 
Subject 
Inpatient Chart 
Clinic chartlResearch chart 
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Date Signed 
Date Signed 
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